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“I wonder about turtles.”  
“What do you wonder about turtles?” Angela asked him.  
“When they pull in their heads,” he said, “do their spines buckle or contract?” 
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The spliceosome is a highly dynamic, megadalton ribonucleoprotein (RNP) molecular 
machine that catalyses the important step of the post-transcriptional processing of eukaryotic 
precursor messenger RNA (pre-mRNA), called splicing. During splicing the non-coding 
nucleotide intervening regions (introns) of newly transcribed pre-mRNA are excised and the 
protein-coding sequences (exons) are ligated via two consecutive transesterification reactions. 
The spliceosome is assembled de novo on each pre-mRNA intron by consecutive recruitment 
of five RNA-protein complexes (snRNPs) and numerous non-snRNP factors in a dynamic 
manner. Initially, the U1 and U2 snRNPs bind to the 5’ splice site and branch point sequence, 
respectively, forming the A complex. In the next step, the preformed U4/U6.U5 tri-snRNP 
binds and complex B is assembled. Thereafter, complex B undergoes multiple rearrangements 
in terms of both its conformation and composition, including the dissociation of U1 and U4, 
resulting in the formation of the Bact complex. After the formation of the catalytically active 
B* complex, the first step of splicing takes place, generating the cleaved 5' exon and intron-3' 
exon lariat intermediates, and creating complex C, which performs the second step of 
splicing, resulting in the ligation of the 5' and 3' exons and release of an intron in the form of 
a lariat. Various assembly intermediates of the spliceosome have been experimentally defined 
and characterized. However, the dynamics of protein exchange, as well as RNA 
rearrangements during the spliceosome assembly remain in many aspects unclear. 
The spliceosome assembly is highly regulated in multiple ways. Disruption or misregulation 
of alternative and constitutive splicing are the cause or severity modulator of many human 
diseases, including among others cancer, neurodegenerative and autoimmune diseases, 
making the spliceosome a highly attractive drug target. Small molecule inhibitors that block 
discrete steps of the extremely dynamic assembly and functional cycle of the spliceosome are 
not only of potential therapeutic value, but also highly useful for the detailed investigation of 
the structure and function of the spliceosome. However, only a limited number of small 
molecule inhibitors that specifically target the pre-mRNA splicing machinery have been 
identified at present. Using a robust, rapid and sensitive high throughput in vitro splicing 
assay, which monitors the formation of step I spliceosomes (i.e. the spliceosomal C complex) 
by measuring the association of a FLAG-tagged version of the DEAD box ATPase Abstrakt, 
a chemical library of ~172,000 small molecules was screened for splicing inhibition activity. 
All compounds showing at least a 50% decrease in the signal intensity of bound Abstrakt 
were subjected to a second test, and reproducible hits were finally tested in an in vitro 
splicing assay using 32P-labeled adenovirus-derived MINX-MS2 pre-mRNA as substrate.  
Ten compounds were confirmed to be inhibitors of pre-mRNA splicing in vitro, and exhibited 
IC50 values ranging from 3 to 50 µM, To determine at which stage they inhibit splicing, I 
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performed a splicing time course and analysed the spliceosomal complexes formed by native 
agarose gel electrophoresis. Analysis of splicing complex formation revealed that at least one 
compound (hereafter designated as 028), led to an accumulation of A complexes and a 
complex denoted as B028 that sediments slightly faster than the pre-catalytic B complex on 
glycerol gradients. Gradient centrifugation experiments indicated that U4/U6.U5 tri-snRNP 
stability is not affected significantly by 028. To characterize in more detail spliceosomal 
complexes formed in the presence of compound 028, I subjected the stalled splicing reactions 
to glycerol-gradient centrifugation and purified the complexes in a given peak by MS2-MBP 
affinity selection. Initial analysis of the RNA and protein composition of complexes affinity-
purified from the “B-like” peak, suggested that compound 028 stalls splicing at a novel stage 
of the spliceosome activation step; i.e., inhibition appears to take place after release of the U4 
snRNP, but prior to the release of the LSm and B-specific proteins and before the stable 
integration of the Prp19 complex, the recruitment of Bact specific proteins and the 
phosphorylation of U2 protein SF3b155. Analysis of the RNA-RNA network within B028 by 
RNA structure probing and psoralen crosslinking suggested, but did not definitively prove, 
that the catalytically important U6-ISL and U2/U6 helix Ia and Ib likely are formed in the 
spliceosomes stalled by compound 028. Purified B028-complexes could be chased into 
catalytically active spliceosomes upon addition of microccocal nuclease-treated nuclear 
extract, demonstrating that they are functional complexes. We thus performed initial “chase” 
experiments with purified B028 complexes to follow the recruitment and release of proteins 
during the activation step. Our results suggest that ATP is required for the recruitment of the 
Prp19/CDC5L complex proteins and B-specific proteins. Negative stain electron microscopy 
of B028-complexes and 3D reconstruction of the B028-particle revealed a unique morphology, 
which is different from the pre-catalytic B and activated Bact spliceosomal complexes, but 
suggest common morphological features with both B and Bact, consistent with them being 
stalled at an intermediate assembly stage. Finally, structure-activity relationship (SAR) 
studies, in which modifications of compound 028 were assayed for their effect on pre-mRNA 
splicing in vitro, revealed structural determinants that are important for the inhibition activity 
of compound 028. Thus, compound 028 allows us to obtain a novel snapshot of the 
spliceosome assembly pathway and to perform detailed structural and functional 
investigations, to improve our limited understanding of the dynamic rearrangement of 




The genetic information of a living organism is stored in its deoxyribonucleic acid 
(DNA). Whereas prokaryotic genes consist of continuous, protein coding DNA 
sequences, most genes of higher eukaryotes display a mosaic structure. Thereby protein-
coding sequences (exons) are interrupted by long non-coding nucleotide intervening 
regions (introns). To allow correct translation of the protein-coding region, the introns of 
newly transcribed pre-mRNA (precursor messenger RNA) have to be removed precisely 
from the primary transcript, and the exons ligated together during the evolutionarily 
conserved process, called splicing. Additionally, the 5’ end of the pre-mRNA is modified 
with a unique cap-structure, consisting of a N7-methylguanosine (m7G) covalently bound 
to the ribose via an unusual 5′ to 5′ triphosphate linkage (Shatkin, 1976; Shatkin and 
Manley, 2000). Furthermore, the 3’ end of the pre-mRNA undergoes polyadenylation 
(post-transcriptionally) (Colgan and Manley, 1997). Capping and polyadenylation are 
essential for the stability of the pre-mRNA/mRNA, regulation of mRNA transport to the 
cytoplasm and efficient translation. Finally, mature mRNA is transported from the 
nucleus to the cytoplasm and used as a template in the protein translation process.  
1.1 Pre-mRNA splicing 
1.1.1 Structure of pre-mRNAs  
Pre-mRNAs vary greatly in the number of introns they contain and their lengths. The 
yeast genome contains very few introns, namely, less then 250 of more than 6200 genes 
contain an intron (e.g. only 3.8%), and in most cases there is only one intron per gene 
(Ares et al., 1999; Spingola et al., 1999). In contrast, metazoan genes contain on average 
8 introns each (Sakharkar et al., 2004).  
Some pre-mRNAs are spliced constitutively, that is all exons in a single pre-mRNA are 
spliced together in the same way, generating the same mRNA without any sequence 
variation (Will and Lührmann, 2011). When alternative splicing takes place, different sets 
of exons from a single pre-mRNA are spliced together, leading to variable mRNAs. In 
higher eukaryotes, alternative splicing leads to the expansion of the genome by vastly 
amplifying the palette of translated proteins (Black, 2003). It is estimated that 40−60% of 
human transcripts undergo alternative splicing (Fox-Walsh et al., 2005; Modrek and Lee, 
2003). Malfunction/defects in the splicing machinery and its regulation, mutations in 
spliceosome components and cis-acting point mutations (e.g. within splice sites) can lead 
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to a large number of pathological diseases and/or alter their severity level, including 
cancer and neuro-denerative diseases (Cooper et al., 2009; Webb et al., 2013). 
1.1.2 Intron recognition sites  
During splicing, different RNA-protein complexes (snRNPs) bind to the conserved 
sequences of the pre-mRNA, thereby assembling a spliceosome. The splice sites of the 
pre-mRNA are recognized with an astonishingly high level of fidelity. For the recognition 
of the introns, the short conserved intron consensus-sequences are of great importance. 
These consensus-sequences include the 5’ splice site, 3’ splice site and branch point 
sequence (BPS), which is located 18-40 nucleotides upstream from the 3’ splice site 
(Burge et al., 1999) (Fig. 1.1). Generally, consensus sequences in higher eukaryotes are 
less evolutionarily conserved than those in S. cerevisiae (Berget, 1995). There are two 
types of introns in higher eukaryotes, so-called U2- and U12-introns, which are removed 
by two different spliceosomes. The U12-type introns, which are not very abundant (less 
than 1 % of introns in human), have more highly conserved 5’ splice site and branch point 
sequences. U2-type introns contain additionally a pyrimidine-rich region (PPT), which is 
located between the BPS and 3’ splice site (Burge et al., 1999). The consensus sequences 
are recognized during splicing by multiple snRNAs and proteins, ensuring the fidelity of 
splice site definition.  
In addition, other cis-acting pre-mRNA elements also are of importance. These include 
exonic or intronic splicing enhancers (ESEs or ISEs) or silencers (ESIs or ISIs), which 
bind regulatory proteins, enabling the repression or stimulation of spliceosome assembly 
on the pre-mRNA substrate (Wang and Burge, 2008).  
 
Figure 1.1 Consensus sequences of pre-mRNA in yeast and human. Here two exons (coloured 
boxes) are separated by an intron (black line). Consensus sequences are found at the 5´ splice site, 
branch point sequence (BPS) and 3’ splice site. A = adenine, C = cytosine, G = guanine, U = uracil, 
R = purine, Y = pyrimidine, pyrimidine-rich region Y(n). N can be A, U, G or C.  
 
1.1.3 Mechanism of pre-mRNA splicing  
Pre-mRNA splicing is catalysed by a multimegadalton, ribonucleoprotein complex 





Human U2 introns CURAYU Yn
3' splice site
GUAUGU YAGS. cerevisiae U2 introns UACUAACA






reactions (Moore et al., 1993). In the first step, a nucleophilic attack by the 2' hydroxyl 
group of the branchpoint adenosine takes place on the phosphodiester bond at the 5′ 
splice site (5´SS). Via this reaction the pre-mRNA is cleaved, and the 5’ end of the intron 
is connected to the BP adenosine via a 2´-5´-phosphodiester bond, leading to the 
formation of a branched RNA lariat structure (Fig. 1.2). The result is a “free” 5´ exon 
with a 3′ hydroxyl group and a lariat intermediate containing the intron and the 
downstream 3’ exon. During the second step, a nucleophilic attack of the free 3′ hydroxyl 
group of the 5' exon occurs on the phosphodiester bond at the 3' SS (Fig. 1.2). Thereby 
both exons are ligated together via a phosphodiester bond and the excised intron is 
released in the form of a lariat. The lariat intron is then debranched and degraded, 
whereas the spliced mRNA can be transported to the cytoplasm for protein biosynthesis.  
 
 
Figure 1.2 Schematic view of the two-step mechanism of pre-mRNA splicing. In the first step a 
nucleophilic attack of the oxygen of the 2' OH group of the BP adenosine at the phoshodiester bond on 
the 5’ splice site (5´SS) results in the formation of the free 5’ exon and intron-3’ exon intermediates. In 
the second step, a nucleophilic attack of the free 3' OH group of the 5’ exon targets the phosphodiester 
bond at the 3' SS. Both exons are ligated together and the intron is released in the form of a lariat. The 
exons are represented as boxes in different colours, and the intron is shown as a solid line. Invariant 
nucleotides at the exon-intron boundaries and branch point adenosine are indicated. Phosphate groups 
involved in the reactions are indicated by (p). 
 
1.1.4 Composition of the spliceosome 
The precise excision of an intron from the pre-mRNA and the following ligation of its 
exons are catalysed by a dynamic macromolecular machine called the spliceosome. The 
spliceosome consists of five small nuclear ribonucleoprotein particles (snRNPs) that 
assemble on the pre-mRNA substrate in a stepwise manner. The small uridine-rich 
nuclear RNA components of these snRNPs (U snRNAs) build a complicated RNA-RNA 
network and participate in the catalysis of splicing. The proteins of snRNPs and many 
additional non-snRNP proteins assist in splice site recognition and in the stabilization of 
the RNA network.  
There are two distinct types of spliceosomes: the major U2-dependent spliceosome, 
























the minor U12-dependent spliceosome, which is found only in a small set of eukaryotes 
and catalyses the excision of the less abundant U12-type introns (Patel and Steitz, 2003; 
Will and Lührmann, 2005). The minor spliceosome contains the snRNPs U11, U12 
U4atac und U6atac, which are functional analogues of the U1, U2, U4 und U6 snRNPs 
which form the major U2-type spliceosomes. U5 snRNP is a component of both kinds of 
spliceosome.  
1.1.4.1 The snRNAs  
The U1, U2, U4/U6 und U5 snRNPs are the basic integral modular components of the 
major spliceosome, which catalyses the excision of more then 99 % of human introns. 
The spliceosomal snRNPs contain a uridine-rich small nuclear RNA molecule (U1, U2 or 
U5 snRNAs) or two associated uridine-rich small nuclear RNA molecules (U4/U6 di-
snRNA). The snRNAs bind to proteins specific to each snRNP (Fig. 1.3) and also seven 
common Sm proteins (Will and Lührmann, 2006).  
The major human snRNAs are short (106-187 nts) and localized in the nucleus (Will and 
Lührmann, 2001). The snRNAs are folded in a characteristic manner, with stem loop 
structures continually interrupted by single-stranded regions (Fig. 1.3). The U4 and U6 
snRNAs engage in stable base-pairing interactions via stem I and stem II, forming the 
U4/U6 di-snRNA (Guthrie and Patterson, 1988). The snRNAs contain highly conserved 
regions that typically are bound by proteins or interact with other RNAs (Will and 
Lührmann, 1997). A typical attribute of U1, U2, U4 and U5 snRNAs is the presence of a 
conserved Sm-site (Branlant et al., 1982), which is the binding site for the seven Sm-
proteins that are present in all snRNPs. The Sm proteins (B/B´, D1, D2, D3, E, F, G) are 
found in all major U snRNPs except for U6 snRNP, and are important for snRNP 
biogenesis (Kambach et al., 1999). The U6 snRNP contains seven Sm-like (Lsm) proteins 
instead, which bind the 3’end of U6 snRNA (Achsel et al., 1999).  
U snRNAs contain posttranscriptional chemical modifications, including site‐ specific 
pseudouridine () formation and 2'-O-methylation (Reddy and Busch, 1983). These are 
often found on extremely well-conserved nucleotides of the snRNAs, such as the branch 
site recognition region of vertebrate U2 snRNA (Massenet et al., 1998) and can be 
important for U snRNA function (Yu et al., 1998). 
The spliceosomal U1, U2, U4 and U5 snRNAs are transcribed in the nucleus by RNA 
polymerase II and, after m7G capping, are transported to the cytoplasm, where the seven 
Sm proteins assemble onto the conserved Sm site of the snRNA, forming the so-called 
Sm core (Will and Lührmann, 2001). The Sm proteins build a heptameric ring structure, 
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and formation of the Sm-core is a pre-requisite for the subsequent cap-hypermethylation 
(Mattaj, 1986), 3´-end-„trimming“ (Seipelt et al., 1999), subsequent re-import to the 
nucleus (Fischer et al., 1993) and final association with snRNP-specific proteins 
(Nelissen et al., 1994). 
 
Figure 1.3 Sequences and predicted secondary structures of the human spliceosomal 
snRNAs. The Sm-sites are indicated as black boxes. 
 
In the next step of snRNP biogenesis, the 5′‐ monomethylated guanosine cap (m7GpppN) 
is converted into a 2,2,7-trimethylguanosine cap structure (m3
2,2,7GpppN), and the RNA–
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where particle-specific proteins bind to the snRNP. Finally, the association of particle-
specific proteins is the last step in the maturation of snRNPs. In contrast, the U6 snRNA 
is transcribed by RNA Polymerase III and contains a γ-monomethyl triphosphate cap. The 
U6 snRNA does not contain an Sm site and associates instead with seven Sm-like 
proteins (LSm2-8), which bind to its 3' end and form a heptameric ring structure (Achsel 
et al., 1999; Seraphin, 1995). The U6 snRNP undergoes all of its maturation steps 
exclusively in the nucleus (Will and Lührmann, 2001). 
1.1.4.2 snRNP-specific proteins 
Each spliceosomal U snRNP also contains a set of particle-specific proteins (Fig. 1.4). 
The snRNP-specific proteins play essential roles during spliceosome assembly and the 
catalytic steps of splicing (Fig. 1.4). The 12S U1 snRNP contains three U1 snRNP-
specific proteins (U1-C, U1-A and U1-70K) (Will and Lührmann, 2006), and U1-C and 
U1-70K aid the association of the U1 snRNA with the 5’ splice site (Heinrichs et al., 
1990). The functionally active 17S U2 snRNP contains at least twelve U2 snRNP-specific 
proteins. First the U2-A` and U2-B`` proteins bind to stem loop IV of U2 snRNA as a 
dimer and build up the 12S U2 snRNP. The heteromeric splicing factors SF3b and SF3a 
bind successively to the 12S U2 snRNP, creating the 17S U2 snRNP (Brosi et al., 1993a). 
U2-related proteins also associate with the U2 snRNP, but dissociate at salt 
concentrations above 250 mM (Will et al., 2002). The SF3a complex consists of 3 
subunits with molecular weights of 120, 66 and 60 kDa (Brosi et al., 1993b), whereas the 
SF3b complex consists of seven subunits (SF3b155, SF3b145, SF3b130, SF3b49, p14, 
SF3b14b and SF3b10) (Will et al., 2002). SF3a and SF3b facilitate the interaction 
between U2 snRNP and the BPS, enabling the formation of spliceosomal complex A 
(Gozani et al., 1996; Kramer and Utans, 1991).  
The 20S U5 snRNP consists of eight U5-specific proteins (Bach et al., 1989; Behrens and 
Lührmann, 1991). The largest, highly conserved U5 protein is 220K/hPrp8, which is 
present at the catalytic core of the spliceosome. It has been shown to interact with other 
U5 snRNP proteins, namely, the GTPase 116K/Snu114 and the DExD/H box helicase 
200K/Brr2 (Achsel et al., 1998) and to cross-link with the pre-mRNA substrate at all 
catalytically important sites (5′ SS, 3′ SS, BP), as well as with U5 and U6 snRNAs (Galej 
et al., 2014; Grainger and Beggs, 2005). 200K/Brr2 is an integral U5 snRNP component, 
catalysing unwinding of the U4/U6 di-snRNA duplex during the spliceosome activation 
step. 100K/Prp28 activity displaces the U1 snRNP from the 5′ splice site (Mohlmann et 




Figure 1.4 Composition of the major spliceosomal U snRNPs. The major spliceosome consists 
of U1, U2, U4/U6 and U5 snRNPs. Each snRNP consists of one (or two) snRNA molecules and 
different numbers of complex-specific proteins. The secondary structure of the human U snRNAs is 
shown schematically. The protein composition of the U snRNPs is shown in boxes of different colour. 
The U4/U6.U5 tri-snRNP is composed of U5 and U4/U6. Sm/Lsm proteins are shown in black boxes.  
 
The 13S U4/U6 di-snRNP contains both LSm and Sm proteins, and 5 specific proteins: 
90K/Prp3, 61K/Prp31, 60K/Prp4, 20K (also known as CypH) and 15.5K/Snu13 (Behrens 
and Lührmann, 1991; Lauber et al., 1997). 
The 25S U4/U6.U5 tri-snRNP consists of the 13S U4/U6 di-snRNP and 20S U5 snRNP 
plus three additional proteins: 110K/Snu66, 65K/Sad1 and 27K (Behrens and Lührmann, 
1991; Lauber et al., 1997). However, the U5-52K protein dissociates upon formation of 
tri-snRNP (Laggerbauer et al., 2005). The U4/U6.U5 tri-snRNP contains two sets of Sm 
proteins and one set of LSm proteins (Achsel et al., 1999; Salgado-Garrido et al., 1999). 
U4/U6-61K/hPrp31 and U5-102K/hPrp6 play a key role in the U4/U6.U5 tri-snRNP 
formation, interacting with each other and thus formating a bridge between the two 
particles (Makarova et al., 2002; Schaffert et al., 2004).   
1.1.5 Spliceosome assembly 
The spliceosome is a highly dynamic RNP machine (Wahl et al., 2009), and assembles on 
the pre-mRNA substrate in a stepwise manner. The spliceosome undergoes dynamic 
structural and compositional rearrangements, bringing the reactive sites of the pre-mRNA 




Figure 1.5 The spliceosome cycle. Spliceosome assembly is activated by the interaction of the U1 
snRNP with the 5’ splice site (complex E). Complex A formation occurs by stable binding of the U2 
snRNP with the BPS. Incorporation of the pre-formed tri-snRNP (complex B) is followed by structural 
rearrangements, including U1 and U4 release, and the spliceosome becomes catalytically active after 
the action of Prp2. The first transesterification reaction results in the formation of complex C. After the 
second transesterification reaction, the mature mRNA and the lariat-intron are released. The 
spliceosomal components dissociate and are regenerated for the next round of splicing.  
 
Native electrophoresis, affinity selection and glycerol gradient centrifugation revealed 
distinct spliceosome assembly stages that form via the sequential association and release 
of spliceosomal snRNPs (Will and Lührmann, 2006) (Fig. 1.5), as well as distinct 
complexes formed during the catalytic steps of splicing and during spliceosome 
dissociation. The initial step of spliceosome assembly occurs when the U1 snRNP binds 
to the 5' SS of an intron in an ATP-independent manner. The base-pairing interaction of 
the 5' end of the U1 snRNA with the 5' SS (Ruby and Abelson, 1988; Seraphin et al., 
1988) is stabilized in higher eukaryotes by members of the SR protein family and U1 
snRNP-associated proteins (Will and Lührmann, 1997). The SF1/BBP protein binds to 
the BPS and U2AF65 (U2 auxiliary factor) binds to the polypyrimidine sequence (PPT) 
(Reed, 1996). Furthermore, the AG-dinucleotide of the 3‘ SS is bound by the U2AF 
subunit U2AF35, which is tightly bound by U2AF65. These molecular interactions play a 
decisive role during the initial recognition of the 5’ SS and 3’ SS of an intron and lead to 







































































snRNA undergoes the ATP-dependent base pairing interaction with the BPS of the pre-
mRNA, driven by the helicases UAP56 and hPrp5 (Zhang and Green, 2001), resulting in 
the formation of complex A. The branch site adenosine is bulged out, and thus prepared 
for its nucleophilic attack during the first catalytic step (Query et al., 1994). The U2/BP 
interaction is stabilized by the U2 snRNP-associated heteromeric protein complexes SF3a 
and SF3b, which contact the pre-mRNA at or close to the branch site (Gozani et al., 1996; 
Will and Lührmann, 2001). The formation of complex B occurs when the U4/U6 and U5 
snRNPs, as a pre-formed U4/U6.U5 tri-snRNP, associate. Even though all snRNPs are 
present in complex B, this complex remains catalytically inactive and needs significant 
compositional and conformational rearrangements for its activation. Prior to catalytic 
activation, the DEAD-box helicase hPrp28 catalyses the release of U1 from the 5'SS of 
the pre-mRNA (Staley and Guthrie, 1999). Subsequently, the helicase Brr2 catalyses 
unwinding of the U4/U6 base pairing interaction (Laggerbauer et al., 1998; Raghunathan 
and Guthrie, 1998). This allows U6 snRNA to base pair with the 5' SS and the U2 
snRNA, bringing the 5' SS and the BP sequence near to each other for the first step of 
splicing, and also to form an internal stem-loop (U6 ISL) which is important for splicing 
catalysis. In this way, the U1 and U4 snRNPs are destabilized, and the activated 
spliceosome Bact is generated. Thereby, U5 snRNA contacts the nucleotides near the 5' 
SS. The action of the DEXH/D-box helicase Prp2 leads to the destabilization of U2 
proteins from the BPS (Kim and Lin, 1996; Warkocki et al., 2009), resulting in the 
formation of the catalytically active complex B*, which is able to perform the first step of 
splicing, thereby creating complex C. The spliceosome undergoes further conformational 
rearrangements catalysed by the helicase Prp16 (Schwer and Guthrie, 1992). After 
catalysing the second step of splicing, a post-spliceosomal complex is formed. The post-
spliceosomal complex dissociates and the mRNA is released in the form of an mRNP, 
catalysed by the RNA helicase Prp22. Finally, U2, U5 and U6 snRNPs can be recycled to 
be used in the next round of splicing. The intron, in the form of a lariat, is also released 
by the action of the helicase Prp43 (Martin et al., 2002), debranched by Dbr1-catalysed 
hydrolysis of the 2'-5' phosphodiester bond (Chapman and Boeke, 1991), and is finally 
degraded. For each intron to be spliced, the spliceosome is assembled de novo. 
1.1.5.1 Exon definition, an alternative early assembly pathway 
The length of an intron determines if the initial assembly of the spliceosome occurs 
across an intron or across an exon. An intron length of 200 to 250 nucleotides ensures 
splice site recognition by spliceosome components initially across an intron (Fox-Walsh 
et al., 2005). When introns are longer (i.e. exceed 250 nts) splice sites are recognized 
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across an exon (Berget, 1995), which is the case for most pre-mRNAs in higher 
eukaryotes (Fox-Walsh et al., 2005). During exon definition, U1 snRNP binds the 5' SS 
downstream of an exon and U2 snRNP binds the BPS upstream of it, (first initiated by the 
association of U2AF with the PPT and the 3' SS). The proteins of the SR family bind ESE 
sequences, stabilizing the exon-defined complex (Hoffman and Grabowski, 1992; Reed, 
2000). Subsequently, these cross-exon interactions are replaced by cross-intron 
interactions, a process that is not well understood. For some pre-mRNAs, this step is 
decisive in determining if an exon is included or skipped during the spliceosome cycle 
(Sharma et al., 2008). After the B complex stage, the cross-exon and cross-intron 
assembly pathways are the same. 
 
Figure 1.6 Cross-exon definition. U1 snRNP binds the 5' SS downstream of an exon and U2 
snRNP binds the BPS upstream of it, initiated by the association of U2AF with the PPT and the 3' SS. 
SR proteins interact with an exonic splicing enhancer (ESE). Subsequently, the exon-defined complex 
is replaced by a complex with cross-intron interactions.  
1.1.6 RNA-RNA interactions in the spliceosome 
During spliceosome assembly and catalysis, a highly complicated, dynamic RNA-RNA 
network is formed (Nilsen, 1994; Will and Lührmann, 2011). At the initial stage of 
spliceosome assembly, the U1 snRNA undergoes base-pairing interactions with exon and 
intron nucleotides at the 5´SS of the pre-mRNA (5´SS-recognition) (Zhuang and Weiner, 
1986) and the U2 snRNA base-pairs with the BPS (Parker et al., 1987; Wu and Manley, 
1989) (Fig. 1.6). Thereby, a short U2 snRNA/pre-mRNA-duplex is formed, and as a 
result the BPS-adenosine is bulged out, freeing its nucleophilic 2′ hydroxyl group for the 
first transesterification reaction at the 5’ SS. After U4/U6.U5 tri-snRNP association, the 
5’ end of U2 snRNA base pairs with the 3’ end of U6 snRNA, forming U2/U6 helix II 
(Madhani and Guthrie, 1992). The nucleotides of U6 snRNA form important regions of 
the spliceosome’s active centre. However, at the beginning of the splicing cycle they 
remain inactive, forming within the U4/U6.U5 tri-snRNP and in complex B, two 











Guthrie, 1988; Rinke et al., 1985). Upon integration of the tri-snRNP, the stem loop I of 
U5 snRNA interacts with exon nucleotides near the 5´SS.  
During activation of the spliceosome, U1 snRNA is destabilized from the 5´SS of the pre-
mRNA by Prp28 (Staley and Guthrie, 1999) and subsequently replaced by the 5′ end of 
U6 snRNA, which builds the base pair interactions with intron nucleotides at the 5´SS via 
the conserved ACAGAG box sequence (Sawa and Abelson, 1992). This interaction is 
important for 5’ SS recognition during the first step of splicing (Fabrizio and Abelson, 
1990; Lesser and Guthrie, 1993). The U4/U6 duplex is disrupted by Brr2 (Laggerbauer et 
al., 1998; Raghunathan and Guthrie, 1998; Staley and Guthrie, 1999), and after U4 
snRNP release, short U2/U6-duplexes are formed, which are called helix Ia and helix Ib, 
which bring the 5' SS and BPS into close proximity for the first step of splicing (Fig. 1.7). 
The U2/U6 interaction can potentially form a structure corresponding to a 3-way junction. 
However, an alternative model for the U2/U6 interaction (a 4-way junction) was also 
proposed (Sun and Manley, 1995). In this model helix Ib is not formed, and instead the 
U6 nucleotides AGC are involved in the formation of a prolonged U6 ISL, whereas the 
U2 snRNA forms an additional stem loop 1 (SL1). Taking into account the highly 
dynamic nature of the RNA-RNA network, both conformations are possible, but recent 
studies showed that in human spliceosome a 3-way U2/U6 junction is formed (Anokhina 
et al., 2013).  
 
Figure 1.7 Dynamic RNA-RNA network in the spliceosome. Exon sequences are highlighted as 
grey boxes and the intron sequence as a black line. Secondary structures of snRNA are shown 
schematically in grey or black, and the regions involved in base-pair interactions (short lines) are 
shown in different colours. The 5´ end of an snRNA is labelled as a black dot. Solely loop I of the U5 
snRNA is shown. During the transition of a pre-catalytic (left) to the catalytically activated 
spliceosome (right), U1 and U4 leave, and U6 and U2 are involved in new base-pair interactions. This 























Release of U4 from U6 also leads to U6 snRNA re-folding such that the intra-molecular 
stem loop (U6-ISL) is formed. This ISL is extremely important for splicing catalysis, 
being involved in the positioning and mediating of metal ion binding (McManus et al., 
2007; Yean et al., 2000).  
After the first transesterification reaction, the spliceosome has to be further re-organized, 
to position the 3´ SS and the 5´ SS in close proximity for the second transesterification 
reaction (Smith and Konarska, 2008; Staley and Guthrie, 1998). The exact temporal 
coordination of these rearrangements and the conformation of RNA-RNA-interactions at 
this stage are still not well understood. Prior to the second transesterification reaction, U5 
contacts exon nucleotides downstream of the 3´SS and binds the 5´ exon to the 
spliceosome after the first transesterification reaction. Moreover, it brings both exons 
close to each other for the second catalytic step (Turner et al., 2004). Currently, 
information about the nature and dynamics of RNA tertiary interactions in the 
spliceosome is not clearly understood.  
The yeast U2 snRNA toggles between two intra-molecular conformations, forming helix 
IIc, created from base pairing between loop nucleotides of U2 stem loop IIa and 
nucleotides downstream of stem loop IIb (Hilliker et al., 2007; Perriman and Ares, 2007). 
This stem IIc is relevant for the first step of splicing, and the refolding back to stem loop 
IIa is important for the second step of splicing. In humans, the formation of U2 helix IIc 
was thus far not detected (Anokhina et al., 2013). 
1.1.7 RNA-based catalysis of pre-mRNA splicing 
Nuclear pre-mRNA introns and the spliceosomal snRNAs are unable to form a 
catalytically active structure in the absence of spliceosomal proteins. In spite of the 
necessity of numerous proteins for catalytic activation, much evidence indicates that the 
spliceosome is a ribozyme, i.e. the transesterification reactions are catalysed by snRNA 
components of the spliceosome, foremost U2 and U6.  
Group II self-splicing introns share common features with nuclear pre-mRNAs such as 
consensus sequences at the 5’ SS, 3’ SS and branch point sequence, but some use water 
for the first nucleophilic attack. This similarity in mechanism and structure gave rise to 
the hypothesis that pre-mRNA introns and the spliceosomal snRNAs were evolutionary 
related to the group II self-splicing introns and therefore that pre-mRNA splicing is 
catalysed by RNA (Cech, 1986; Jacquier and Michel, 1990; Madhani, 2013; Sharp, 
1985). Moreover, it was shown that both catalytic splicing reactions can be reversible 
under appropriate conditions, demonstrating further similarity between the splicing 
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mechanisms of these two types of introns (Tseng and Cheng, 2008). Furthermore, it was 
shown that U6 and U2 snRNAs are able to catalyse a splicing-related reaction with pre-
mRNA-like substrates even in the absence of proteins (Valadkhan et al., 2007). 
The crystal structure of a self-splicing group II intron from the alkaliphile Oceanobacillus 
iheyensis revealed a bulge-containing catalytic domain V in the ribozyme core, as well as 
a conserved catalytic triad coordinating two divalent metal ions. The structural 
similarities of the intramolecular stem loop of the U6 snRNA (U6 ISL) with the AGC 
catalytic triad were previously noted and evidence was provided that the U6 ISL also 
coordinates a metal ion (Yean et al., 2000). The divalent metal ions are bound by the U6 
ISL in a manner similar to that of domain V of group II intron RNA, strongly suggesting 
evolutionary similarity between pre-mRNA splicing and the self-splicing of group II 
introns, including a two–metal ion catalytic mechanism (Toor et al., 2008).  
Recently, the RNA-based catalysis of pre-mRNA splicing was verified, namely, the U6 
snRNA was shown to drive both transesterification reactions by binding and positioning 
two divalent metal ions (Fica et al., 2013). These metal ions are thought to stabilize the 
leaving groups of both splicing reactions. The five catalytic metal ligands identified in the 
U6 snRNA structure correspond exactly to the ligands mediating catalytic divalent metal 
ions in crystal structures of a group II intron RNA. Thus, the group II introns and the 
spliceosome appear to use the identical RNA-driven catalytic mechanisms, strongly 
suggesting that they originate evolutionarily from a common ancestor (Fica et al., 2013). 
The crystal structure of yPrp8, which is a component of the U5 snRNP and is located in 
the catalytic centre of the spliceosome, revealed domains that were suggested to 
contribute to the formation of spliceosome’s catalytic core, that resemble catalytic 
cofactors of group II introns (Galej et al., 2014). Thus, Prp8 may contribute in some way 
to the catalytic core of the spliceosome. 
 1.1.8 Protein composition of the spliceosome 
Proteins account for the largest share of the spliceosome’s mass, and play important roles 
in the splicing process. The spliceosomal proteins enable and stabilize the dynamic RNA-
RNA and RNA-protein interactions important for splice site recognition (Will and 
Lührmann, 2006). They enable all conformational and structural rearrangements needed 
for the catalytic activity of the spliceosome, mediating the organization of the catalytic 
centre for catalysis. More then 170 spliceosome-associated proteins were identified in 
affinity-purified, human major spliceosomal complexes by mass spectrometry analysis, 
whereas the individual complexes (i.e. B, Bact, C) contain ~ 120 of the various proteins 
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(Wahl et al., 2009). The spliceosomal proteome contains U snRNP-associated proteins, as 
well as a large amount of non-snRNP proteins. Some of them interact with the 
spliceosome as individual proteins and the others are components of pre-formed 
subcomplexes.  
1.1.8.1 non-snRNP spliceosomal proteins 
Aside from snRNP proteins (see 1.1.4.2) a notable number of non-snRNP factors are 
associated with the spliceosome during the course of splicing (Wahl et al., 2009), 
including SR, hnRNP proteins and DExD/H-box RNA helicases. Members of the 
serine/arginine (SR)-rich protein family share common structural features, such as one or 
more amino-terminal RNA recognition motif(s) (RRMs) and a variable number of 
arginine/serine (RS) repetitive dipeptides in their carboxy-terminal domain (Birney et al., 
1993; Graveley, 2000; Long and Caceres, 2009). Therefore, these proteins can interact at 
the same time with both RNA via their RRM domains and with other proteins via their 
RS domain (Graveley and Maniatis, 1998). For example, the recognition of exonic 
splicing enhancer (ESEs) regions of a pre-mRNA by SR proteins promotes spliceosome 
assembly at adjacent splice sites. SR proteins can also promote snRNP interactions with 
the pre-mRNA such as stabilisation of the U1/5′SS base pairing interaction at the initial 
stage of splicing assembly and thus modulate alternative splicing events (reviewed in 
Graveley, 2000). RS domains are also found in non-SR proteins, for instance, in U2AF-
subunits (Zamore et al., 1992).  
Most hnRNP proteins have RRMs and glycine-rich domains (RG) and also regulate 
alternative splicing. They bind to exonic splicing silencer (ESS) elements of the pre-
mRNA and impede/obstruct exon recognition by hindering the use of neighboring splice 
sites. HnRNP proteins counteract the positive regulators of splicing and/or recruit factors 
that block splicing, thereby initiating splicing repression/silencing (Smith and Valcarcel, 
2000). 
Another functionally important group of non-snRNP proteins is composed of the 
spliceosomal DExD/H-box RNA helicases (Unwindases/RNPases), which are the driving 
forces for all of the structural remodelling events taking place at different stages of 
spliceosome assembly or disassembly (Staley and Guthrie, 1998). These proteins include 
Sub2/UAP56, hPrp5, hPrp28, hBrr2, hPrp2, hPrp16, hPrp22 and hPrp43. They possess 
evolutionary conserved amino acid sequence motifs, which are essential for their 
functionality. These proteins modulate the structure and the function of specific RNAs 
and/or RNPs at different stages of spliceosome assembly (Rocak and Linder, 2004), by 
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catalysing the unwinding of RNA-RNA base pair interactions and/or RNA-proteins 
interactions, which allows the RNAs to partake in new interactions (Pyle, 2008; Staley 
and Guthrie, 1998). In this way, they enable structural rearrangements of the spliceosome, 
using the energy of ATP hydrolysis. They also facilitate the discard of non-productive 
splicing intermediates ensuring the fidelity of pre-mRNA splicing (Koodathingal and 
Staley, 2013). The aforementioned eight spliceosomal helicases are evolutionarily 
conserved between yeast and humans.  
The DEAD-box helicases Prp5 and Sub2/UAP56 function during pre-spliceosome 
formation. Sub2/UAP56 catalyses the displacing U2AF and/or BPP from the BPS 
promoting the addition of U2 snRNP to the spliceosome (Kistler and Guthrie, 2001). Prp5 
facilitates the stable binding of the U2 snRNP to the BPS (Xu and Query, 2007). The 
DEAD-box protein Prp28 and the DExD/H-box helicase Brr2 play key roles in the 
structural rearrangements of the spliceosome prior to/during activation of the spliceosome 
and are integral components of the U5 snRNP and the spliceosome. Prp28 catalyses the 
release of U1 snRNA from the 5' SS (Staley and Guthrie, 1999), apparently by 
dissociation of U1-C from the 5' SS (Chen et al., 2001). In humans, the phosphorylated 
form of Prp28 is necessary for its association with the tri-snRNP and the subsequent 
integration of the tri-snRNP into the spliceosome during B complex formation (Mathew 
et al., 2008). Brr2 catalyses the unwinding of the U4/U6 di-snRNA base pair interactions 
during spliceosome activation, and its activity is regulated by Prp8 and the GTPase 
Snu114 (Mozaffari-Jovin et al., 2013; Small et al., 2006). 
Prp2 promotes a poorly understood rearrangement that converts the Bact complex into the 
B* complex prior to the first step of splicing (Warkocki et al., 2009). Prp16 facilitates 
conformational changes required for the second step of splicing, which have been poorly 
investigated up to now. Subsequently, Prp22 acts during the second step of splicing, and 
is needed for the release of the spliced mRNA (Company et al., 1991). Prp43 is necessary 
for the release of the excised lariat-intron from the post-splicing complex, which is 
accompanied by release of U2, U5 and U6, promoting the final disassembly of the 
spliceosome (Fourmann et al., 2013; Martin et al., 2002).  
The human hPrp19/CDC5L complex (in yeast, NineTeen Complex, NTC) consists of the 
Prp19 protein and a number of other splicing factors that are stably recruited to the 
spliceosome during activation and remain associated during both catalytic steps 
(Bessonov et al., 2008; Makarov et al., 2002; Makarova et al., 2004). The NTC complex 
stabilizes the association of U5 and U6 with the spliceosome after release of U4 (Chan 
and Cheng, 2005; Chan et al., 2003). An additional group of hPrp19/CDC5L-related 
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proteins was shown to associate with Prp19/CDC5L complex (Deckert et al., 2006). 
hPrp19/CDC5L complex proteins interact with U5 snRNP during the activation step and 
remain associated during both catalytic steps. They are present in the RNP core of the C 
complex even after treatment with 1M NaCl (Bessonov et al., 2008). They have been 
detected in the 35S U5 snRNP that is proposed to be a dissociation product of a post-
spliceosomal, intron-containing complex (Makarov et al., 2002).  
A group of Bact-specific proteins consisting of KIAA1604, Prp17, hPrp2, GPKOW, 
MGC20398, PPIL2, MGC23918, NY-CO-10, RNF113A and FRG1 as well as a group of 
proteins previously detected in Bact complex associate with the spliceosome stably during 
Bact complex formation, but they appear to be destabilized during the Bact to C transition 
(Bessonov et al., 2010). These proteins appear to be required during the activation of the 
spliceosome, however, the role of these proteins in the splicing is not well understood. 
The pre-mRNA retention and splicing (RES) complex consists of the Snu17, Bud13 and 
Pml1 proteins, and acts prior to the first step of splicing in yeast (Dziembowski et al., 
2004). During splicing in yeast, it is essential for the retention of unspliced pre-mRNAs 
in the nucleus (Dziembowski et al., 2004). 
1.1.8.2 Dynamics of the spliceosome’s protein composition 
Mass spectrometry analysis of purified spliceosomes confirms that the protein 
composition of the spliceosome is highly dynamic, with extensive exchanges of proteins 
from one splicing step to another (Behzadnia et al., 2007; Bessonov et al., 2008; Deckert 
et al., 2006; Fabrizio et al., 2009). The human spliceosomal A complex consists of U1, 
U2 snRNPs and about 50 non-snRNP proteins (Behzadnia et al., 2007), several of which 
dissociate during the transition from the A to B complex. The human B complex contains 
in addition to U1 and U2 proteins, the U4/U6.U5 tri-snRNP proteins, B-specific proteins, 
and low amounts of the hPrp19/CDC5L complex and related proteins and proteins of the 
mRNA retention and splicing (RES) complex (Deckert et al., 2006). During the B to Bact 
transition, about 30 proteins leave the spliceosome (Bessonov et al., 2010) (Fig. 1.8), 
including U1 and U4/U6 associated proteins, whereas about 25 other proteins incorporate, 
such as Bact-specific proteins, including the hPrp2 helicase required for catalytic 
activation. The hPrp19/CDC5L complex proteins and related proteins are stabilized at 
this stage and present in stochiometric amounts in Bact, thereby the U5 snRNP undergoes 
remarkable remodelling generating a 35S form of the U5 snRNP (Makarov et al., 2002). 
During transition from the Bact to C complex, SF3a and SF3b proteins are destabilized 
both in yeast and humans (Bessonov et al., 2008; Fabrizio et al., 2009; Warkocki et al., 
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2009), suggesting these proteins are no longer required after the first step of splicing. Bact-
specific proteins are also underrepresented in the C complex. At the same time about 20 
proteins are recruited to the spliceosome at this stage, including the group of C-complex 
specific proteins, and step II factors required prior to or during the second step of 
splicing, and the exon junction complex (EJC) (Bessonov et al., 2010; Bessonov et al., 
2008) (Fig. 1.8). The exon junction complex (EJC) is deposited onto mRNA during 
splicing and is transported to the cytoplasm, regulating the cytoplasmic metabolism of 
spliced mRNAs. In particular, it modulates translational efficiency, detection of target 
mRNAs for the nonsense-mediated decay pathway, and assists in the localization of the 
spliced mRNA (Bono et al., 2006). Interestingly, C complexes treated with high salt 
reveal an RNP core consisting of only ∼35 proteins, including Prp19/CDC5L proteins 
and Prp19-related factors, and U5 proteins such as Prp8 (Bessonov et al., 2008), 
indicating these proteins play important roles in maintaining the catalytically active RNA 
network of the spliceosome. 
Fewer proteins were identified in yeast spliceosomal complexes compared to human 
complexes; however, nearly all of these proteins are evolutionarily conserved (Fabrizio et 
al., 2009). Many of the proteins identified in human but not found in the yeast 
spliceosome, are thought to be required for alternative splicing, which is absent in yeast. 
The large exchange of proteins observed during spliceosome assembly and activation is 
evolutionarily conserved in both human and yeast (Bessonov et al., 2008; Deckert et al., 
2006; Fabrizio et al., 2009). 
1.1.9 Posttranslational modification of proteins during splicing 
Some spliceosomal proteins undergo posttranslational modification such as reversible 
phosphorylation, which is involved in the regulation of spliceosome assembly. The 
phosphorylation of hPrp28 is essential for the stable integration of the U4/U6.U5 tri-
snRNP during formation of the B complex, with hPrp28 phosphorylated by the kinase 
SRPK2 (Mathew et al., 2008). The tri-snRNP proteins Prp6 and Prp31 are phosphorylated 
by Prp4 kinase in human and this phosphorylation has been proposed to be necessary for 
stable tri-snRNP binding (Schneider et al., 2010). Dephosphorylation of the U1-70K 
protein (Tazi et al., 1993) and SR proteins (Cao et al., 1997) is required for the 1st step in 
mammals. The U2-associated SF3b155 protein is phosphorylated before or at the time of 
the first catalytic step (Wang et al., 1998) and dephosphorylated during the 2nd step of 




Figure 1.8 Compositional dynamics of the human spliceosomal complexes B, Bact, and C. 
Protein composition of human B, Bact, and C spliceosomal complexes detected by mass spectrometry is 
shown. Proteins are grouped according to their function or association with an snRNP, protein complex 
or spliceosomal complex. The relative abundance of the proteins is indicated by light 
(substoichiometric amounts) or dark (stoichiometric amounts) lettering. This figure was kindly 
provided by Dr. S. Bessonov.  
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Additionally, some spliceosomal proteins undergo ubiquitination (Bellare et al., 2008), 
which appears to be required to prevent the premature unwinding of U4/U6 in the tri- 
snRNP (Bellare et al., 2006). The ubiquitination of Prp8 is proposed to facilitate the 
regulation of U4/U6 unwinding during catalytic activation, and U2/U6 unwinding during 
spliceosome disassembly (Bellare et al., 2008) via modulating Brr2 activity.  
1.1.10 Structure of the spliceosome and spliceosomal snRNPs 
The structure of the spliceosome has been intensively investigated for many years. 
However, the determination of the structure of the spliceosome at the atomic level 
appears to be a very challenging task. The most obvious obstacles here are the highly 
dynamic nature and complex composition of the spliceosome. X-ray crystallography and 
NMR analyses have been restricted to particular snRNPs and spliceosomal proteins, alone 
or in complex with RNA or their protein interaction partner (Ritchie et al., 2009). These 
studies provide structural information with high resolution, which can be used to localize 
proteins or protein domains in the lower resolution structures obtained from EM studies. 
At present, structural features of the whole spliceosome can be visualized only by EM. 
Electron microscopy is a powerful tool to study the architecture and morphology of 
spliceosomal snRNPs and their components. The resolution of the spliceosome is mainly 
limited by the heterogeneity of the spliceosomal complexes, their instability, and by the 
damage caused to the spliceosome particles during purification and preparation for cryo-
EM. The GraFix method (Kastner et al., 2008) allowed the stabilization of the individual 
particles by mild chemical fixation during the centrifugation step prior to visualization 
resulted in the significant improvement of quality of samples destined for electron 
microscopy. Low resolution (∼12–40 Å) 3D structures of the human spliceosomal 
snRNPs and spliceosomal complexes include the U1 snRNP (Stark et al., 2001), U2-
associated SF3b subcomplex (Golas et al., 2003, 2005), U4/U6.U5 tri-snRNP and its 
components (Sander et al., 2006) and are shown in Figure 1.9. Additionally, 3D structures 
of endogenous yeast and human splicing complexes have been reported (Azubel et al., 
2004; Ohi et al., 2007). Furthermore, 3D structures of the human complexes A, C and 
B∆U1 have been obtained (Behzadnia et al., 2007; Boehringer et al., 2004; Golas et al., 
2010). Recently, EM techniques have been greatly improved, including enhanced quality 
of the spliceosome preparation, chemical fixation and computational processing and 
refinement methods, allowing a much higher level of resolution. Single-particle cryo-
electron microscopy is the most promising method to study the higher-order structure of 




Figure 1.9 The currently available EM 3D structures of the spliceosome and spliceosomal 
components. From the left to the right: U1 snRNP, SF3b, U11/U12 di-snRNP, U5 snRNP, U4/U6.U5 
tri-snRNP, BΔU1 spliceosome, C complex (adapted from Lührmann and Stark, 2009).  
 
Different labeling techniques can be applied to localize individual components in the 
whole spliceosome structure (Lührmann and Stark, 2009), extending the information 
obtained from EM structures with low to moderate resolution. These include labeling 
with antibodies and introducing tags into spliceosomal proteins. For example, genetic 
tagging was applied to map the position of key proteins in the yeast tri-snRNP (Hacker et 
al., 2008) and/or U6 snRNP.  
2D EM views of various spliceosomal complexes purified under physiological conditions 
from human, D. melanogaster and S. cerevesiae have also been reported (Deckert et al., 
2006; Fabrizio et al., 2009; Herold et al., 2009). Single-particle cryo-electron microscopy 
analysis of B, Bact, and C complexes has confirmed remarkable morphological differences 
between these complexes (Fabrizio et al., 2009), which is consistent with the large 
compositional changes occurring at each stage of spliceosome assembly.  
1.1.11 Small molecule inhibitors of pre-mRNA splicing 
There is a growing interest in identifying small molecules that inhibit splicing. Small 
molecule inhibitors of pre-mRNA splicing can be used to stall spliceosomes at distinct 
and more defined stages of the spliceosome assembly, and thus potentially obtain more 
homogeneous/stabilised populations of spliceosomes for structural and functional studies 
of pre-mRNA splicing. Alternatively, they could potentially block splicing at a novel 
stage revealing new assembly intermediates of the spliceosome.  
At present, only a limited number of inhibitors of pre-mRNA splicing have been 
identified. For example, the selective chelator of zinc, 1,10-phenanthroline causes a dose-
dependent inhibition of the second step of pre-mRNA splicing in vitro (Shomron et al., 
2002). Spliceostatin A (SSA), a methylated derivative of the natural chemical product 
FR901464, was reported to inhibit pre-mRNA splicing at submicromolar concentrations 
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by non-covalent interaction with the U2 snRNP associated SF3b protein complex (Kaida 
et al., 2007). During the A to B complex transition/conversion, SSA prevents the proper 
interaction of the SF3b155 protein with pre-mRNA, resulting in the unstable, non-
productive base-pairing interaction between the U2 snRNA and sequences 5’ of the BPS 
(Corrionero et al., 2011; Roybal and Jurica, 2010). Another structurally related 
compound, pladienolide D (Kotake et al., 2007; Yokoi et al., 2011), was also found to 
inhibit pre-mRNA splicing by binding to the SF3b protein complex. The synthetic 
derivative of pladienolide D, compound E7107, was shown to prevent stable binding of 
U2 snRNP to the pre-mRNA, abolishing the ATP-dependent remodelling event in U2 
snRNP that exposes the branch point binding region (Folco et al., 2011). Recently, 
another synthetic analogue of FR901464 and derivative of SSA, sudemycin E, was shown 
to bind to SF3b155 and to induce U2 snRNP dissociation, and it altered alternative 
splicing events (Convertini et al., 2014). In addition, the natural product isoginkgetin was 
reported to inhibit splicing, presumably by preventing stable recruitment of the U4/U5/U6 
tri-snRNP, resulting in accumulation of the pre-spliceosomal A complex (O'Brien et al., 
2008). Moreover, cardiotonic steroids were identified to be alternative splicing 
modulators (Stoilov et al., 2008). Several small-molecule inhibitors of protein 
acetylation/deacetylation were found to block the splicing cycle in vitro at distinct stages; 
these include three small-molecule inhibitors of histone acetyltransferases (HATs), as 
well as three small-molecule inhibitors of histone deacetylases (HDACs). Two of these 
inhibitors, anacardic acid and garcinol, allow only the formation of A-like spliceosomes, 
while the other compounds inhibit spliceosome activation after incorporation of all U 
snRNPs into the spliceosome (Kuhn et al., 2009). A series of naphthalen-2-yl 
hydroxamate compounds was reported to inhibit splicing in vitro at the A complex stage 
(Patil et al., 2012). Four new compounds were confirmed to be pre-mRNA splicing 
inhibitors including lichen secondary metabolites, namely, psoromic and norstictic acids 
(Samatov et al., 2012). Psoromic acid was shown to lead to an accumulation of what 
appears to be mainly Bact spliceosomal complexes (Samatov et al., 2012).  
1.2 Aim of this study 
The spliceosome is a large macromolecular complex that is assembled de novo for each 
splicing event on a substrate pre-mRNA in a stepwise and very dynamic manner. Its main 
task is to catalyse the splicing of non-coding sequences (introns) and subsequent ligation 
of the exons with astonishing fidelity. Large structural and compositional rearrangements 
occur during each step of spliceosome assembly, driven by the action of RNA helicases. 
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The most exciting and dramatic rearrangements occur during the activation of the B 
complex intermediate, which contains all snRNPs, but is still catalytically inactive, 
resulting in an activated spliceosome.  
Small molecule inhibitors of the pre-mRNA splicing are potentially powerful tools to 
investigate splicing due to their potential ability to stall spliceosome assembly either at 
distinct known stages or at novel stages of the spliceosome assembly, leading to the 
isolation of highly pure and structurally more homogeneous populations of the 
spliceosome. At present there are only a limited number of potent inhibitors of pre-
mRNA splicing that have been identified, and very little is known about the precise 
mechanisms by which these particular molecules inhibit splicing. Thus, I set out as a 
main goal of my thesis to identify novel compounds that inhibit pre-mRNA splicing in 
vitro, by screening different chemical libraries, employing a previously established 
screening assays. Of particular importance has been to determine the exact stage where 
the spliceosome is stalled in the presence of a particular compound. This has been 
achieved by analysing their RNA and protein composition, as well as the RNA-RNA 
network formed within the stalled spliceosomes. Based on this information, I have also 
tried to elucidate in more detail the molecular mechanism of inhibition by the identified 
splicing inhibitors. Furthermore, I have set out to elucidate whether the stalled complexes 
formed in the presence of a given compound are functionally active under splicing 
conditions and thus potentially can be used as a tool for functional studies such as 
examining the dynamic exchanges of the proteins after the inhibition step. Structural 
studies using different electron microscopy techniques were also carried out to see if the 
stalled complexes are good candidates for higher resolution EM studies. Identified 
compounds have been also subjected to SAR to identify structural determinants (motifs) 
of the molecule that confer splicing inhibition activity onto compound molecule, and that 
could potentially be used to increase its potency and/or be used for tagging without 
significant loss of its inhibition activity in order to further investigate possible targets of 
the compound under study in the splicing reaction. Taken together, this work should 
extend our knowledge about defined steps of spliceosome assembly, stalled by the 
presence of inhibiting compounds, and provide insights into the structure of this particular 
stage of the spliceosome and the potential function of proteins targeted by the inhibitor(s).  
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Acetic acid (AcOH) Merck, Germany 
Acetone Merck, Germany 
Agarose electrophoresis grade (low melting point) Invitrogen, UK 
Ammonium peroxidisulphate (APS) Merck, Germany 
Boric acid Sigma-Aldrich, Germany 
Bovine serum albumin Sigma-Aldrich, Germany 
Bromophenol blue Merck, Germany 
Coomassie brilliant blue G-250 Serva, Germany 
Coomassie brilliant blue R-250 Serva, Germany 
Cacodylic acid Sigma-Aldrich, Germany 
Calcium chloride dihydrate Merck, Germany 
Chlorophorm Roth, Germany 
Creatine phosphate Sigma-Aldrich, Germany 
1-cyclohexyl-3-(2-morpholinoethyl) carbodiimide  
metho-p-toluene sulfonate (CMCT) 
Sigma-Aldrich, Germany 
Dimethylsulphoxide (DMSO) Roth, Germany 
Dimethylsulfate (DMS) FLUKA 
DNA molecular weight marker New England Biolabs, 
Germany 
1,4-dithiothreitol (DTT) Roth, Germany 
Ethylenediamine-N;N;N’,N’-tetraacetic acid,  
disodium salt dihydrate (EDTA) 
Roth, Germany 
Ethylene glycol bis(2-amoniethyl)-tetraacetic acid (EGTA) Roth, Germany 
Ethanol Merck, Germany 
Ethidium bromide (10 mg/ml) (3,8-Diamino- 
5-Ethyl-6-phenyl-phenanthridiniumbromid) 
Roche, Germany 
Fish sperm DNA (10 mg/ml) Roche, Germany 
Formaldehyde Merck, Germany 
Glycerol (87%) Merck, Germany 
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Glycerol (100 %) Merck, Germany 
Glycogen Roche, Germany 
Glycine Merck, Germany 
Gluteraldehyde 25 % aqueous solution EM Sciences 
Heparin, sodium salt Sigma-Aldrich, Germany 




IgepalR CA-630 (NP-40) Sigma-Aldrich, Germany 
-ethoxy--ketobutyral aldehyde (Kethoxal, KE) Research Organics Inst. 
Magnesium chloride hexahydrate Merck, Germany 
-Mercaptoethanol (β-ME) Roth, Germany 
Methanol Merck, Germany 
Milk powder, dry Heirler, Germany 
Phenol/Chloroform/Isoamyl alcohol (25:24:1) Roth, Germany 
Phenylmethylsulfonylfluoride (PMSF) Roche, Germany 
Ponceau S Serva, Germany 
Potassium chloride Merck, Germany 
Potassium hydroxide Merck, Germany 
2-Propanol Merck, Germany 
Protease inhibitor, EDTA free Roche, Germany 
Protein molecular weight marker (unstained, pre-stained) Bio-Rad 
Rotiphorese Gel 30 (30% acrylamide, 0.8%  
N,N'-methylene-bis-acrylamide) 
Roth, Germany 
Rotiphorese Gel 40 (38% acrylamide, 2% B  
N,N'-methylene-bis-acrylamide) 
Roth, Germany 
Roti-Phenol-Chloroform Roth, Germany 
Silver nitrate Merck, Germany 
Sodium acetate Merck, Germany 
Sodium carbonate Merck, Germany 
Sodium chloride Merck, Germany 
Sodium hydrogen carbonate Merck, Germany 
Sodium hydroxide Merck, Germany 
Sodium thiosulfate pentahydrate Merck, Germany 
Sodiumdodecylsulfate (SDS) Serva, Germany 
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N, N, N’, N’-Tetramethylethylendiamine (TEMED) Sigma-Aldrich, Germany 
Tricine Sigma-Aldrich, Germany 
Trichloroacetic acid acid (TCA) Merck, Germany 
Tris-(hydroxymethyl)-aminomethane (Tris) VWR International, 
Germany 
Triton X-100 Sigma-Aldrich, Germany 
tRNA E. coli Boehringer 
Tween 20 Sigma-Aldrich, Germany 
Urea Merck, Germany 
Xylene cyanol FF Sigma-Aldrich, Germany 
 
2.1.2 Antisera, monoclonal and polyclonal antibodies 
 
Rabbit polyclonal antibodies were raised against peptides (indicated in brackets) derived 
from human proteins. All antibodies were affinity purified prior to use. 
 
-CDC5: C1 (aa 106-124) Dept. Lührmann; Makarova et al., 2004 
-hPrp17: 17.1 (aa 92-107) Dept. Lührmann; Dr. E. Makarov 
-hPrp19: 19.2 (aa 176-191) Dept. Lührmann; Makarova et al., 2004 
-SF3b155: 155.1 (aa 99-113) Dept. Lührmann; Will et al., 2001 
-phospho-SF3b155: pT313 (aa 308-318) Dept. Lührmann; Girard et al., 2012 
-Lsm4: Supermario (aa 119-139) Dept. Lührmann; Makarova et al., 2004 
-MS2-MBP Dept. Lührmann 
-60K: (aa 67-93) Dept. Lührmann; Makarova et al., 2004 
-Npw38 (aa 250-265) Dept. Lührmann; Dr. E. Makarov 
-Npw38BP (aa 3-19) Dept. Lührmann; Dr. E. Makarov 
-Prp38 (aa 1206-1223) Dept. Lührmann 
-U5-116k: STAN (aa 1-109) Dept. Lührmann; Fabrizio et al., 1997 
-rabbit peroxidase Dianova, Germany 




2.1.3 Enzymes and enzyme inhibitors, and MS2-MBP protein 
 
Calf intestine pyrophasphotase (CIP) New England Biolabs, Germany 
Complete protease inhibitor, EDTA free Roche, Germany 
Pfu DNA polymerase (10 U/µl) Dept. Görlich, MPI-bpc 
Klenow fragment of DNA polymerase I New England Biolabs 
Proteinase K Fluka, Switzerland 
Rnasin (RNase inhibitor, 40 U/µl) Promega, Germany 
RQ1 Dnase (1 U/µl) Promega, Germany 
Restriction enzymes: XbaI (20 U/µl), 
BamHI (20 U/µl), HincII (20 U/µl) 
New England Biolabs, Germany 
SP6 RNA polymerase New England Biolabs, Germany 
AMV Reverse Transcriptase USB Products® Affymetrix, USA 
Taq DNA polymerase Promega, Germany 
T4 DNA Ligase New England Biolabs, Germany 
T4 Polynucletide kinase (PNK) New England Biolabs, Germany 
T7 RNA polymerase Dept. Görlich, MPIbpc 
MS2-MBP Dept. Lührmann, MPIbpc 
2.1.4 Nucleotides 
 
Nucleoside-5´-triphosphate (100 mM): 
ATP, CTP, UTP, GTP 
Promega, Germany 
Deoxynucleoside-5´-triphosphate (100 mM): 
dATP, dCTP, dTTP, dGTP 
Promega, Germany 
Di-deoxynucleoside-5´-triphosphate (100 mM): 
dATP, dCTP, dTTP, dGTP 
Promega, Germany 




-32P-UTP (10 µCi/µl, 3000 Ci/mmol)  
-32P-ATP (10 µCi/µl, 6000 Ci/mmol) 





DNA oligonucleotides for reverse transcription were purchased from Eurofins Genomics, 
Ebersberg, Germany. 
 











Name Description  
pPM5 Plasmid encoding PM5 pre-mRNA Bessonov et al., 2008 
pPM5-10 Plasmid encoding PM5-10 pre-mRNA Bessonov et al., 2010 
pMINX Plasmid encoding MINX pre-mRNA in 
pSP65-vector under control of SP6 
promoter, AmpR 
Zillman et al., 1988 
pMS2-MBP Plasmid encoding MS2-MBP fusion 
protein in pMAL vector cloned between 
StuI (site destroyed) and HindIII, AmpR. 




2.1.7 Cell lines 
 
HeLa S3 cells (human cervical cancer cells) 
HeLa S3 cells (FLAG-tagged AD002) 
HeLa S3 cells (FLAG-tagged Abstrakt) 
GBF, Germany 
Grote et al., 2010 




Commonly used media, buffers and solutions were prepared with Milli-Q deionized water 
and filter-sterilized (0.22 μm) or autoclaved according to Sambrook et al., 1989. 
Solutions were autoclaved if necessary (121°C, 20 min, 1 bar). The pH was adjusted with 
(by the addition of) 37% HCl or 10 M NaOH if not stated otherwise.  
10X TBE: 
0.89 M Tris, pH 8.0 
0.89 M Boric Acid 
25 mM EDTA 
SLAB4 
50 mM Tris  
380 mM glycine  
0.1% (w/v) SDS 
Blotting buffer (for western blot) 
1.5 l SLAB4 
0.6 l methanol 
0.9 l deionized water 
Blotting buffer (for northern blot) 25 mM NaPO4, pH 6.5 
Blocking buffer 
1×TBS 
0.1% (v/v) Tween-20 
5% (w/v) milk powder 
Coomassie staining solution I 
0.025% (w/v) Coomassie (R250) 
50% (v/v) methanol 
7.5% (v/v) acetic acid 
Coomassie staining solution II 
0.008 % (w/v) Coomassie (G250) 
0.035 M HCl 
2x DMS Stop buffer 
400 mM Tris-HOAc pH 7.5 
400 mM -mercaptoethanol 
5 mM EDTA 
600 mM NaOAc 
Destaining solution (RNA gel) 10% (v/v) acetic acid 
Destaining solution (protein gel) 
40% (v/v) ethanol  
10% (v/v) acetic acid 
10X G150 buffer 
200 mM HEPES-KOH, pH 7.9 
1.5 M KCl 
15 mM MgCl2 
10x HY buffer: 
0.5 M Tris-HCl, pH 8.4 
0.6 M NaCl 




1.3 M NaCl 
200 mM KH2PO4/K2HPO4 
1X Roeder C buffer: 
25 % (v/v) glycerol 
20 mM HEPES-KOH, pH 7.9 
420 mM NaCl 
1.5 mM MgCl2 
0.2 mM EDTA, pH 8.0 
0.5 mM DTT 
0.5 mM PMSF 
1X Roeder D buffer: 
10% glycerol 
20 mM HEPES-KOH, pH 7.9 
100 mM KCl 
0.2 mM EDTA 
1.5 mM MgCl2 
0.5 mM PMSF 
0.5 mM DTT 
2X PK buffer: 
200 mM Tris-HCl, pH 7.5 
25 mM EDTA, pH 8.0 
0.3 M NaCl or KCl 
2 % (w/v) SDS 
20X SSC: 
3 M NaCl 
0.3 M sodium citrate 
2X SDS gel loading buffer: 
20% glycerol 
0.25 mM β-mercaptoethanol 
100 mM Tris-HCl, pH 6.8 
6.8% (w/v) SDS 
0.05 % (w/v) Xylene cyanol 
0.12 % (w/v) Bromphenol blue 
TNES (RNA extraction buffer): 
20 mM Tris-HCl pH 8.0 
300 mM NaCl 
5 mM EDTA, pH 8.0 
0.1 % (w/v) SDS 
4X agarose gel loading buffer: 
1X TBE 
30% (v/v) glycerol 
0.05 % (w/v) Xylene cyanol 
0.05% (w/v) Bromophenol blue 
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RNA loading dye: 
80 % Formamide 
1 mM EDTA, pH 8.0 
0.05 % (w/v) Bromphenolblue 
0.05 % (w/v) Xylene cyanol 
10X TBS buffer: 
200 mM Tris-HCl, pH 7.6 
1.5 M NaCl 
1 % Tween 20 
Northern blotting pre-hybridisation 
and hybridisation buffer: 
 
25 mM Na2HPO4 , pH 6.5 
6X SSC 
0.5 % (w/v) SDS 
50% deionized formamide 
5X Denhardt’s solution 
100 μg/ml fish sperm DNA 
5X SP6 transcription buffer: 
600 mM HEPES-KOH, pH 7.5 
160 mM MgCl2 
10 mM spermidine 
200 mM DTT 
5X T7 transcription buffer: 
1 M HEPES-KOH pH, 7.5 
160 mM MgCl2 
10 mM spermidine 
200 mM DTT 
1X Running buffer SDS-PAGE (Laemmli): 
25 mM Tris-HCl, pH 6.8 
1.92 mM glycine 
1% (w/v) SDS 
4X Separating gel buffer (Laemmli): 
1.5 M Tris-HCl, pH 8.8 
0.4% (w/v) SDS 
4X Stacking gel buffer (Laemmli): 
0.5 M Tris-HCl, pH 6.8 
0.4% (w/v) SDS 
1X Western blot transfer buffer: 
20 mM Tris 
150 mM NaCl 
0.1 % (v/v) Tween 20 
10x RT buffer: 
0.5 M Tris-HCl, pH 8.4 
0.6 M NaCl 
0.1 M MgCl2 




2.1.9 Commercial kits 
 
ECL Western Blot Detection Kit, Amersham  GE Healthcare, Germany 
Prime It II Random Primer Labelling Kit Stratagene, USA 
QIAgen Plasmid Mini/Maxi Preparation Kit Qiagen, USA 
QIAquick Gel Extraction Kit Qiagen, USA 
 
2.1.10 Chromatography materials and consumables 
 
Anti-FLAG M2 beads Sigma, Steinheim 
Amersham Hyperfilm ECL GE Healthcare, Germany 
Amersham™ Protran™ 0.2 µm NC membrane GE Healthcare, Germany 
Amylose resin New England Biolabs, Germany 
Autoradiography X-ray films BioMax MR Kodak, USA 
Chromatography columns (2.0, 10 ml)  Bio-Rad, Germany 
Column MBPTrap™ HP (1 ml) GE Healthcare, Germany 
Column Illustra ProbeQuantTM G-25/G50  GE Healthcare, Germany 
Column Zeba spin desalting (7K MWCO) Thermo Fisher Scientific, USA 
Dialysis membranes (MWCO 6000-8000 Da) SpektraPor, USA 
FLAG 1 x Peptide Sigma-Aldrich, Germany 
Fluotrac600 black plates (Cat. No 781077) Greiner-Bio-One, Germany 
Needles Henke Sass Wolf, Germany 
Needles BD Spinal 18GA 3.50 IN 1.2 x 90 mm Becton Dickinson, Spain 
Nylon membrane Biodyne B 0.45 μm  Pall Life Sciences, Mexico 
Nitrocellulose membrane Protran BA 83  Whatman, Germany 
Nesco-Parafilm Roth, Germany 
Pipettes Gilson, USA 
Pipettes Eppendorf, Germany 
Pipette tips  (blue, yellow) Roth, Germany 
Probe Quant G-50 micro columns GE Healthcare, Germany 
Protein A Sepharose  GE Healthcare, Germany 
Tubes (0.5 ml, 1.5 ml and 2.0 ml) Eppendorf, Germany 
Tubes (15 ml und 50 ml) Sarstedt, Germany 
Sterile filters (0.2 µm or 0.45 µm) Sarstedt, Germany 
Surgical blades Martin, Tuttlingen 
Syringes Braun, Germany 
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Whatman Paper Biometra, Germany 
96-well-Plates  Greiner, Germany 
 
2.1.11 Small Molecule Screening Apparati 
 
Multidrop Combi Thermo Fisher Scientific, USA 
Robotic arm “FS”  Thermo CRS, USA 
Elx405 BioTek, USA 
Echo 520 Labcyte, USA 




Autoclaves H+P Labortechnik, Germany 
Centrifuge Biofuge fresco Heraeus, Germany 
Centrifuge Biofuge pico Heraeus, Germany 
Centrifuge Megafuge 1.0R Heraeus, Germany 
Centrifuge Sorvall® Evolution RC Lynx 6000 Thermo Scientific, USA 
Centrifuge Sorvall® Evolution RC Kendro, USA 
Centifuge Sorvall® Discovery™ 90SE Thermo Scientific, USA 
Centrifuge Sorvall® WX ultra Series Thermo Scientific, USA 
Cryo electron microscope CM200 FEG Philips, Netherlands 
Cryo electron microscope Titan Krios FEI, Netherlands 
Ultracentrifuge Discovery M150 Thermo Scientific, USA 
Fractionator BR-184X Brandel, USA 
Fractionator LKB-FRAC-100 Pharmacia, Sweden  
Gel documentation unit Bio-Rad, Germany 
Gel electrophoresis apparatus in-house 
Gel dryer Model 583 Bio-Rad, Germany 
Glassware VWR International, Germany 
Gradient Master™ Modell 106 BioComp Instruments, USA 
Ice machine Ziegra, UK 
Incubators Heraeus, Germany 
“Head-over-tail” Rotor Cole-Parmer, USA 
Heating blocks Eppendorf, Germany 
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Hybridization oven Hybaid Biometra, Germany 
4800 MALDI ToF/ToF Applied Biosciences/MDS Sciex 
Kodak X-Omat 2000 Processor  Kodak, USA 
LTQ-Orbitrap Velos Thermo Fisher Scientific, Germany 
Magnetic Stirrer IKA Staufen, Germany 
Microfuge 5415D Eppendorf, Germany 
Microwave oven Bosch 
Milli-Q-water supply apparatus Millipore 
Orbitrap XL Thermo Fisher Scientific, Germany 
pH-meter, Orion 2-Star Thermo Scientific, USA 
pH-meter, Professional Meter PP-20 Sartorius, Germany 
Phosphorimager screens  GE Healthcare, Germany 
Phosphorimager Typhoon Trio+ GE Healthcare, Germany 
PerfectBlue Semi-Dry Electro blotter PeqLab 
Phosphorimager Typhoon 8600 Amersham Pharmacia, Germany 
Pipetman Eppendorf, Germany 
Power supply EPS 2A200 Hoefer 
Power supply EPS 3501/XL Amersham Pharmacia, Germany 
Rocking platform MAX Q3000 und Q2000 Thermo Scientific, USA 
S100AT4 rotor 
F14-14x50cy rotor 
Thermo Fisher Scientific, USA 
Thermo Fisher Scientific, USA 
Sorvall TST 41.14 rotor Thermo Fisher Scientific, USA 
Sorvall T660 rotor Thermo Fisher Scientific, USA 
Sorvall SureSpin rotor Thermo Fisher Scientific, USA 
Scale BP211D Sartorius, Germany 
Scale BP41OS Sartorius, Germany 
Scale XS4002S DeltaRangeR Mettler Toledo 
Scale XS205 DualRangeR Mettler Toledo 
Scintillation counter LS 1701/TRI-CARB 2100TR Beckman/Packard, USA 
Speed Vac Concentrator 5301 Eppendorf, Germany 
Spectrophotometer Nanodrop ND-1000  Thermo Fisher Scientific, USA 
Spectrophotometer Ultrospec 3000 pro Amersham Pharmacia, Germany 
Thermomixer Eppendorf, Germany 
UV-Stratalinker 2400 Stratagene, USA 
Vitrobot Mark IV FEI, Netherlands 
Vortex Scientific Industries, USA 




Unless otherwise stated, all molecular biological methods were performed as described in 
Sambrook, 1989. Commercial kits were used according to the instructions of the 
manufacturer. 
2.2.1 Molecular biology standard methods 
2.2.1.1 in vitro transcription 
[32P]-labeled, m7G(5’)ppp(5’)G-capped pre-mRNAs were synthesized in vitro by SP6 or 
T7 runoff transcription. A typical 100 µl transcription reaction (see below) was 
assembled at room temperature and subsequently incubated at 40°C (SP6) or 37°C (T7) 
for 2.5 h. The DNA template was hydrolysed by addition of 5 µl of 1 U/µl RQ1 DNase to 
the reaction mix and further incubation at 37°C for 10 min. In order to purify the RNA 
from free nucleotides and small fragments, the reaction mixture was mixed with an equal 
amount of formamide loading buffer and loaded onto a denaturing polyacrylamide gel.  
 






5X T7 (SP6) transcription buffer 20 1X 
0.1 M ATP 7.5 7.5 mM 
0.1 M CTP 7.5 7.5 mM 
0.1 M UTP 1.5 1.5 mM 
0.1 M GTP 1.5 1.5 mM 
0.151 M m7G(5’)ppp(5’)G-cap 3.312 5 mM 
RNase inhibitor (40 U/µl) 3.75  
SP6 (T7) RNA polymerase (20 U/µl) 10  
DNA template (250 ng/µl) (PCR product or plasmid insert) 10  
α-[32P]-  5  
H2O 29.938  
Total 100  
The RNA band was detected by autoradiography, in case of radioactive RNA or by UV-
shadowing in case of unlabelled RNA, and cut out of the gel. RNA was eluted from the 
gel by incubating overnight in TNES buffer. RNA was Phenol / Chloroform / 
Isoamylalcohol (PCI) extracted and precipitated with 3 volumes of ethanol. The RNA 
precipitate was dissolved in sterile water. Transcribed pre-mRNA was purified from 
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unincorporated nucleotides by gel filtration using G50 micro columns. The radioactivity 
of 1 μl of the solution was determined by counting in a scintillation counter according to 
the Cherenkov protocol and the specific activity of the transcript was calculated. 
Unlabelled RNA was transcribed according to the same protocol in the absence of α-
[32P]-labelled UTP, adjusting the final concentration of the cold UTP to 7.5 mM. 
2.2.1.2 Concentration determination of nucleic acids 
To determine the concentration of nucleic acids, the absorption of an aqueous solution 
was measured at a wavelength of 260 nm against the reference (H2O). The nucleic acid 
concentration was determined using a NanoDrop spectrophotometer according to the 
manufacturer’s instructions. The 260/280 nm ratio was used to determine the purity 
grade. A ratio lower than 1.8 indicates the presence of protein, phenol or other 
contaminants absorbing at 280 nm.  
 
The following equations were used to determine concentrations: 
1 OD260 = 50 µg/ml double-stranded DNA 
1 OD260 = 33 µg/ml single-stranded DNA 
1 OD260 = 40 µg/ml single-stranded RNA 
 
Alternatively, the concentration of 32P-labeled pre-mRNA was determined by the ratio of 
hot and cold UTP, the reference date of the -32P-UTP used and the absolute number of 
uridines in the transcript. 
2.2.1.3 Agarose gel electrophoresis of nucleic acids 
Agarose gel electrophoresis was used for analysis and/or for purification of preparative 
amounts of nucleic acids, in particular, to separate DNA fragments after restriction 
enzyme digestions. Using agarose gel electrophoresis nucleic acids are first separated in 
an electric field, thereby the DNA fragments of different size migrate with a different 
speed due to the net negative charge of its sugar-phosphate backbone. Depending on the 
size of the DNA fragments, gels contain 0.8 – 2 % agarose (w/v) in 1x TBE buffer (0.8-
1.0 % agarose for the purification of pUC-MINX-MS2 digestion products). The DNA 
was supplemented with 4x agarose gel loading dye and separated by electrophoresis at a 
constant voltage of 60-100 V in 1x TBE buffer. For detection of DNA an organic 
intercalating agent ethidium bromide at a concentration of 0.5 µg/ml was added to the gel 
solution. DNA bands were visualized by illumination with UV-light at a wavelength of 
365 nm. Commercial DNA ladders from Roche were used as a size marker. 
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To isolate the DNA fragments of interest from the gel, the corresponding DNA bands 
visualized by UV light at a wavelength of 365 nm were excised from the gel with a sterile 
razor blade and DNA was extracted using a QIAquick gel extraction kit (Qiagen) 
following the instructions of the manufacturer. Thereby, the agarose was melted, the 
DNA bound to the matrix, washed and eluted. The concentration of eluted DNA was 
determined by Nanodrop (as described in 2.2.1.2). 
2.2.1.4 Phenol-chloroform-isoamyl alcohol extraction 
Phenol-chloroform-isoamyl alcohol extraction (PCI-extraction) was used to separate 
nucleic acids from proteins. During PCI-extraction proteins are denatured by phenol and 
isoamyl alcohol, ensuring the complete inactivation of RNase activity. The solution was 
extracted with an equal volume of PCI-solution and mixed by vortexing. To separate the 
aqueous and organic phases, the emulsion was centrifuged for 10 min at room 
temperature at 13000 rpm in a microfuge. The upper aqueous phase containing nucleic 
acids was transferred to a new tube and nucleic acids were precipitated by the addition of 
1/10 volume of 3M NaOAc (pH 5.2) and 3 volumes of ethanol in the presence of 1 µl 
glycogen. 
2.2.1.5 Proteinase K digestion 
Proteinase K digestion was used to remove proteins from preparations of nucleic acid. In 
a standard proteinase K digestion reaction, 10 µl of a splicing reaction aliquot was 
supplemented with 10 µl 2x PK buffer and 2 µl of 10 mg/ml proteinase K, and incubated 
for 30 min at 37°C. After the digestion, the volume was adjusted to 200 µl with H2O, and 
RNA was isolated by PCI extraction (described in 2.2.1.4). The RNA pellet was dried in a 
Speed Vac Concentrator for 2 min, subsequently resuspended in RNA loading dye and 
analysed on a 0.5 mm 10-14 % denaturing polyacrylamide gel (PAGE) as described 
below.  
2.2.1.6 Denaturing Urea polyacrylamide gel electrophoresis 
Denaturing polyacrylamide gel electrophoresis in the presence of urea was used to separate 
RNA molecules. Urea is used as a denaturant to break the hydrogen bonds between the base 
pairs of the nucleic acid. Depending on the size of the RNA, the gels contained 5, 8, 10 or 
14 % polyacrylamide, 8 M urea and 0.5x TBE. The gel was polymerized by addition of 30 
µl TEMED and 300 µl 10 % (w/v) APS to 40 ml of the gel solution. The RNA samples 
were dissolved in formamide loading buffer, subsequently heated for 3 min at 96°C to 
promote denaturation of the RNA molecules prior to loading, and immediately chilled on 
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ice. The electrophoresis was performed at a constant voltage of 60-100 V in 0.5X TBE 
buffer. The RNA was visualized by silver staining, autoradiography or with a 
PhosphoImager.  
2.2.1.7 RNA silver staining 
Silver staining of RNA polyacrylamide gels was used for detecting nucleic acids and 
performed according to Caetano-Anollés and Gresshoff, 1994. For the fixation, the gel 
was incubated in a 10 % acetic acid solution for 30 min. Then, the gel was washed three 
times for 5 min with deionized water and incubated for 30 min in solution containing 1.5 
g/L AgNO3 and 0.056 % formaldehyde. The gel was then briefly rinsed twice with water 
and developed with solution containing 30 g/L Na2CO3, 0.056 % formaldehyde and 400 
mg/L Na2S2O3. When the desired intensity was achieved, the development was stopped 
with 10 % acetic acid. The gel was scanned and dried on a vacuum gel dryer at 80°C for 
45 min.  
2.2.1.8 Radioactive labeling of the 5´-end of DNA oligonucleotides 
To perform primer extension analysis, DNA oligonucleotides (primers) were 
radioactively labeled at their 5´-end in the presence of γ-[32P] ATP using T4-
polynucleotide kinase (PNK) prior to hybridization. To this end, a standard labeling 
reaction (10 µl) containing 10 pmol of the DNA oligo, 1 µl of 10x PNK buffer (New 
E -[32P]-ATP (6000 Ci/mmol, 10 
mCi/ml) was incubated for 45 – 60 min at 37°C. After incubation, the reaction volume 
was adjusted to 40 μl with dH2O and the [
32P]-labeled oligonucleotides were purified 
from unincorporated γ-[32P] ATP using ProbeQuant G-50 micro columns  according to 
the manufacturer’s instructions. 
2.2.1.9 Northern blotting 
Northern blot analysis was used for detecting RNA molecules in a sample via a [32P]-
labeled DNA probe complementary to an RNA target sequence. First, RNA samples are 
separated by denaturing PAGE. Afterwards, RNAs were transferred to a nylon membrane 
(Biodyne B) by semi-dry blotting for 2 h at 2 mA/cm2 in 0.5X TBE buffer. Alternatively, 
transfer occurred by blotting for 12 h at 1 mA in 25 mM NaPO4. After blotting, the nylon 
membrane was UV irradiated in a UV Stratalinker apparatus and pre-blocked with pre-
hybridization buffer for 1 h at 42°C. Then the membrane was incubated for 12-24 h at 
42°C with the [32P]-labeled DNA probe in hybridization buffer. To this end, the probe 
was incubated at 95°C for 5 min, chilled on ice and added to pre-hybridization buffer. 
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After hybridization, the membrane was washed thoroughly to avoid background signal 
and ensure to that the probe has bound specifically as follows: twice with wash buffer 1 
(2x SSC, 0.5 % (w/v) SDS) for 10 min at room temperature, once with wash buffer 2 (2x 
SSC, 0.1 % (w/v) SDS) for 10 min at room temperature, and once more with wash buffer 
2 for 30 min at 50°C. After washing, RNA was visualized by autoradiography. 
2.2.2 Standard protein biochemical methods 
2.2.2.1 TCA precipitation of protein 
The protein samples were precipitated prior to gel electrophoresis to reduce the sample 
volume. For this purpose, to one volume of protein solution, 1/100 volume of 2% sodium 
deoxycholate (DOC) was added, which is an anionic detergent. The mix was vortexed and 
incubated for 30 min at 4ºC. Trichloroacetic acid (TCA) was added to a final concentration 
of 10 %. The mix was vortexed, incubated at 4ºC overnight and centrifuged 15 min at 4ºC 
in a microfuge at maximum speed (13000 rpm). The supernatant was discarded and the 
pellet was washed at least twice with 1 ml of -20°C acetone, vortexed and centrifuged for 
10 min at 13000 rpm in a microfuge. The pellet was dried in Speed Vac Concentrator for 2 
min and resuspended in 10-  
2.2.2.2 Acetone precipitation of protein 
To one volume of protein solution 5 volumes of ice-cold acetone (-20°C) were added and 
vigorously mixed (vortex). The mixture was incubated for 10-12 h at -20°C and 
centrifuged for 15 min at 4°C in a microfuge at 13000 rpm. The pellet was washed twice 
with 80 % ethanol, dried in Speed Vac Concentrator for 2 min and resuspended in SDS 
loading buffer. 
2.2.2.3 Denaturing SDS polyacrylamide gel electrophoresis. 
Denaturing sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE) was 
used to separate proteins according to their molecular mass. An anionic detergent, sodium 
dodecyl sulphate (SDS), was applied as a detergent. SDS-PAGE was adapted from 
Laemmli (Laemmli, 1970). Protein samples were dissolved in protein loading buffer and 
heated to 95°C for 5 min prior to loading on the gel. The gel consisted of a stacking gel 
and a separating gel. The stacking part of the gel, used to compress (stack) proteins into a 
thin layer before they reach the separating gel, contained 4 % polyacrylamide. The 
stacking gel was polymerized with 0.05 % (w/v) APS and 0.25 % (v/v) TEMED. The 
separating gel, which is used to separate polypeptides by size, contained usually 10 or 13 
% polyacrylamide, and was polymerized with 0.033 % (w/v) APS and 0.33 % (v/v) 
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TEMED, and run vertically in SDS-PAGE running buffer. The gel was subsequently 
fixed and stained with Coomassie brilliant blue G-250 (2.2.2.4) or with silver (2.2.2.5). 
Protein molecular weight marker from Bio-Rad was used as a size standard. 
 
Stacking gel: 
1.66 ml Rotiphorese Gel 30 (30% acrylamide, 0.8% N,N'-
methylene-bis-acrylamide) 
2.5 ml 4x stacking buffer  
5.84 ml dd H2O 
50 μl 10 % (w/v) APS 
25 μl TEMED 
Separating gel (10 %): 
10 ml Rotiphorese Gel 30 (30% acrylamide, 0.8% N,N'-
methylene-bis-acrylamide) 
7.5 ml 4x separating buffer  
12.5 ml dd H2O 
100 μl 10 % (w/v) APS 
100 μl TEMED 
Running buffer: 
250 mM Tris-HCl, pH 8.8 
0.1 % (w/v) SDS 
0.192 M Glycine 
 
2.2.2.4 Coomassie staining of SDS-PAGE gels  
Coomassie blue (triphenylmethane) dyes (R-250 and G-250) interact with proteins 
through interactions between dye sulfonic acid groups and protein amine groups, as well 
as through Van der Waals attractions. Gels are fixed in 40 % (v/v) methanol / 10 % (v/v) 
HoAc for 30 min and soaked in G-250 dye until the gel has a blue colour. Then the gel 
background is destained with 40 % (v/v) methanol and 10 % (v/v) acetic acid. The gel can 
be stored in 5 % acetic acid, or, alternatively, it can be scanned and dried on Whatmann 
paper with a vacuum gel dryer at 80°C for 45 min. 
2.2.2.5 Silver staining of SDS-PAGE gels  
Silver staining of SDS-PAGE gels was performed as described in Blum et al., 1987. 
During the procedure, all solutions were used at 10 times the gel volume and all steps 
were performed on a shaker. The protein gel was first fixed in a 50 % (v/v) methanol / 12 
% (v/v) acetic acid solution for at least 30 min or overnight. After fixation, the gel was 
washed twice with 50 % (v/v) ethanol and once with 30 % (v/v) ethanol for 20 min each. 
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Then the gel was incubated with 0.8 mM Na2S2O3 for exactly 60 seconds, and 
immediately washed three times with ddH2O for 20 sec each to remove the thiosulfate 
from the gel surface. For staining, the gel was incubated in a 0.012 M AgNO3 / 0.026 % 
(v/v) formaldehyde solution for 20 min. The stained gel was then washed three times with 
ddH2O to remove unbound silver nitrate. The gel was rinsed briefly with a solution 
containing 0.56 M Na2CO3, 0.0185 % (v/v) formaldehyde, and 16 µM Na2S2O3 to remove 
excess silver from the surface of the gel. Then the solution was replaced with a solution 
containing 0.56 M Na2CO3, 0.0185 % (v/v) formaldehyde, and 16 µM Na2S2O3, and the 
gel was developed until the protein bands showed the desired staining intensity. The 
developing was stopped by incubating with a 50 % (v/v) methanol / 10 % (v/v) acetic 
acid solution. The stained gel was stored in 5 % acetic acid, or, alternatively, scanned and 
dried on Whatman paper with a vacuum gel dryer at 80°C for 45 min. 
2.2.3 Immunological Methods 
2.2.3.1 Immunoblotting (Western blotting) 
Western blotting was performed to detect specific proteins in a sample. First, the proteins 
were separated by SDS PAGE. A pre-stained MW protein marker from Bio-Rad was used 
as a size standard and to control for good transfer efficiency. Then the proteins were 
transferred from the gel to a nitrocellulose membrane. To this end, the polyacrylamide gel 
was placed on the blotting membrane, previously soaked in blotting buffer, avoiding air 
bubbles. It was subsequently covered by Whatman paper, placed between two sponges, 
assembled in a Trans-blot cell (BioRad). The transfer was carried out in blotting buffer 
for 2 h at 60 V, 4°C, followed by staining with Ponceau S dye to check the efficiency of 
the transfer. Subsequently, to prevent non-specific binding of antibodies to the 
membrane, the membrane was incubated in blocking buffer, containing 0.1 % (v/v) 
Tween-20 and 5 % (w/v) dry milk powder, overnight at 4°C or for 1 h at room 
temperature, and washed with TBS-Tween buffer (optional). To detect proteins of 
interest, the membrane was incubated with a primary antibody for 2 h at room 
temperature and washed one time for 15 min and four times for 5 min each with TBS-
Tween buffer, containing 5 % (w/v) dry milk powder, to remove unbound antibodies. 
Subsequently, the membrane was incubated with horseradish peroxidase-conjugated anti-
rabbit or anti-mouse antibodies for 1 h at room temperature (1:50000 dilution), followed 
by washing with TBS-Tween (1x 15 min, 4x 5 min). Next, the proteins were detected by 
enhanced chemiluminescence using an ECL kit according to the manufacturer’s 
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instructions. The luminescence was detected by exposure to ECL Hyperfilm. The film 
was developed using a X-Omat 2000 developing machine. 
2.2.3.2 Immunoprecipitation 
Protein A Sepharose was washed twice with three volumes of 1x PBS (pH 8.0) and 
subsequently incubated with antibodies in 1x PBS buffer at 4°C overnight with head-
over-tail rotation. Next, sepharose with bound antibodies was washed four times with five 
volumes of 1x PBS and distributed in a defined number of tubes. The splicing reaction 
mixture was added to the Sepharose beads in IPP buffer containing 150-400 mM salt, and 
incubated at 4°C for 4 h with head-over-tail rotation. Then, the Sepharose beads with 
bound material were washed 5 times with IPP buffer containing the desired salt 
concentration. RNA was recovered by proteinase K digestion and subsequent PCI 
extraction, and precipitated with ethanol. Precipitated RNA was separated by denaturing, 
10 % polyacrylamide gel electrophoresis and subjected to Northern gel analysis.  
2.2.4 Special Methods  
2.2.4.1 Preparation of HeLa cell nuclear extract 
Nuclear extracts were prepared from HeLa cells essentially as described by Dignam et al., 
1983, frozen in liquid nitrogen in Roeder C buffer and stored at -80°C. Prior to use in 
splicing reactions, nuclear extracts were thawed and dialyzed against 50 – 100 volumes of 
Roeder D buffer (100 mM KCl, 1.5 mM MgCl2, 20 mM HEPES-KOH, pH 7.9) and 10 % 
(v/v) glycerol, twice for 2.5 h. The extract was subsequently centrifuged at 8330 rpm at 4 
°C for 10 min in F14-14x50cy rotor (centrifuge Sorvall® Evolution RC Lynx 6000). The 
precipitate was discarded. The HeLa nuclear extract was aliquoted, frozen in liquid 
nitrogen and stored at –80 °C. 
2.2.4.2 In vitro splicing reactions 
For in vitro splicing reactions, MINX and PM5 or PM5-10 pre-mRNA substrates were 
used. The 5’-end of the PM5 pre-mRNA and 3’-end of MINX pre-mRNA are 
preceded/followed by three MS2 coat protein binding sequences which are used for 
purification of spliceosomal complexes (Bessonov et al., 2010). A standard splicing 
reaction contained 10 nM pre-mRNA and 40 % HeLa nuclear extract in buffer containing 
3 mM MgCl2, 65 mM KCl, 20 mM HEPES-KOH (pH 7.9), 2 mM ATP and 20 mM 
creatine phosphate (final concentrations). Additionally, splicing reaction contained 
defined concentration of one of the compounds, and the control reaction contained 
DMSO, which is a solvent for the compounds. The reaction mixture was incubated at 30 
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°C for the times indicated. After splicing, reactions were chilled on ice. To analyse RNA 
products of splicing, reaction aliquots were first digested with proteinase K. RNA was 
subsequently recovered by PCI extraction, followed by ethanol or TCA precipitation, 
resolved on a denaturing polyacrylamide gel and visualized by autoradiography. The 
formation of spliceosomal complexes was analysed by native agarose gel electrophoresis 
(2.2.2.4). 
2.2.4.3 In vitro high throughput-screening assay of small molecules 
An in vitro high throughput-screening assay was used (Samatov et al., 2012) to screen 
large chemical libraries for splicing inhibition activity (Fig. 2.1). For screening, 
Fluotrac600 black plates were covered with -MS2-MBP antibodies at the concentration 
of 0.02 mg/ml (10 µl/well) in 20 mM HEPES-KOH (pH 7.9) shaking at 4°C overnight 
using an automated setup. Next, the plates were washed three times with wash buffer, 
containing 1 mM HEPES-KOH (pH 7.9), 0.075 mM MgCl2, 7.5 mM NaCl, 0.005 % 
Tween 20 (100 µl/well). Next, 20 nl compound were added to the wells at a concentration 
of 50 µM followed by 10 µl of an ice-cold splicing reaction containing HeLa nuclear 
extract prepared from cells expressing a FLAG-tagged version of the Abstract protein,  
 


























































which first associates with the spliceosome at the C complex stage. This FLAG-tagged 
Abstract protein is marked by adding peroxidase conjugated anti-FLAG antibody to the 
splicing reaction. After brief shaking of the plate (20 sec), the mixture was incubated for 
3 h at 20-25°C without shaking. During this incubation time, the pre-mRNA substrate 
becomes immobilized in the wells of the microtiter plate by the bound antibodies that 
react with the MS2-MBP protein that binds the pre-mRNA via MS2 aptamers. Next, the 
plates were washed six times with wash buffer (100 µl/well) and then luminescent 
solution (100 µl/well) was added. The extent of C complex formation was then measured 
by a peroxidase luminescence reaction. The intensity of the luminescence detected 
reflects the amount of tagged protein present in the spliceosomal C complex, and 
therefore the efficiency of step I catalysis. 
2.2.4.4 Analysis of splicing complexes by native agarose gel electrophoresis 
Spliceosomal complexes A, B, Bact and C are formed in a subsequent manner and show 
different mobility on a native agarose gel (Lamond et al., 1987; Das and Reed, 1999; 
Bessonov et al., 2010). Native agarose gel electrophoresis was used to resolve spliceosomal 
complexes for analytical purposes. Standard splicing reactions (2.2.4.1) were incubated at 
30°C for the times indicated. Subsequently, heparin was added to the splicing reaction to a 
final concentration of 0.4 mg/ml and the mixtures were incubated for another 1 min at 
30°C. Finally, 6 µl of 5x agarose loading dye was added and the samples were loaded onto 
a native agarose gel (26 cm x 15 cm) containing 1.5 % (w/v) low melting point agarose 
(Invitrogen) in 0.5 x TBE buffer. The electrophoresis was performed at a constant voltage 
of 40 V for 16 h in 0.5x TBE buffer. Gels were dried on a vacuum gel dryer at 60°C for 4 h 
and bands were visualized by exposing the gel to a phosphoimager screen.  
2.2.4.5 Purification of spliceosomal complexes 
Spliceosomal complexes were isolated using the MS2-MBP-affinity selection method 
(Deckert et al., 2006). Pre-mRNA was incubated with 20 mM HEPES-KOH (pH 7.9) and a 
20-fold molar excess of purified MS2-MBP fusion protein. Then, a 1 ml standard splicing 
reaction containing 3 mM MgCl2, 65 mM KCl, 2 mM ATP, 20 mM CP, 20 mM HEPES-
KOH (pH 7.9) and 10 nM of [32P]-labeled pre-mRNA (MINX or PM5-10) was incubated 
for 4 (B complex), 22 (B028 complex) or 170 min (Bact complex) at 30°C. A 25-fold molar 
excess of DNA oligonucleotide complementary to nucleotides -6 to -18 and -12 to -24 
relative to the 5’ splice site (M6 and M12 oligos; PM5-10 complexes) was added to the 
reaction with Bact complexes and incubated at 30°C for an additional 20 min. 1 ml of the 
splicing reaction was loaded onto 14 ml, linear 10-30 or 15-30 % (v/v) glycerol gradients 
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containing G-150 buffer. Gradients were centrifuged at 30000 rpm for 18 h (B and B028 
complexes) or at 28000 rpm for 16 h (Bact complex) in a Sorvall TST 41.14 rotor and 
harvested manually in 500 µl fractions from the top. Peak fractions containing the 
complexes were pooled and loaded onto a column containing 250 µl packed volume of 
amylose beads equilibrated with G-150 buffer. The matrix was washed 6 times with 1 ml of 
G-150 buffer. Spliceosomal complexes were eluted dropwise with 500 µl of G-150 buffer 
containing 20 mM maltose. RNA was recovered from the complexes, analysed on an 8 M 
urea-14 % polyacrylamide gel, and visualized by silver staining and autoradiography. To 
analyse the protein composition of the eluted complexes, proteins were precipitated, 
separated by 8-10 % SDS-PAGE and subjected to mass spectrometry. Alternatively, 
proteins were separated by 8-10 % SDS-PAGE and analysed by Western blotting. 
2.2.4.6 Micrococcal nuclease treatment of HeLa nuclear extract 
To deplete splicing active HeLa nuclear extract of all endogenous snRNPs, CaCl2 was 
added to HeLa nuclear extract in Roeder D buffer to a final concentration of 1.5 mM 
followed by addition of micrococcal nuclease (10 U/µl, Amersham Pharmacia) to a final 
concentration of 0.5 U/µl. The mixture was incubated for 15 min at 30°C and 
immediately transferred to ice. To quench the nuclease activity, EGTA-KOH, pH 8.0 was 
added to a final concentration of 4.5 mM. 
2.2.4.7 ATP depletion 
To deplete ATP from nuclear extract, 1 unit hexokinase and 6 mM glucose was added to 
1 ml nuclear extract and incubated for 10-15 min at 30°C. Then, the nuclear extract was 
chilled in ice. 
2.2.4.8 Chasing of stalled complexes in the presence or absence of ATP 
1.0 pmole of affinity purified stalled complexes (2.2.4.5) still bound to the matrix were 
washed 6 times with 1 ml of G-150 buffer and subsequently incubated under in vitro 
splicing conditions either with 400 µl buffer alone or with nuclear extract treated with 
micrococcal nuclease under standard splicing conditions in the presence or in the absence 
of ATP at 30°C to 1 h. To ensure the absence of ATP in the reaction mixture, the HeLa 
nuclear extract was ATP depleted prior to the splicing reaction. Spliceosomal complexes 
were eluted dropwise using a BioRad column with 500 µl of G-150 buffer containing 20 
mM maltose. RNA was recovered from the complexes, analysed on a 8 M urea-14 % 
polyacrylamide gel, and visualized by silver staining and autoradiography. To analyse the 
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protein composition of the eluted complexes, proteins were precipitated, separated by SDS-
PAGE and subjected to mass spectrometry.  
2.2.4.9 Purification of protein complexes with anti-FLAG-beads 
To purify hPrp19/CDC5L protein complexes, splicing reactions were performed under 
standard conditions in the presence of HeLa nuclear extract from cells expressing FLAG-
tagged AD002/Cwc15 protein. Subsequently, the salt concentration was adjusted to 250 
mM. FLAG-tagged protein and/or complexes containing FLAG-tagged protein were 
bound to anti-FLAG-M2 agarose beads by incubating at 4°C for 4 h with “head-over-tail” 
rotation. Then, the agarose beads with bound complexes were extensively washed with 
G250 buffer, and complexes were eluted by incubating with 0.2 mg/ml FLAG peptide for 
10-15 min. The eluted proteins were precipitated with TCA and analysed by SDS-PAGE. 
2.2.5 RNA cross-linking and structure probing 
2.2.5.1 Psoralen crosslinking 
Psoralen crosslinking was used for the identification of double-stranded (base paired) 
regions and higher-order structures within RNA in affinity-purified spliceosomes. 
Psoralen is an aromatic tricyclic furocumarin, which intercalates between RNA base pairs 
and photoreacts with double-stranded regions via formation of cycloadducts with 
pyrimidine bases. This reaction is initiated by the long wavelength UV irradiation of 
nucleic acids at 364 nm in the presence of psoralen upon the absorption of the photon to 
form monoadducts, and the absorption of another photon results in the formation of a 
crosslink between the strands. The crosslinked RNAs were identified by Northern blot 
analysis by sequential probing, or by direct autoradiography of the blot to detect the 
position of 32P-labelled, crosslinked pre-mRNA. Briefly, MS2-affinity purified 
spliceosomes (0.5-1.0 pmole) formed on PM5-10 pre-mRNA were subjected to long-
wave UV irradiation in the presence of psoralen, and RNA was separated by gel 
electrophoresis. Northern blotting was performed by sequential hybridization of 32P-
labelled probes against U1, U2, U4, U5 and U6 prepared with a Prime It II Random 
Primer Labelling Kit (Stratagene). The migration of different bands detected with each 
probe can be compared and correlated with each other to identify the cross-linked RNA. 
2.2.5.2 Chemical modification 
To study RNA structure in stalled complexes, spliceosomal complexes were formed on 
PM5-10 and/or MINX pre-mRNAs under splicing conditions in vitro, and isolated via 
MS2 selection. Chemical modifications were then performed with 100 µl of purified 
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complexes (3-5 pmoles) in the presence of E. coli tRNA (10ng/ml) using three chemical 
reagents: 1-cyclohexyl-3-(-2-morpholinoethyl) carbodiimide metho-p-toluene sulfonate 
(CMCT) which modifies Watson-Crick interactions mainly at positions N1-G and N3-U, 
dimethylsulfate (DMS) which reacts with N1-A and N3-C, and β-ethoxy-α-
ketobutyralaldehyde (Kethoxal) which modifies specifically N1-G and N2-G. DMS-
containing reactions (0.5 µl DMS per 100 µl reaction volume) were incubated at 20°C for 
8 min in IPP buffer, the reaction was stopped with 100 µl 2x DMS Stop buffer and 
precipitated immediately with five volumes of ethanol in the presence of 1/10 volume of 
3M NaOAc (pH 5.2). CMCT-containing reactions (final concentration, 70 mg/ml) were 
incubated at 20°C for 30 min in IPP buffer, and precipitated immediately with five 
volumes of ethanol in the presence of NaOAc and 1 µl glycogen (20 mg/ml). Kethoxal-
containing reactions (2 µl Kethoxal per 100 µl reaction volume) were incubated on ice for 
1 hr in IPP buffer, and precipitated immediately with five volumes ethanol in the presence 
of 1/10 volume of 3M NaOAc (pH 5.2) and 1 µl glycogen (20 mg/ml). After stopping the 
reactions and precipitating with ethanol, all samples were dissolved in proteinase K buffer 
(for Kethoxal-containing reactions potassium borate (pH 7.0) was added to 50 mM) and 
digested with proteinase K. RNA was isolated by phenol/chloroform extraction and 
finally precipitated with ethanol.  
2.2.5.3 Primer extension 
To perform primer extension, oligonucleotides complementary to chosen sequences in the 
U snRNAs or pre-mRNA were radioactively labelled on their 5’ end using T4 
polynucleotide kinase prior to hybridization and used as primers for reverse transcriptase. 
Primer was added to isolated RNA and allowed to first hybridize by heating and then 
cooling down. Primer extension was performed (in the direction 3’ to 5’ end) by adding 
reverse transcriptase and the four dNTPs (0.1 mM each) to RNA samples, incubating 
them for 45-60 min at 37°C. If chemical modification takes place on the RNA template, 
the primer extension product will be stopped exactly one nucleotide before the chemical 
modification point, resulting in truncated cDNA fragments instead of fully-elongated 
chains. To obtain a sequencing ladder, in vitro transcribed snRNAs were treated in an 
identical manner, but in the presence of 0.5 mM dideoxy-NTPs. Reverse transcripts were 
separated on denaturing, 9.6 % polyacrylamide sequencing gels (8.3 M urea) and 
visualized by autoradiography.  
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2.2.6 Electron microscopy 
The structure of isolated spliceosomal B028 complex was analysed by electron microscopy 
(EM). All EM experiments were performed in collaboration with Dr. Berthold Kastner, and 
3D Electron Cryo-Microscopy with Prof. Dr. Holger Stark. 
2.2.6.1 Sample Preparation for Electron Microscopy 
For electron microscopy (EM) studies, B028 spliceosomes were isolated via the MS2 affinity 
selection method, and the B028 complexes eluted from the amylose column were subjected 
to a second glycerol gradient centrifugation step, using the GraFix procedure (Kastner et 
al., 2008), which stabilizes the individual particles by mild chemical fixation during the 
centrifugation step. Briefly, 15 pmol of spliceosomes were loaded onto a glycerol gradient 
(10-30 %) in G150 buffer supplemented with a fixation agent, namely an increasing 
concentration of glutaraldehyde (0 to 0.1 %). The gradients were centrifuged for 4 h 42 min 
at 50000 rpm in a TH660 rotor at 4°C. Fractions of 175 µl were collected from the bottom 
using a Pharmacia fractionator. Peak fractions were identified by scintillation counting and 
used for EM studies. 
2.2.6.2 Negative staining 
For negative staining, the particles were adsorbed onto a carbon film floated on the surface 
of sample solution for approximately 2-60 min, depending on the concentration of particles 
in the sample, using the single carbon method. Subsequently, the carbon film was 
transferred to the staining solution (~2 % uranyl formate in ddH2O). The carbon film was 
extracted from the staining solution using a copper EM grid covered with a perforated 
carbon film. Excess liquid was removed by blotting using Whatman filter paper. For room 
temperature negative staining, the EM grid was dried and stored in a dry place.  
2.2.6.3 Preparation of unstained samples for electron cryo microscopy 
For an unstained cryo EM preparation, the high percentage of glycerol in the sample 
solution was removed by buffer exchange of the sample with G-150 buffer, performed with 
a Zeba spin desalting column (Thermo Fischer Scientific Inc.). Sample loss during the 
buffer-exchange procedure was judged by scintillation counting and by negative stain 
electron microscopy, which also allowed a determination of the appropriate adsorption 
time. The particles were adsorbed onto a carbon film floated on the surface of sample 
solution for a defined period of time (dependent on the concentration of particles in a 
sample). Then, the carbon film was picked out of the particle solution by using a copper 
EM grid, and several microliters of ddH2O were applied to the grid. This EM grid was 
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subsequently mounted in a Vitrobot Mark IV. Careful blotting using Whatman filter paper 
was used to remove excess liquid desirable for the vitrification. Then the grid was plunged 
into liquid ethane cooled down by liquid nitrogen. Finally, the cryo grids were transferred 
and stored in liquid nitrogen until imaging.  
2.2.6.4 Electron microscopy 
Negative stained EM speciments were visualized with a Philips CM200 FEG Transmission 
Electron Microscope (TEM) at a room temperature at an acceleration voltage of 160 kV.  
2.2.6.5 Single-Particle Image Processing 
Individual particle images were selected semi-automatically (Sander et al., 2003a, b). For 
each data set, several thousands of individual single-particle images were collected. 
Iterative rounds of image processing were performed with IMAGIC-5 and CowEyes 
program. The two-dimensional (2D) image processing was performed until the result was 
stable, including alignment using resampling to polar coordinates (Sander et al., 2003b) and 
multivariate statistical classification (van Heel, 1984). The three-dimensional (3D) structure 
was determined by Prof. Holger Stark using the angular reconstitution method (Van Heel, 
1987; van Heel et al., 2000). 
2.2.7 Mass spectrometry 
For MS analysis, proteins from purified complexes were separated on 4-12 % NuPAGE 
gradients gels (Invirtogen) and stained with Coomassie staining solution. For protein 
identification, lanes were cut into 23 slices and proteins were in-gel digested with trypsin 
and extracted as previously described (Shevchenko et al., 1996). Peptides were analysed 
in an Orbitrap (LTQ Velos Orbitrap or Orbitrap XL) mass spectrometer under standard 
conditions. Proteins were identified by searching fragment spectra against the NCBI non-
redundant (nr) database using Mascot as search engine. Peptides were constrained to be 
tryptic with a maximum of two missed cleavage sites. Carbamidomethylation of cysteines 
and oxidation of methionine residues were considered as variable modifications. The 
highest scoring peptide from each protein, as well as single hit peptides were manually 
inspected to eliminate any false positives in the data set. The overall numbers of 
sequenced peptides were counted and only fragment spectra with an ion score above 30 




3.1 Identification of new small molecule inhibitors of pre-mRNA 
splicing 
Small molecule inhibitors that block or stall splicing at a specific stage can potentially be 
used for isolating homogeneous/stabilised populations of spliceosomes for structural and 
functional studies of pre-mRNA splicing. Furthermore, they could potentially block 
splicing at a novel stage and thus help to isolate new assembly intermediates of the 
spliceosome. Finally, misregulation of alternative splicing can cause or modify the 
severity of many human diseases, such as autoimmune and neurodegenerative diseases 
and cancer. Thus, small molecule inhibitors could potentially be of therapeutic value if 
they also affect alternative splicing outcomes. We thus set out to identify novel 
compounds that inhibit pre-mRNA splicing in vitro. 
3.1.1 Search for small molecule inhibitors of pre-mRNA splicing using a high 
throughput screening assay 
In order to screen large chemical libraries we used an in vitro high throughput-screening 
assay that was developed in our laboratory (Samatov et al, 2002) (Fig. 3.1). This assay 
measures the interaction of one of the spliceosomal proteins, the DEAD box ATPase 
Abstract, with the spliceosome and can be used to search for inhibitors of pre-mRNA 
splicing. This protein is first recruited to the spliceosome when the C complex is formed, 
before the second catalytic step of splicing, and thus can be used as a marker for catalysis 
of the first step of splicing. In this assay, the pre-mRNA substrate is immobilized in the 
wells of a microtiter plate by antibodies that react with the MS2-MBP protein that binds 
the pre-mRNA via MS2 loops (three aptamers). This pre-mRNA, called PM5, contains a 
5’exon, 5’splice site, an intron containing a branch point sequence (BPS) and a 60 nts 
long polypyrimidine tract (PPT), but lacks a 3’splice site and 3’exon. Under splicing 
conditions, this truncated RNA substrate undergoes 5’splice site cleavage, but cannot 
proceed to step II due to the lack of both the 3’splice site sequence and 3’exon. For this 
reason splicing is stalled at the C complex step after splicing intermediates have formed, 
but before the second step of the splicing reaction. Splicing is performed with nuclear 
extract obtained from HeLa cells stably-expressing a FLAG-tagged version of the 
Abstract protein. This protein is marked by adding peroxidase conjugated anti-FLAG 
antibody to the splicing reaction. If C complexes form, the Abstract protein will be 
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incorporated and also immobilized on the plate even after extensive washing. The extent 
of C complex formation is then measured by a peroxidase luminescence reaction. If 
splicing is inhibited by a compound at any stage prior to step II, a loss of this signal, 
compared to the positive control, will be observed. The intensity of the luminescence 
detected reflects the amount of tagged protein present in the spliceosomal C complex, and 
therefore the efficiency of step I catalysis.  
 
 
Figure 3.1 Schematic of the high throughput in vitro screening assay. A pre-mRNA substrate 
lacking a 3’ splice site and 3’ exon is shown bound by the MS2-MBP protein via three MS2 protein 
aptamers introduced at its 5’ end. It is immobilized in the well of a microtiter plate by anti-MBP 
antibodies that react with the MS2-MBP protein. Splicing is performed with nuclear extract containing 
a FLAG-tagged Abstract protein, and this protein is recognized by peroxidase conjugated anti-FLAG 
antibody. The extent of C complex formation is then measured by a peroxidase luminescence reaction. 
The figure is adapted from Samatov et al, 2002. 
 
To screen large chemical libraries, an automated setup using pipetting robots for most 
steps was established by Timur Samatov and Sonja Sievers at the COMAS (Compound 
Management and Screening centre) facility in Dortmund. Using this automated setup, 
they initially screened a chemical library of about 160,000 compounds at the 
concentration of 50 µM for splicing inhibition activity (primary screen). Approximately 
2000 primary hits (~1.5%) showing at least a 50 % decrease in signal intensity were 
subjected to the second test (retested in plates in duplicate) and only 30 reproducible hits 
with at least a 50% decrease in signal intensity were selected for further test in an in vitro 
splicing assay in order to eliminate any false positives. In a second round of screening, I 
tested an additional 12,000 compounds from the COMAS small molecule libraries, 
yielding 48 positive hits. I also performed a third screening with ca. 2,000 compounds 
from the LDC library (commercial and proprietary project-related compounds), including 
a sub-library of kinase inhibitors. From this screen 44 reproducible hits were selected for 
further testing in an in vitro splicing assay.  
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3.1.2 Confirmation of splicing inhibition activity in an in vitro splicing assay  
Reproducible hit compounds from the first screen were tested in an in vitro splicing assay 
using radioactively-labelled, adenovirus-derived MINX-MS2 pre-mRNA as substrate. We 
tested their effect on pre-mRNA splicing using a wildtype HeLa nuclear extract. We 
could observe a dramatic decrease (compared to the DMSO control) in the formation of 
the splicing products, with an increase in the unspliced pre-mRNA and/or intermediates, 
on denaturing gels upon addition of some of these compounds at a concentration of 50 
µM (Fig. 3.2A). In this way, eight compounds were initially confirmed to be inhibitors of 
pre-mRNA splicing in vitro. The structures of these compounds are shown in Fig. 3.2B. 




Figure 3.2 Analysis of in vitro splicing performed in the presence of different compounds at a 
concentration of 50 µM. A. Splicing of 32P-labeled MINX-MS2 pre-mRNA in HeLa nuclear extract 
for 60 min. in the presence of the indicated compounds. RNA was analysed by denaturing PAGE and 
visualized by autoradiography (DMSO: control reaction with solvent). The positions of lariat-intron/3′-
exon, excised lariat intron, pre-mRNA, spliced mRNA, and 5′-exon (top to bottom) are indicated on the 
left. Performed by Dr. T. Samatov. B. Chemical structures of the confirmed inhibitors of pre-mRNA 












































































































































































































































Next, 48 primary hits from screen Nr. 2 were tested in a similar manner (Fig. 3.3A and 
data not shown). One of these compounds, designed 187042 (nr. 33 in Fig. 3.3A) was 
confirmed to inhibit pre-mRNA splicing in vitro at a concentration of 50 µM after 60 
min. (Fig. 3.3A). This compound is structurally related to compound 296, which is one of 
the confirmed hits from screen Nr. 1 (Fig. 3.3C). 
Finally the 44 positive hits from screen Nr. 3 were tested in an in vitro splicing assay 
(Fig. 3.3B and data not shown). At least one of them was shown to inhibit pre-mRNA 
splicing at the concentration of 50 µM. All together, 10 novel compounds were confirmed 
to be small molecule inhibitors of pre-mRNA splicing in vitro.  
 
Figure 3.3 Analysis of in vitro splicing performed in the presence of a subset of hit 
compounds from screen nr. 2 and 3 of the COMAS library at the concentration of 50 µM. A. 
Splicing of 32P-labeled MINX-MS2 pre-mRNA in HeLa nuclear extract for 60 min. in the presence of 
compounds from screen nr. 2 (Nr. 25-48). B. Splicing of 32P-labeled MINX-MS2 pre-mRNA in HeLa 
nuclear extract after 60 min. in the presence of compounds from screen nr. 3 (LDC library, including 
set of kinase inhibitors). RNA was analysed by denaturing PAGE and visualized by autoradiography 
(DMSO: control reaction with solvent). The positions of lariat-intron/3′-exon, excised lariat-intron, pre-
mRNA, and spliced mRNA (top to bottom) are indicated on the left. C. Chemical structure of the 
confirmed hit 187042 (nr. 33) and structurally-related compound S003 296.  
 
3.1.3 Determination of IC50 values and the stage at which spliceosome assembly is 
inhibited 
We next investigated pre-mRNA splicing inhibition in more detail. First, we performed in 
vitro splicing assays, varying the concentration of the various hit compounds. We 
measured the formation of the splicing products and intermediates on denaturing gels. In 
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this way, IC50 values (i.e. the concentration at which the second step of splicing is 
inhibited by 50 %) for each compound could be determined enabling the estimation of the 
potency of each compound. Additionally we investigated splicing complex formation on 
native agarose gels in order to determine at which stage each compound blocks splicing.  
 
A.                                                                                           B. 
 
Figure 3.4 Effects of increasing compound concentrations on the splicing of 32P-labeled 
MINX-MS2 pre-mRNA in vitro. A. Splicing was performed in the presence of various concentrations 
of three different compounds in HeLa nuclear extract for 1 h. RNA was analysed by denaturing PAGE 
(upper panel) and spliceosomal complexes were analysed on an agarose gel (lower panel). The 
positions of lariat-intron/3′-exon, lariat-intron, pre-mRNA, spliced mRNA and the positions of 
spliceosomal complexes C, B, A, H are indicated on the left. Bands were visualized by 
autoradiography. DMSO, control reaction with the solvent. B. Quantification of splicing efficiency and 
determination of IC50 values. The splicing efficiency values for different concentrations c were 
determined from the gels shown in panel A using the IMAGE J program (circles in plots).  These 
values were fitted using the logistic function 𝒇(𝒄) =
𝟏𝟎𝟎
𝟏+𝐞𝐱𝐩[(𝒄−𝐈𝐂𝟓𝟎)/𝐬𝐥𝐨𝐩𝐞]
 (solid curve). The fitting 
parameters, including the IC50, were determined by the nonlinear least-square fit method implemented 
in the Microsoft Office Excel program.  
 
With the DMSO control (which is the solvent for the inhibitors) after 10 minutes of 
splicing, the lariat-3’exon intermediate (a product of the first step of splicing) could be 
seen on a denaturing polyacrylamide gel, and the intensity of the substrate (pre-mRNA) 









1.0 10 503.0 25 37.5
compound 120















1.0 10 503.0 25 37.5
compound 120



















































































step of splicing (spliced mRNA and lariat-intron) were clearly visible after 20 min, and 
after 60 min predominantly spliced mRNA and excised lariat-intron were visible on the 
gels, with only traces of the pre-mRNA and lariat-3’ exon intermediate.  
 
A.                                                                       B. 
 
Figure 3.5 Effects of increasing compound concentrations on the splicing of 32P-labeled 
MINX-MS2 pre-mRNA in vitro. A Splicing was performed in the presence of various concentrations 
of the indicated two compounds in HeLa nuclear extract for 1 h. RNA was analysed by denaturing 
PAGE (upper panel) and spliceosomal complexes were analysed on an agarose gel (lower panel). The 
positions of lariat-intron/3′-exon, lariat-intron, pre-mRNA, spliced mRNA and the positions of 
spliceosomal complexes C, B, A, H are indicated on the left. Bands were visualized by 
autoradiography. DMSO, control reaction with the solvent. B. Quantification of splicing efficiency and 
determination of IC50 values. IC50 values were determined as described in the legend to Fig. 3.4. 
 
When increasing amounts of inhibitor 028 were added to the in vitro splicing reaction, 
unspliced pre-mRNA and/or lariat-3’ exon intermediate started to accumulate at 50 µM 
relative to the DMSO control, after 60 min. of splicing (Fig. 3.4A). We could observe 
strong inhibition of mRNA formation at 75 µM. An accumulation of the A and a B-like 
complex was observed at concentrations above 75 µM on a native agarose gel after 60 
min of splicing. With the DMSO control only C complexes and trace amounts of B and A 
were visible after 60 min. At a concentration of 150-175 µM splicing was inhibited 
completely. The IC50 value for compound 028 was determined to be 51 µM (Fig. 3.4B; 
Table 3.1). Compound 027 inhibited mRNA formation completely at 50 µM, with an IC50 
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on a native agarose gel, suggesting that it probably inhibits splicing before complex A 
formation. Compound 120 inhibited splicing completely at 75 µM, with an IC50 value of 
24 µM (Fig. 3.4B; Table 3.1), and the native gel analysis revealed an accumulation of 
spliceosomal complexes A and B, but to a lesser extend as observed with compound 028. 
 
A.                                                                       B. 
 
Figure 3.6 Effects of increasing compound concentrations on the splicing of 32P-labeled 
MINX-MS2 pre-mRNA in vitro. A and B. Splicing was performed in the presence of various 
concentrations of the indicated two compounds in HeLa nuclear extract for 1 h. RNA was analysed by 
denaturing PAGE (upper panel) and spliceosomal complexes were analysed on an agarose gel (lower 
panel). The positions of lariat-intron/3′-exon, lariat-intron, pre-mRNA, spliced mRNA and the 
positions of spliceosomal complexes C, B, A, H are indicated on the left. Bands were visualized by 
autoradiography. DMSO, control reaction with the solvent. B. Quantification of splicing efficiency and 
determination of IC50 values. IC50 values were determined as described in the legend to Fig. 3.4. 
 
Compound 119 inhibited pre-mRNA splicing fully at the concentration of 75 µM with an 
IC50 of 25 µM (Fig. 3.5; Table 3.1), and native gel analysis revealed the accumulation of 
spliceosomal complex A, but at low amounts compared to the 2 min. DMSO control (Fig. 
3.5). Compound 196 was found to inhibit splicing with high potency, blocking 
completely at the concentration of 10 µM and exhibiting an IC50 of 2 µM (Fig. 3.5; Table 
3.1). However, mainly A complexes accumulated at 3 µM, and at higher concentrations 
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Compounds 296 and 297 showed similar inhibition patterns, with IC50 values of 23 and 
25 µM, respectively (Table 3.1), and both A and B spliceosomal complexes accumulating 
at a concentration of 75 µM or higher (Fig. 3.6). Compound 187042, which is structurally 
related to compound 296 (Fig. 3.3B), inhibited splicing with an IC50 value of 55 µM (Fig. 
3.7A), indicating that it is approximately two times less potent. In contrast to compound 
296, mainly complex A accumulated in the presence of 75 µM or higher concentrations 
of compound 187042. Finally, compound L2 from LDC library inhibited pre-mRNA 
splicing in vitro with an IC50 value of 40 µM, blocking splicing mainly at the A complex 
stage (data not shown). 
 
A.                                                                    B. 
         
Figure 3.7 Effects of increasing compound concentrations on the splicing of 32P-labeled 
MINX-MS2 pre-mRNA in vitro. A. Splicing was performed in the presence of various concentrations 
of the indicated compound in HeLa nuclear extract for 1 h. RNA was analysed by denaturing PAGE 
and spliceosomal complexes were analysed on an agarose gel. The positions of lariat-intron/3′-exon, 
lariat-intron, pre-mRNA, and spliced mRNA, and the positions of spliceosomal complexes C, B, A, H 
are indicated on the left. Bands were visualized by autoradiography. DMSO, control reaction with the 
solvent. B. Quantification of splicing efficiency and determination of IC50 values (see the caption of 
Fig. 3.4 for details). 
 
Several of these compounds were not analysed further due to either the lack of 
accumulation of splicing complexes in their presence (e.g. S003_027 in Fig. 3.2) or the 
inactivity of the subsequent batches of the compounds (e.g. S001_194 in Fig. 3.2). Or in 
some cases, the structures of the compounds suggested that they might be non-specific 
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Table 3.1 Summary of IC50 values determined for small molecules confirmed to be inhibitors 
of pre-mRNA splicing in vitro and the stage at which spliceosome assembly is inhibited. The 
splicing efficiency values for different concentrations c were determined from the gels using the 




The IC50, was determined by the nonlinear least-square fit method implemented in the Microsoft Office 
Excel program.  
Compound IC50 value Splicing complexes accumulating 
028 51 µM A and B-like complexes 
027 25 µM Non-spliceosomal complex H 
120 24 µM A and B-like complexes 
119 25 µM A complexes 
196 2 µM A complexes 
296 23 µM A and B-like complexes 
297 25 µM A and B-like complexes 
187042 55 µM Mainly A and B-like complexes 
 
3.2 Purification and characterization of spliceosomal complexes 
stalled with different splicing inhibitors 
3.2.1 Time course of splicing complex formation at the lowest concentration at which 
splicing is completely inhibited 
Several hit compounds inhibited pre-mRNA splicing in vitro and led to the accumulation 
of spliceosome assembly intermediates. With the goal of affinity purifying splicing 
complexes stalled by these inhibitors, we next analysed splicing complex formation as a 
function of time. For these studies we used a concentration where the first and second 
step of splicing were completely inhibited. These data allowed us to determine the time 
point when one or more complexes had accumulated to the highest amount.  
After 2 min of splicing, mainly A complexes were seen on the native agarose gels with 
the DMSO control, and after 10 min of splicing predominantly B complexes and lower 
levels of C complexes (Fig. 3.8). After 20 min, A and B complexes were converted into C 
complexes and after 60 min only traces of the C complexes are still visible. In the 
presence of 150 µM of compound 028, the kinetics of splicing complex assembly differs 
dramatically. Here, after 10 min, A complexes and complexes migrating faster than B are 
mainly observed. These complexes appear to accumulate to the highest amount after 20 
min of splicing. Similar results were obtained for compounds 120, 296 and 297, which 
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were tested at 75 µM, except that at later time points mainly complex A was observed 
with compounds 296 and 297. At a concentration of 10 µM, an accumulation of mainly 
spliceosomal complex A, which peaked at the 20 min time point, was seen with 
compound 196. Based on these results, we could choose the splicing incubation time, 
where the most spliceosomal complexes accumulated for each compound. 
 
 
Figure 3.8 Kinetics of splicing complex formation with 32P-labeled MINX-MS2 pre-mRNA in 
the presence of the indicated concentrations of various compounds. Splicing was performed for 0 
to 90 min in the presence of an inhibitor at the concentration resulting in full inhibition of pre-mRNA 
splicing in HeLa nuclear extract. Reactions were stopped at the indicated time points. RNA was 
analysed by denaturing PAGE (upper gels) and splicing complexes were analysed on an agarose native 
gel (lower gels), and visualized by phosphorimaging (DMSO: control reaction with the solvent). The 
positions of the lariat-intron/3′-exon, lariat-intron, pre-mRNA, and spliced mRNA (top to bottom), and 
the positions of spliceosomal complexes C, B, A, H are indicated on the left.  
 
3.2.2 Sedimentation behaviour of splicing complexes stalled with compounds 028, 
120, 296 and 297 
We next checked the sedimentation behaviour of complexes stalled in the presence of 
various small molecule inhibitors on glycerol gradients on an analytical scale. The control 
splicing reaction was performed in the presence of DMSO and incubated for 2 min, 
during which mainly A and B complexes were formed. Splicing mixtures were loaded on 
to glycerol gradients. Splicing complexes formed on 32P-labelled MINX-MS2 pre-mRNA 
were then separated by glycerol gradient centrifugation and fractionated from the top. The 
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DMSO control revealed two peaks in fractions 12-14 and 18-20 that sediment with S-
values of approximately 30 and 40-45S, respectively, which correspond to the S-values of 
spliceosomal complexes A and B, respectively (Fig. 3.9). When the splicing reaction was 
performed in the presence of compound 120 (75 µM) for 20 min, a main peak in fractions 
16-19 was detected. In contrast, when splicing was performed for 20 min. in the presence 
of compound 028 (150 µM), complexes sedimenting similar to the A complex were 
observed plus complexes that sediment slightly slower than the B complex (Fig. 3.9). 
This shift was a first hint that the B-like complex accumulating in the presence of 
compound 028 is different from wildtype B/Bact complexes that have higher S-values. 
When splicing was performed for 20 min in the presence of 75 µM compound 296, a 
main peak was seen in fractions 18-20 and thus complexes migrating like B/Bact 
complexes in the DMSO control were formed (Fig. 3.11A). Interestingly, spliceosomal 
complexes formed in the presence of 75 µM compound 297 after 10 min appeared to 
have a higher S-value than the B complexes, peaking ~ 2 fractions closer to the bottom of 
the gradient (Fig. 3.11A). Native gel analysis of splicing complex formation in the 
presence of these compounds revealed predominantly A complexes (Fig. 3.8), which 
seems to contradict the lack of an A complex peak when analysed on glycerol gradients. 
However, the B-like complexes observed on gradients after incubating with compound 
296 or 297 may be unstable and thus dissociate during native gel analysis which is 




Figure 3.9 Glycerol gradient sedimentation profiles of splicing complexes formed in the 
presence of compounds 028 (150 µM) and 120 (75 µM). In vitro splicing was performed under 
standard splicing conditions. Spliceosomal complexes formed on radioactively-labelled MINX pre-
mRNA were separated on a linear 10-30% glycerol gradient containing 150 mM salt, and fractionated 
from the top. The radioactivity of spliceosomal complexes detected in each gradient fraction is plotted. 
Peaks corresponding to the H, A and B spliceosomal complexes are indicated with arrows. * = “B-like” 
complexes formed in the presence of compound 028. 
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3.2.3 Affinity-purification of spliceosomal complexes stalled in the presence of 
selected compounds 
To characterize the complexes stalled with various compounds under study in more 
detail, we purified preparative amounts of them via the MS2 affinity selection method 
(shown schematically in Fig. 3.10A). To this end, in vitro splicing reactions were carried 
out using a radioactively-labelled, adenovirus-derived MINX pre-mRNA substrate 
containing three MS2 bacteriophage coat protein-binding aptamers at its 3’ end (MINX- 
MS2). This MS2-tagged MINX pre-mRNA substrate was first bound by MBP-MS2 
fusion protein, consisting of MS2 bacteriophage coat protein and the maltose-binding 
protein MBP. In vitro splicing was then performed under standard splicing conditions in 
the presence of HeLa nuclear extract. Spliceosomal complexes that form were then 
separated by glycerol gradient centrifugation and the distribution of 32P-pre-mRNA 
determined by Cherenkov counting. Complexes from individual gradient peaks (30S 
region for complex A and ~40S region for complex B) were then incubated with amylose 
beads, which are bound by MBP, and after washing, complexes were eluted with maltose, 
which competes with amylose for binding to MBP. The RNA and protein composition of 
the eluted complexes was then analysed by denaturing PAGE (RNA) and LC-MS/MS 
mass spectrometry (protein).  
We first purified complexes formed in the presence of 75 µM compound 120. The 
glycerol gradient profile of splicing complexes formed in the presence of inhibitor 120 
revealed two gradient peaks: peak I in a ~30S region of the gradient, and peak II in a 
~40S region of the gradient (Fig. 3.10B). Subsequently, complexes were affinity purified 
from peak I and peak II, and the RNA composition from each peak was analysed by 
denaturing PAGE and subsequent silver staining (Fig. 3.10C). RNA analysis of peak I 
revealed mainly the presence of the pre-mRNA, U1 and U2 snRNAs, indicating that they 
are A complexes. The A complex peak of the DMSO control was found to be 
contaminated by B complexes, based on the presence of low levels of U4, U5 and U6 
snRNAs and tri-snRNP proteins as determined by mass spectrometry (Table 3.2). This 
hindered a comparison of the protein composition of ADMSO with A120 complexes. 
Affinity-purified complexes from the 40-45S region (peak II) of the DMSO control and 
compound 120 contained pre-mRNA, U1, U2, U4, U5 and U6 snRNA, indicating they 
are mainly B complexes. Mass spectrometry of 40S complexes stalled by compound 120 
confirmed that they are B complexes, because the protein composition of B120 and B 





Figure 3.10 Purification of complexes stalled with compound 120. A. Schematic view of MS2-
affinity purification of human spliceosomal complexes. MS2-tagged pre-mRNA substrate was pre-
incubated with MS2-MBP fusion protein. Subsequently, splicing was performed in the presence of 40 
% HeLa nuclear extract under standard splicing conditions. Spliceosomal complexes formed were then 
32 -labelled pre-
mRNA. Spliceosomal complexes from each peak were affinity-selected using amylose beads and 
eluted with maltose. B. Glycerol gradient sedimentation profiles of the spliceosomal complexes formed 
in control (DMSO) or compound 120 containing splicing reactions. C. RNA composition of MS2-
affinity purified splicing complexes formed in the presence of DMSO or compound 120. RNA 
recovered from splicing complexes affinity-purified from peaks I and II was analysed by denaturing 
PAGE and detected by silver staining. RNA identities are indicated at the left. 
 
We next affinity-purified complexes stalled by compounds 296 and 297 (Fig. 3.11). RNA 
analysis of spliceosomal complexes formed in the presence of compounds 296 and 297 
recovered from peak II revealed equimolar amounts of pre-mRNA and U2, U5, U6 
snRNAs, with U1 and U4 snRNA underrepresented to some extent, suggesting that these 
“B-like” complexes are different from the B complex formed in the presence of DMSO 
(BDMSO), but their snRNA composition is more similar to the Bact complex (Fig. 3.11B). 
The protein composition analysis of these two complexes was determined by LC-MS/MS 
mass spectrometry (Table 3.2). Complexes stalled in the presence of compounds 296 and 
297 contain similar amounts of U2 and U5 snRNP proteins as complex B, with U4/U6 
and tri-snRNP proteins somewhat underrepresented based on the number of peptides 
























































Skip and RBM22 appear to be incorporated reasonably well, but there is only little 
recruitment of typical Bact-specific proteins, such as RNF113 and Prp17. This is a first 
indication that compounds 296 and 297 may stall spliceosomes during activation, 
specifically after stable incorporation of Prp19/CDC5L complex proteins, but before 
recruitment of Bact-specific proteins. However, B-specific proteins and even second step 
factors (in the case of 296) were also present in these stalled complexes. This suggests 
that these purified complexes contain a mixture of B, Bact and later complexes. Thus, 
further optimization of the purification of these complexes is necessary to characterize 
them in more detail. 
 
     A.                                                                                     B. 
     
Figure 3.11 RNA composition of MS2-affinity purified B/B-like splicing complexes formed in 
the presence of compounds 296 and 297. A. Glycerol gradient sedimentation profiles of splicing 
complexes formed in the presence of compounds 296 and 297. In vitro splicing was performed under 
standard conditions. Spliceosomal complexes formed on radioactively-labelled MINX-MS2 pre-
mRNA were separated on a linear 10-30% glycerol gradient containing 150 mM salt and fractionated 
from the top. The gradient profiles were determined by counting the 32P-MINX radioactivity in each 
fraction. Peaks corresponding to the H, A and B of spliceosomal complexes are indicated with arrows. 
B. RNA recovered from splicing complexes affinity-purified from peak II was analysed by denaturing 
PAGE and detected by silver staining. RNA identities are indicated at the left. 
 
3.2.4 Isolation of splicing complexes stalled with compound 028 
Finally, we affinity-purified complexes formed in the presence of compound 028 and 
investigated their RNA and protein composition. To get a better separation of complexes 
formed in the presence of compound 028 (B028) from other complexes in the glycerol 
gradient, we first optimized the gradient centrifugation conditions, namely, we changed 
the glycerol gradient from 10-30% to 15-30%, and optimized sedimentation parameters 
so, that the B028 complexes sediment closer to the bottom (Fig. 3.12A). We then isolated 


















































Table 3.2 Proteins identified by LC-MS/MS in human spliceosomal complexes A, B and 
complexes stalled in the presence of compounds 120 (B120), 296 (B296) and 297 (B297). The number 
shown is the total number of peptides sequenced for the indicated protein. Proteins are grouped 
according to function or association. Proteins widely considered as common contaminants, such as 




kDa A A 120 B B 120 B B 296 B 297
fmol 250 250 250 250 1,000 1,000 1,000
Sm	proteins
B gi|4507125 24.6 1 7 18 12 108 127 88
D1 gi|5902102 13.3 1 3 7 5 11 12 9
D2 gi|29294624 13.5 7 3 13 11 87 82 87
D3 gi|4759160 13.9 5 6 10 5 79 67 67
E gi|4507129 10.8 6 5 13 6 54 48 42
F gi|4507131 9.7 4 5 8 6 32 30 18
G gi|4507133 8.5 3 2 5 1 24 15 19
U1	snRNP
U1-70K gi|29568103 51.6 10 6 8 3 5 10 0
U1-A gi|4759156 31.3 1 8 7 6 21 32 22
U1-C gi|119624201 17.4 2 2 2 2 4 3 2
U1	snRNP	associated
FBP11 gi|151301228 105.8 1 30 27
S164	(fSAP94) gi|219520438 100.1 0 20 10
17S	U2	snRNP 5 9 12
U2A' gi|50593002 28.4 2 13 26 24 87 142 128
U2B'' gi|4507123 25.4 1 9 11 9 33 67 30
SF3a120 gi|5032087 88.9 37 34 53 56 430 387 350
SF3a66 gi|21361376 49.3 8 7 17 13 48 52 55
SF3a60 gi|5803167 58.5 18 17 30 24 140 167 133
SF3b155 gi|54112117 145.8 77 65 110 78 666 489 545
SF3b145 gi|55749531 100.2 23 19 57 46 359 329 371
SF3b130 gi|54112121 135.5 70 53 84 78 626 662 648
SF3b49 gi|5032069 44.4 3 3 5 4 17 26 24
SF3b14a/p14 gi|7706326 14.6 10 9 11 9 61 75 81
SF3b14b gi|14249398 12.4 5 7 6 7 25 39 50
SF3b10 gi|13775200 10.1 1 1 6 4 24 29 16
17S	U2	related
hPRP43 gi|68509926 90.9 24 7 35 22 137 118 94
SPF45 gi|14249678 45 5 5 9 7 23 16 12
SPF30 gi|37087924 26.7 26 21 15
U2AF65 gi|6005926 53.5 3 7 10 8 29 29 23
U2AF35 gi|5803207 27.9 2 6 2 9 16 9
SPF31	 gi|3599415 31 1 0 0 3 2
hPRP5 gi|664806097 117.4 1 0 0
SR140	(fSAPa) gi|122937227 118.2 51 45 30
CHERP gi|119226260 100 11 4 5 4 41 32 23
PUF60 gi|74761960 59.9 4 21 1 15 3 27 23
SF3b125 gi|45446747 103 2 0 5 0 1 1
A	proteins
THRAP3	(TRAP150) gi|167234419 108.5 13 8 0 1 10 6
BUB3 gi|56550081 37.2 8 42 37
FLJ10839,	CCAR1 gi|46852388 132.8 1 88 70
RBM10 gi|12644371 103.5 9 8 12 10 30 13 23
SF1 gi|42544130 68.3 2 14 11
RBM5/LUCA15 gi|5032031 92.1 6 0 7 2 18 14 27
SF4	(F23858) gi|33469964 72.5 0 19 13
U5	snRNP
220K	/	Prp8 gi|3661610 273.7 90 16 185 122 836 799 798
200K	/	Brr2 gi|45861372 244.5 100 17 189 129 934 859 821
116K	/	Snu114 gi|41152056 109.4 60 17 82 69 468 503 445
40K gi|4758560 39.3 1 4 33 31 130 138 160
102K	/	Prp6 gi|40807485 106.9 29 59 36 424 222 262
15K	/	Dib1 gi|5729802 16.8 32 12 8
100K	/	Prp28 gi|41327771 95.6 7 23 3 20 24 24
52K	/	Lin1 gi|5174409 37.6 25 11 6
LSm	proteins
LSm2 gi|10863977 10.8 4 2 8 5 35 22 20
LSm3 gi|7657315 11.8 12 11 11
LSm4 gi|6912486 15.4 1 10 5 39 28 23
LSm5 gi|10720081 9.9 2 2 4
LSm6 gi|5919153 9.1 1 2 2 24 18 14
LSm7 gi|7706423 11.6 0 3 2 14 10 11






kDa A A 120 B B 120 B B 296 B 297
fmol 250 250 250 250 1,000 1,000 1,000
U4/U6	di-snRNP
90K gi|4758556 77.6 19 2 48 32 246 118 165
60K gi|45861374 58.4 16 5 41 27 226 80 131
20K gi|5454154 20 9 2 16 7 82 31 55
61K gi|40254869 55.4 13 1 27 13 126 38 76
15.5K gi|4826860 14.2 20 12 13
U4/U6.U5	tri-snRNP
110K gi|13926068 90.2 19 1 62 41 431 223 225
65K gi|56550051 65.4 10 12 17 5
27K gi|24307918 18.9 2
B	proteins
hSnu23 23.6 20 43 24
hPRP38 gi|24762236 37.5 1 17 52 66 41
hSmu-1	(fSAP57) gi|8922679 57.5 8 8 33 34 275 270 289
MFAP1 gi|50726968 51.9 1 4 12 15 73 101 90
RED gi|10835234 65.6 1 0 37 37 246 230 230
FBP21 gi|67461858 42.5 10 7 42 10 18
hPRP19/CDC5L	complex
hPRP19 gi|7657381 55.2 3 1 17 22 32 216 218
CDC5L gi|11067747 92.2 0 30 36 41 218 237
SPF27 gi|5031653 21.5 10 6 8 61 60
PRL1 gi|4505895 57.2 20 124 94
CCAP1	(hsp73) gi|5729877 70.4 7 9 11 11 24 17 6
CCAP2	(	AD-002) gi|7705475 26.6 0 4 3 18 24
CTNNBL1 gi|18644734 65.1 1 6 2 30 39
Npw38BP gi|7706501 70 0 11 23 43 109 89
Npw38 gi|5031957 30.5 11 44 37
hPRP19/CDC5L	related
RBM22	(fSAP47) gi|8922328 46.9 2 9 15 59 63
hSYF1	(XAB2) gi|55770906 100 2 8 9 4 147 128
CRNKL1	/	hSYF3 gi|30795220 100.6 13 133 81
hIsy1	(fSAP133) gi|20149304 33 3 7 5 29 26
SKIP gi|6912676 51.1 8 20 30 160 161
Cyp-E gi|5174637 33.4 3 48 23
PPIase-like	1	(PPIL1) gi|7706339 18.2 11 39 39
KIAA0560	(fSAP164) gi|38788372 171.3 1 11 12 11 219 149
G10	(fSAP17) gi|32171175 17 2 5 8 38 26
A/B	proteins
TCERG1	(CA150) gi|21327715 123.9 0 65 44
ELAV	(HuR) gi|38201714 36.1 12 39 29
p72/DDX17 gi|3122595 80.5 3 2 7
DDX9,	DHX9 gi|4503297 142 30 4 15 1 42 19 2
NFAR gi|62512150 95.4 5 1 1 22 8 1
NF45 gi|24234747 43 5 4 0
LOC124245 gi|31377595 104 6 0 14 17 15 64 52
YB-1 gi|34098946 35.9 3 6 9 10 33 51 15
ASR2B gi|33383233 100 22 7 18 23 4 103 128
p68	(DDX5) gi|4758138 69.2 2 3 8 9 20 35 30
Recruited	prior	to	Bact
hsp27 gi|4504517 22.8 0 2 0
UBL5 gi|13236510 8.5 14 19 26
hPRP4-Kinase gi|89276756 117.1 1 6 0 6 11
HsKin17 gi|13124883 45.4 0 47 52
BCLAF1 gi|7661958 106 1 11 3
SKIV2L2	(KIAA0052) gi|193211480 117.8 18 1 11 4 22 6 7
Abundant	first	in	Bact
KIAA1604	(fSAPb) gi|55749769 105.5 0 45 8
hPRP17 gi|7706657 65.5 8 7 17 76 40
hPRP2 gi|4503293 119.2 0 77 24
GPKOW	 gi|15811782 52.1 0 11 0
NY-CO-10 gi|64276486 53.8 0 15 7
RNF113A gi|5902158 38.8 0 9 5
MGC20398 gi|49472814 42 0 23 28
PPIL2	/	Cyp-60 gi|7657473 59.5 0 53 55







kDa A A 120 B B 120 B B 296 B 297
fmol 250 250 250 250 1,000 1,000 1,000
2nd	step	factors
hPRP22 gi|4826690 139.3 0 31 0
hPRP16 gi|17999539 140.5 0 9 0
hSLU7 gi|27477111 68.4 0 15 0
Abstrakt gi|21071032 69.8 17
GCIP	p29	(fSAP29) gi|46371998 28.7 1 25 1
detected	in	C	complex
eIF3	S6 gi|7705433 66.6 17 8 0
RBM4 gi|93277122 40.2 2 4 3 7 7 8
matrin	3 gi|21626466 94.6 7 5 9 13 4
EJC/mRNP
eIF4A3 gi|7661920 46.9 3 16 6
Magoh gi|4505087 17.2 0 3 0
Y14 gi|4826972 19.9 0 3 0
DDX3 gi|87196351 73.3 1 6 6 13 10 41 38
mRNA	binding	proteins
PABP1 gi|46367787 70.5 2 23
cap	binding	complex
CBP20 gi|110349727 18 4 2 5 7 13 17 12
CBP80 gi|4505343 91.8 26 12 36 29 91 225 150
RES	complex
SNIP1 gi|21314720 45.8 0 28 26
MGC13125	(fSAP71) gi|14249338 70.5 4 8 1 53 66
CGI-79 gi|4929627 39.7 0 23 27
SR	proteins
SF2/ASF gi|5902076 27.8 14 39 41
9G8 gi|72534660 27.4 8 22 26
SRp20 gi|4506901 19.4 0 21 11
SRp30c gi|4506903 25.5 9 10 1
SRp38 gi|5730079 31.3 0 3 3
SRp55 gi|20127499 39.6 4 10 37
hTra-2	beta	/	SFRS10 gi|4759098 33.7 4 3 3
SR	related	proteins
SRm300 gi|4759098 300 0 32 21
hnRNP
hnRNP	A0 gi|8134660 30.9 10 6 4
hnRNP	A1 gi|4504445 38.7 27 28 26
hnRNP	A3 gi|34740329 39.6 24 24 17
hnRNP	A2/B1 gi|14043072 37.4 11 4 4
hnRNP	C gi|4758544 33.3 17 11 10
hnRNP	D gi|14110420 2 2 1
hnRNP	F gi|148470406 45.7 5 16 19
hnRNP	G gi|56699409 42.4 14 12 12
hnRNP	H1 gi|5031753 49.1 11 26 21
hnRNP	H2 gi|2500576 49.3 0 18 0
hnRNP	H3 gi|23503095 36.9 0 0 0
hnRNP	K gi|14165435 51 0 22 17
hnRNP	R gi|5031755 70.9 8 10 4
hnRNP	U gi|14141161 90.6 9 10 8
hnRNP	U-L2 gi|118601081 85 7 2 3
PCBP1 gi|5453854 37.5 14 15 36
E1B-AP5 gi|8051631 95.7 4 5 11
Miscellaneous	proteins
RBM7 gi|4503293 30.5 5 2 0
dermcidin gi|20141302 11.3 50 28 36
RACK1	(GNB2L1) gi|54037168 35.1 34 17 12
desmoglein	1 gi|292495005 114 36 26 21
desmoplakin gi|115502381 332 37 22 26
S100a18,	Hornerin gi|45476906 282 42 24 52
IGF2BP3	(Koc1) gi|30795212 63.6 13 16 8
DHX36 gi|313104099 115 15 7 1
filaggrin	2 gi|74096732 248 14 31 26
GAPDH gi|120649 36 8 9 2
human	serum	albumin gi|4502027 66 24 19 41
beta-actin gi|46397333 41 10 7 6
tubulin	beta-5 gi|56757569 50 55 33 45
RBM39 gi|124297482 57 5 9 4
FUBP2 gi|313104306 77 0 24 9
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splicing complexes from peaks I, II and III using MS2 affinity selection. With compound 
028, complexes in peak II contained equimolar amounts of unspliced pre-mRNA and U2, 
U5 and U6, but had much less U1 snRNA, and nearly no U4 snRNA, suggesting they are 
mainly activated spliceosomes. However, with compound 028, complexes in peak II were 
shifted 1-2 fractions toward the top; thus, they have a lower S-value than Bact and B 
complexes, suggesting they might be a novel spliceosome assembly intermediate. Peak I 
corresponds to H complexes, while peak II contained A complexes, with only U1, U2 and 
pre-mRNA. 
 
Figure 3.12 Purification of splicing complexes stalled with compound 028. A. Glycerol 
gradient sedimentation profiles of the separated spliceosomal complexes. B. RNA composition of 
MS2-affinity purified splicing complexes. RNA recovered from complexes affinity-purified from 
peaks I, II and III was analysed by denaturing PAGE and detected by silver staining. RNA identities 
are indicated at the left. 
 
3.2.5 Protein composition of affinity-purified spliceosomal A and B-like complexes 
formed in the presence of compound 028  
The protein composition of MS2 affinity-purified B028, B and Bact spliceosomal 
complexes, as well as A028 and A complexes was determined by LC-MS/MS mass 
spectrometry in several independent experiments. The MS analysis was performed in 
collaboration with the group of Prof. Dr. H. Urlaub. The number of peptides sequenced 
for spliceosomal proteins in the purified A or B/Bact complexes is shown in Table 3.2. To 
isolate Bact complexes we used the PM5-10 substrate, which is a truncated version of the 
PM5 pre-mRNA, containing a 5’exon, an intron with a branch site, a 5 nt stretch between 
the BPS and PPT, and a polypyrimidine tract shortened to 10 nt (compared to 60 nt in the 
full-length version), but no terminal AG dinucleotide and no 3'exon. Additionally, it 
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contains triple MS2 aptamers at its 5’ end, enabling affinity selection of spliceosomal 
complexes. Spliceosome assembly utilizing this pre-mRNA is stalled prior to the catalytic 
activation step (i.e. B* formation), and thus allows activated spliceosomes (Bact) to be 
isolated.  
Mass spectrometry showed that the A complexes formed in the presence of compound 
028 contain similar amounts of U1 and U2 proteins, compared to A complexes, formed in 
the presence of DMSO (Table 3.3). However there were some differences in the amounts 
of some U2-related proteins, such as SPF45, SPF30, CHERP and also the A or A/B 
proteins DDX9 and RBM5 (based on total peptides identified for each protein), which 
appear to be less abundant in A028 complexes. The SPF30 protein is known to associate 
with both the U2 snRNP and the tri-snRNP (Rappsilber et al., 2001; Meister et al., 2001), 
suggesting the accumulation of A complexes in the presence of compound 028 could 
potentially be caused by the absence of SPF30, blocking the transition from A complex to 
B complex. Purified A complexes from the DMSO control apparently also contain low 
amounts of contaminating B complexes, based on the presence of U5, U4/U6 and tri-
snRNP proteins.  
Based on the number of detected peptides, many proteins appear to be present in 
equal/similar amounts in B028 and B complexes formed in the presence of DMSO (Table 
3.3). These include nearly all proteins associated with U1 snRNP, U2 snRNP, and also 
U5 snRNP, including the DExD/H-box protein Brr2, which catalyses the unwinding of 
U4/U6, and Prp8 and the GTPase Snu114, which among others regulate/activate Brr2 
activity during the activation step (Small et al., 2006; Maeder et al. 2009; Mozaffari-Jovin 
et al., 2013). However, several U5-specific proteins appear to be underrepresented in B028 
such as 102K/Prp6, 15K/Dib1 and the DEAD-box phosphoprotein 100K/hPrp28, which 
catalyses the release of U1 from the 5’SS of pre-mRNA during spliceosome activation, so 
that U6 can interact with the 5’ splice site (Staley and Guthrie 1999, Chen et al. 2001).  
Distinct from B complexes, B-like complexes formed in the presence of compound 028 
contain highly underrepresented amounts of U4/U6 snRNP proteins, which is 
characteristic for Bact spliceosomal complexes (Table 3.3). Indeed, only few peptides were 
sequenced for U4/U6 snRNP proteins in purified Bact complexes. Lsm proteins, which 
dissociate during activation, are detected in B complexes. They appear to be still 
abundant in B028; by comparison only low levels of them are detected in activated 
spliceosomes (Bact), suggesting the inhibition of spliceosome assembly by 028 occurs 
before Lsm destabilisation. 
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Table 3.3 Proteins identified by LC-MS/MS in human spliceosomal complexes B, Bact and 
complexes stalled in the presence of compound 028 (B028). The number shown is the total number 
of peptides sequenced for the indicated protein. Proteins are grouped according to function or 
association. Proteins considered as common contaminants, such as ribosomal proteins and non-




kDa A A 028 A A 028 B B 028 B B 028 Bact
fmol 250 250 400 500 250 250 800 800 800
MS2-MBP 196 276 316
Sm proteins
B gi|4507125 24.6 1 7 39 15 18 12 55 55 57
D1 gi|5902102 13.3 1 3 3 20 7 4 8 13 14
D2 gi|29294624 13.5 7 7 40 17 13 7 33 47 64
D3 gi|4759160 13.9 5 6 30 24 10 6 37 39 47
E gi|4507129 10.8 6 6 16 13 7 19 19 27
F gi|4507131 9.7 4 4 5 8 6 18 23 29
G gi|4507133 8.5 3 3 5 1 5 4 6 9 14
U1 snRNP
U1-70K gi|29568103 51.6 10 7 36 58 8 3
U1-A gi|4759156 31.3 1 7 34 21 7 3 7 15 9
U1-C gi|119624201 17.4 2 3 2 2 4 2
U1 snRNP associated
FBP11 gi|151301228 105.8 9 9
S164 (fSAP94) gi|219520438 100.1 5 1 6 1 9 6
17S U2 snRNP
U2A' gi|50593002 28.4 2 13 89 60 26 15 47 91 87
U2B'' gi|4507123 25.4 1 6 37 40 11 9 23 30 47
SF3a120 gi|5032087 88.9 37 41 322 355 53 50 205 210 194
SF3a66 gi|21361376 49.3 8 13 50 43 17 13 24 33 34
SF3a60 gi|5803167 58.5 18 22 135 138 30 25 62 95 75
SF3b155 gi|54112117 145.8 77 70 671 652 110 91 337 404 327
SF3b145 gi|55749531 100.2 23 15 219 313 57 37 185 238 228
SF3b130 gi|54112121 135.5 70 60 833 723 84 86 365 481 496
SF3b49 gi|5032069 44.4 3 3 43 15 5 3 10 15 18
SF3b14a/p14 gi|7706326 14.6 10 10 38 24 11 11 14 25 28
SF3b14b gi|14249398 12.4 5 6 32 29 6 8 13 22 25
SF3b10 gi|13775200 10.1 1 2 9 6 4 10 12 11
17S U2 related
hPRP43 gi|68509926 90.9 24 6 115 84 35 16 41 39 56
SPF45 gi|14249678 45 5 3 56 18 9 3 2 7 5
SPF30 gi|37087924 26.7 44 9
U2AF65 gi|6005926 53.5 3 5 5 12 10 5 7 13
U2AF35 gi|5803207 27.9 2 2 4 6 6 2 7 1
SPF31 gi|3599415 31 2 0 6 2 4
hPRP5 gi|664806097 117.4
SR140 (fSAPa) gi|122937227 118.2 10 40 5 12 16
CHERP gi|119226260 100 11 1 87 19 5 3 2 4 6
PUF60 gi|74761960 59.9 4 8 1 6 1
SF3b125 gi|45446747 103 0 1
A proteins
THRAP3 (TRAP150) gi|167234419 108.5 13 8 0
BUB3 gi|56550081 37.2 0 2 6 4
FLJ10839, CCAR1 gi|46852388 132.8 3 7
RBM10 gi|12644371 103.5 9 10 84 30 12 7 4 13 7
SF1 gi|42544130 68.3 2 1 14 1
RBM5/LUCA15 gi|5032031 92.1 6 48 1 7 1
ZNF207 gi|6137311 50.8
SF4 (F23858) gi|33469964 72.5 3 40
U5 snRNP
220K / Prp8 gi|3661610 273.7 90 7 39 185 141 505 644 748
200K / Brr2 gi|45861372 244.5 100 12 44 189 160 563 702 820
116K / Snu114 gi|41152056 109.4 60 9 65 0 82 79 256 338 407
40K gi|4758560 39.3 1 1 13 33 29 59 85 123
102K / Prp6 gi|40807485 106.9 29 1 8 59 26 181 77 24
15K / Dib1 gi|5729802 16.8 15 3 9 5 1
100K / Prp28 gi|41327771 95.6 7 23 31 21 17
52K / Lin1 gi|5174409 37.6 6 8 3 4
LSm proteins
LSm2 gi|10863977 10.8 4 1 1 8 6 11 18 9
LSm3 gi|7657315 11.8 2 6 2
LSm4 gi|6912486 15.4 1 0 10 7 10 18 5
LSm5 gi|10720081 9.9 2 3 2
LSm6 gi|5919153 9.1 1 2 2 7 11 4
LSm7 gi|7706423 11.6 0 3 2 7 6 1





kDa A A 028 A A 028 B B 028 B B 028 Bact
fmol 250 250 400 500 250 250 800 800 800
U4/U6 di-snRNP
90K / Prp3 gi|4758556 77.6 19 1 26 0 48 19 128 47 9
60K / Prp4 gi|45861374 58.4 16 1 22 41 12 90 35 11
20K gi|5454154 20 9 2 4 16 9 37 27 4
61K / Prp31 gi|40254869 55.4 13 0 3 27 12 52 16 5
15.5K / Snu13 gi|4826860 14.2 10 4 1
U4/U6.U5 tri-snRNP
110K / Snu66 gi|13926068 90.2 19 5 62 31 238 108 21
65K / Sad1 gi|56550051 65.4 10 6 2 3
27K gi|24307918 18.9 2
B proteins
hSnu23 gi|52783532 23.6 6 6 13 19 12
hPRP38 gi|24762236 37.5 1 7 61 81 35
hSmu-1 (fSAP57) gi|8922679 57.5 8 5 33 34 131 191 78
MFAP1 gi|50726968 51.9 1 2 12 11 63 73 46
RED gi|10835234 65.6 1 0 37 28 91 147 60
FBP21 gi|67461858 42.5 10 3 21 7
hPRP19/CDC5L complex
hPRP19 gi|7657381 55.2 3 3 17 8 77 33 296
CDC5L gi|11067747 92.2 0 30 5 89 35 249
SPF27 gi|5031653 21.5 0 10 2 17 9 56
PRL1 gi|4505895 57.2 4 0 38 23 193
CCAP1 (hsp73) gi|5729877 70.4 7 10 11 8 21 26 55
CCAP2 ( AD-002) gi|7705475 26.6 0 0 8 2 24
CTNNBL1 gi|18644734 65.1 1 1 10 34
Npw38BP gi|7706501 70 0 11 24 43 115 44
Npw38 gi|5031957 30.5 6 7 4 27 9
hPRP19/CDC5L related
PRCC gi|40807447 52.4 0 0 9 1 15
RBM22 (fSAP47) gi|8922328 46.9 2 0 29 6 73
hSYF1 (XAB2) gi|55770906 100 2 8 2 45 7 290
CRNKL1 / hSYF3 gi|30795220 100.6 4 60 17 200
hIsy1 (fSAP133) gi|20149304 33 3 1 16 6 86
SKIP gi|6912676 51.1 8 5 60 24 143
Cyp-E gi|5174637 33.4 3 12 3 66
PPIase-like 1 (PPIL1) gi|7706339 18.2 3 1 8 13 30
KIAA0560 (fSAP164) gi|38788372 171.3 1 11 4 60 13 432
G10 (fSAP17) gi|32171175 17 2 3 13 26 30
A/B proteins
TCERG1 (CA150) gi|21327715 123.9
ELAV (HuR) gi|38201714 36.1
p72/DDX17 gi|3122595 80.5 2
DDX9, DHX9 gi|4503297 142 30 5 77 32 15 5
NFAR gi|62512150 95.4 5 3 1 3 8
NF45 gi|24234747 43 5 8
LOC124245 gi|31377595 104 6 0 1 14 3
YB-1 gi|34098946 35.9 3 10 29 24 9 8
ASR2B gi|33383233 100 22 1 4 9 18 23
p68 (DDX5) gi|4758138 69.2 2 1 2 8 4 5 16 15
Recruited prior to Bact
hsp27 gi|4504517 22.8 4 2 2 4
UBL5 gi|13236510 8.5 12 14 14
hPRP4-Kinase gi|89276756 117.1 1 6 2 1
HsKin17 gi|13124883 45.4 16 7 18
BCLAF1 gi|7661958 106 2
SKIV2L2 (KIAA0052) gi|193211480 117.8 18 1 11 2 10 1 5
Abundant first in Bact
KIAA1604 (fSAPb) gi|55749769 105.5 8 183
hPRP17 gi|7706657 65.5 8 1 42 7 171
hPRP2 gi|4503293 119.2 18 7 184
GPKOW gi|15811782 52.1 5 104
NY-CO-10 gi|64276486 53.8 6 54
RNF113A gi|5902158 38.8 1 41
MGC20398 gi|49472814 42 11 40
PPIL2 / Cyp-60 gi|7657473 59.5 20 3 111
MGC23918 gi|21389497 19.2 11 1 36
FRG1 gi|4758404 29.2 9
Detected in Bact
TRIM24 gi|47419911 116.7 9
LENG1 gi|24308289 30.4 62
DDX50 gi|13129006 82.4 4
FLJ38348 gi|167900474 30.1 11
CRIPT, HSPC139 gi|7661798 11.1 1
GTL3 (fSAP23) gi|8392875 22.6 1 22
MOV10 gi|14211540 113.5 9 2






kDa A A 028 A A 028 B B 028 B B 028 Bact
fmol 250 250 400 500 250 250 800 800 800
2nd	step	factors
hPRP22 gi|4826690 139.3 89
hPRP16 gi|17999539 140.5
hPRP18 gi|4506123 39.9
hSLU7 gi|27477111 68.4 31
Abstrakt gi|21071032 69.8 39
HSP70 gi|5123454 70 10 34
GCIP	p29	(fSAP29) gi|46371998 28.7 20





RBM4 gi|93277122 40.2 4 0
BCAS1	(AIBC1,	NABC1) gi|191251777 61.2
DBPA gi|20070160 40.1 25 16
matrin	3 gi|21626466 94.6 7 1 5 6
EJC/mRNP
eIF4A3 gi|7661920 46.9 0 0 50
Magoh gi|4505087 17.2
Y14 gi|4826972 19.9 5
Pinin gi|33356174 81.6 8
RNPS1 gi|6857826 34.2 3
Acinus	(fSAP152) gi|7662238 151.8
UAP56 gi|18375623 49.1
ELG gi|8923771 38.9 2 14
DDX3 gi|87196351 73.3 1 6 3 8 6
mRNA	binding	proteins
PABP1 gi|46367787 70.5 2 23 3
PABPC4,	IPABP,	APP1 gi|4504715 70.6
PABPN1,	PAB2 gi|4758876 32.6 1 1
cap	binding	complex
CBP20 gi|110349727 18 4 4 4 3 5 6 7 20 18
CBP80 gi|4505343 91.8 26 13 30 57 36 32 80 124 213
TREX
THOC1	(HPR1) gi|154448890 75.6 1 2
THOC2 gi|125656165 169.6 1 3
THOC3 gi|14150171 38.8 1 2
THOC5	(KIAA0983,	fSAP79) gi|50959110 78.5
THOC6	(WDR58,	MGC2655) gi|31543164 37.5 1 5
THOC7	(FLJ23445,	fSAP24) gi|13376623 23.7 1
RES	complex
SNIP1 gi|21314720 45.8 13 3 64
MGC13125	(fSAP71) gi|14249338 70.5 4 0 24 15 115
CGI-79 gi|4929627 39.7
SR	proteins
SF2/ASF gi|5902076 27.8 0 7 5 14 12 12
9G8 gi|72534660 27.4 1 2 21
SRp20 gi|4506901 19.4 1 10
SRp30c gi|4506903 25.5 2 2 3 1 4 12
SRp38 gi|5730079 31.3 35
SRp46 gi|14141216 3
SRp55 gi|20127499 39.6 9 2 11 5 2 22
SRp75 gi|21361282 56.8 3 2
hTra-2	alpha gi|9558733 32.7 9
hTra-2	beta	/	SFRS10 gi|4759098 33.7 5 10 4 1 19
SR	related	proteins
SRm160 gi|42542379 102.5
SRm300 gi|4759098 300 23 10 196
hnRNP
hnRNP	A0 gi|8134660 30.9 3 9 1 3 1 6 8
hnRNP	A1 gi|4504445 38.7 3 1 1 11 5 15 12 3
hnRNP	A3 gi|34740329 39.6 2 4 4 8 6 5
hnRNP	A2/B1 gi|14043072 37.4 4 1 8 4 1 3 1
hnRNP	C gi|4758544 33.3 5 21 10 7 3
hnRNP	D gi|14110420 38.4
hnRNP	F gi|148470406 45.7 2 2 2 5 11 7
hnRNP	G gi|56699409 42.4 1 4 0 6 2 5 4 23
hnRNP	H1 gi|5031753 49.1 0 8 4 4 10 3 21 12
hnRNP	H2 gi|2500576 49.3 1 11
hnRNP	H3 gi|23503095 36.9 1 2 4
hnRNP	K gi|14165435 51 2 6 1 5 5 6 2 14 1
hnRNP	L gi|215274006 64.1 1
hnRNP	M gi|14141152 77.5 6 1 11 3
hnRNP	R gi|5031755 70.9 1 10 2 8
hnRNP	U gi|14141161 90.6 7 3 0 3 0
hnRNP	U-L2 gi|118601081 85 10 2 6 1 5 2 1 4





MS analysis also revealed that most B-specific proteins are present in B and B028 
complexes in similar amounts. One exception was the FBP21 protein, which appears to 
be underrepresented in B028 complexes. In contrast to Bact complexes, B028 complexes 
have little or no Bact-specific spliceosomal proteins that are recruited during activation. 
Thus, the inhibition by 028 occurs prior to Bact complex formation. Based on the detection 
of low amounts of Bact-specific proteins, BDMSO complexes also appear to contain a low 
level of Bact complexes. Interestingly, B028 complexes also have much fewer 
Prp19/CDC5L complex proteins as well as Prp19/CDC5L related factors, relative to Bact 
complexes. These proteins are usually detected in B complexes in low amounts, but they 
are stabilized during activation, and thus found enriched in Bact and subsequently formed 
C complexes (Bessonov et al, 2008). On the other hand, there are higher amounts of 
Npw38BP and Npw38 in the B028 complex compared to B and Bact complexes. These 
proteins normally dissociate during the activation step and are not detected in Bact, 
suggesting that spliceosome assembly is stalled in the presence of compound 028 prior to 
the stable integration of the Prp19/CDC5L complex and prior to Npw38 and Npw38BP 
dissociation. Taken together, the protein composition of B028 complexes suggests that 
compound 028 stalls splicing at an early stage of the spliceosome activation step. 
3.2.6 Immunoblotting confirms the absence/presence of selected proteins in affinity-
purified spliceosomal complex B028  
To confirm the presence or absence of selected proteins in B028 complexes we performed 
immunoblotting with affinity-purified B, B028 and Bact complexes. The signal intensity of 
U5 116K/Snu114 protein was used as a loading control. As shown in figure 3.13, the 
U4/U6 60K/Prp4 protein, also a component of the tri-snRNP, was detected in complex B, 
but not in B028 complexes with anti-60K antibodies. The B-specific protein Prp38 was 
GenBank 
accession no.
kDa A A 028 A A 028 B B 028 B B 028 Bact
fmol 250 250 400 500 250 250 800 800 800
Miscellaneous proteins
RBM7 gi|4503293 30.5 8
dermcidin gi|20141302 11.3 5 7 47 79 4 4
S100 A9 gi|115444 13 4 10
S100 A8 gi|115442 11 3 4 10 19 3 7 15 10 11
desmoglein 1 gi|292495005 114 18 19 4 20 15 20 57 71 59
desmoplakin gi|115502381 332 25 13 8 47 15 54 17 14 35
S100a18, Hornerin gi|45476906 282 23 10 35 84 13 16
FABP5 gi|232081 15 4 2 2 3 3
IGF2BP3 (Koc1) gi|30795212 63.6 6 5 4 2 5 0
filaggrin 2 gi|74096732 248 7 6 21 32 5 19 30 34 47
PDCD6 gi|29791717 25 7 1 7 5
GAPDH gi|120649 36 5 2 3 20 1 5
human serum albumin gi|4502027 66 9 5 109 18 10 10 7 7 6
alpha tubulin gi|37492 46 8 12 25 13 19 21
beta tubulin gi|338695 30 26 74
beta-actin gi|46397333 41 3 2 3 5
tubulin beta-5 gi|56757569 50 12 17 13 7 26 19 11 7 5
JUP, PDGB, gamma-Catenin gi|15080189 82 15 9 0 17 12 23 15 8 14
RBM39 gi|124297482 57 11
FUBP2 gi|313104306 77 3
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detected both in B and B028 complexes in approximately equal amounts. In contrast, 
Npw38 and Npw38BP, which belong to the group of Prp19/CDC5L-related proteins, 
were not detected by immunoblotting in the B complex, but were present in the stalled 
B028 complexes. Spliceosomes formed in the presence of compound 028 contained 
underrepresented amounts of Prp19/CDC5L complex proteins (i.e. Prp19 and CDC5L) 
(Fig. 3.13B), which are normally first abundant in the Bact complex (i.e. after activation). 
Furthermore, the amount of these proteins is even less than in the affinity purified B 
complexes, suggesting compound 028 might affect the association of the Prp19/CDC5L 
complex in a negative way. Additionally B028 complexes lack the Bact specific protein 
Prp17 that is recruited during activation. However they still contain similar amounts of 
the Lsm4 protein as the B complex.  
  A.                                     B. 
 
Figure 3.13 Western blot analyses of the purified B, B028 and Bact complexes. Affinity-purified 
B and B028 (A) or B, B028 and Bact complexes (B) were subjected to the western blot analysis. Purified 
complexes were separated on an 10% SDS-PAGE, transferred to a nitrocellulose membrane and blotted 
with the indicated antibodies. To ensure that equal amounts of the both complexes were analysed, 
antibodies against the U5-116K protein, a stable core component of the spliceosome, were used. 
 
A component of the U2 snRNP, the SF3b155 protein, is known to be phosphorylated 
during/after the activation step but prior the first catalytic step of splicing (Wang et al., 
1998). If detected by anti-SF3b155 antibodies, both states of this protein – 
phosphorylated and not phosphorylated – can be identified, but they exhibit different 
migration behaviour during SDS-PAGE. To check whether the SF3b155 in the B028 
complexes is phosphorylated, we performed immunoblotting with anti-SF3b155 
antibodies. Indeed, we could observe that the SF3b155 band in B and also in B028 
complexes migrates faster than the SF3b155 signal detected by the same antibodies in Bact 
complexes, suggesting that SF3b155 is phosphorylated in Bact complexes, but not in B or 
B028. An antibody against phosphorylated threonine 313 of SF3b155 is able to detect only 







































antibodies revealed a slower migrating SF3b155 band solely in Bact complexes, but not in 
the B or B028 complexes consistent with our results with –SF3b155 antibodies. Taken 
together, these results show that B028 complexes are stalled before phosphorylation of the 
SF3b155 protein. 
Thus, our western blot analyses generally correlate with the mass spectrometry data. 
Taken together, our results demonstrate that the spliceosomal B-like complex stalled with 
compound 028 represents a novel intermediate between B and Bact, in which U4/U6 
proteins have dissociated but not most B-specific proteins nor the U6 Lsm proteins. On 
the other hand, Prp19/CDC5L proteins are clearly underrepresented, if present at all, and 
Bact proteins have not yet associated. Thus, structural and functional investigation of B028 
may provide insight into the dynamic RNP rearrangements occurring during the 
activation step.  
3.2.7 Attempts to isolate more homogeneous B028 complexes  
The RNA composition of B028 spliceosomes suggests there is a mixture of complexes 
lacking U1 and U4 with those still containing them. We thus checked whether more 
pronounced changes in the RNA composition of B028 complexes, namely, complete loss 
of U1 and U4 occur at later time points. We thus performed the splicing reaction for 20, 
40 or 60 min and isolated the spliceosomal complexes using MS2 affinity selection. The 
RNA composition of the A and B complexes formed in the presence of compound 028 
appeared to be identical even at later (40 and 60 min) time points (Fig. 3.14). Also, no 
significant changes in the protein composition of B028 were observed by mass 
spectrometry at later incubation times (data not shown). 
 
 
Figure 3.14 RNA composition of MS2-affinity purified B028 complexes formed in the presence 
of compound 028 at different time points of the splicing reaction. RNA recovered from complexes 
affinity-purified from peaks I and II was analysed by denaturing PAGE and detected by silver staining. 



































































We also purified complexes from every fraction of the B028-containing peak and analysed 
their RNA composition (Fig. 3.15). In the fractions located closer to the top (# 29-30) 
higher amounts of U1 snRNA were detected, probably due to contamination from the 
neighbouring peak containing complex A. On the other hand, the fractions located closer 
to the bottom (# 33-34) displayed slightly increased amounts of U4 snRNA, suggesting 
the presence of B spliceosomal complexes. Thus, highly purified B028 complexes 
subsequently used for structural and functional studies were taken only from the middle 





Figure 3.15 Purification of stalled B028 complexes and characterization of different fractions 
of the B-like peak. A. Glycerol gradient sedimentation profile of the spliceosomal complexes formed 
under splicing conditions in the presence/absence of compound 028. B. RNA composition of MS2-
affinity purified splicing complexes formed in the presence of compound 028. RNA recovered from the 
indicated fractions of each gradient was analysed by denaturing PAGE and detected by silver staining. 
RNA identities are indicated at the left. 
 
3.2.8 Analysis of RNA-RNA interactions in spliceosomes stalled by compound 028  
During activation, the RNA-RNA network of the spliceosome is rearranged. Unwinding 
of the U4/U6 base pairing by Brr2 enables U6 to form new base pairs with U2 (U2/U6 
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stem loop (U6 ISL) is formed (Fig. 3.16). A major question is whether U6 has rearranged 
in the B028 complex, and what the RNA-RNA network looks like in this complex. 
 
Figure 3.16 Dynamic network of RNA-RNA interactions in the spliceosome. Exon sequences 
are highlighted as grey boxes and the intron sequence as black line. Secondary structures of snRNA are 
shown schematically in grey or black, and the regions involved in base-pair interactions (short lines) 
are shown in different colours. The 5´ end of an snRNA is labelled as a black dot. Solely loop I of the 
U5 snRNA is shown. During the transition of a pre-catalytic (left scheme) to the catalytically-activated 
spliceosome (right scheme) U1 and U4 leave, and U6 and U2 are involved in new base-pair 
interactions. 
 
To study RNA-RNA interactions in B028, complexes were formed under splicing 
conditions in vitro, and purified by MS2 affinity selection, using PM5-10 and/or MINX 
pre-mRNAs as substrates. B and Bact complexes were isolated in parallel. RNA 
denaturing gel analysis demonstrated that complexes formed on PM5-10 in the presence 
of 028, have a similar RNA composition relative to those formed on MINX (Fig. 3.17).  
 
Figure 3.17 RNA composition of MS2 affinity-purified splicing complexes B, B028 and Bact 
formed on PM5-10 and used for structure probing studies. RNA recovered from the complexes was 




































3.2.8.1 Identification of RNA-RNA interactions in B028 complexes via psoralen 
crosslinking  
RNA-RNA interactions in B028 were first monitored using UV light-induced psoralen-
mediated crosslinking in collaboration with Dr. M. Anokhina. Psoralen crosslinking is an 
efficient method that allows the identification the double-stranded (base paired) regions 
and higher-order structure within the RNA molecule. Psoralen is an aromatic tricyclic 
furocumarin, which intercalates between RNA base pairs and photoreacts with double-
stranded regions via formation of cycloadducts with pyrimidine bases. This reaction is 
initiated by the long wavelength UV irradiation of nucleic acids at 364 nm in the presence 
of psoralen upon the absorption of the photon to form monoadducts, and the absorption of 
other photon results in the formation of a crosslink between the strands. The crosslinked 
regions of the RNA(s) can be followed by northern blot analysis by sequential probing, or 
by direct autoradiography of blot to detect the position of 32P-labelled crosslinked pre-
mRNA. The migration of different bands detected with each probe can be compared and 
correlated with each other to identify the cross-linked RNA. If a band is detected by two 
different probes we can conclude it represents a crosslink between those two snRNAs.  
 
         A.                     B.                   C.                    D.                   E.                  F. 
 
Figure 3.18 Identification of RNA-RNA interactions via psoralen crosslinking in purified 
complexes B, B028 and Bact. RNAs were visualized by Northern blot analysis with 32P-probes against 
U2, U6, U4, U1 and U5 and/or the 32P-labelled pre-RNA was visualized by autoradiography. Ps: 
psoralen. Crosslinks and the PM5-10 pre-mRNA are indicated on the left of the panel.  
 
Purified B, B028 and Bact spliceosomes formed on PM5-10 pre-mRNA were subjected to 
long-wave UV irradiation in the presence of psoralen, and RNA was separated by gel 
electrophoresis. Northern blotting was performed with 32P-labelled probes against U1, 
U2, U4, U5 and U6 sequentially. First, autoradiography revealed the position of 
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crosslinks containing radioactively labelled PM5-10 pre-mRNA (Fig. 3.18A). 
Hybridization with 32P-probes against U2 and U6 revealed a U2/U6 crosslink, based on 
the signal from both U2 and U6 probes and its migration behaviour indicates it is U2/U6 
helix II crosslink (Anokhina et al., 2013). U2/U6 helix II was detected mainly in Bact 
complex and to a lesser extend in B and B028 complexes, suggesting it was shielded in 
B/B028 by proteins and therefore less accessible to psoralen (Fig. 3.18, B and C). In 
addition, U4/U6 crosslinks were also detected with both U4 and U6 probes in complex B, 
but not in B028 and Bact, due to release of U4 snRNA from B028 and Bact complexes (Fig. 
3.18, C and D). Similarly, a U2/U4/U6 triple crosslink was detected with U2, U4 and U6 
probes in complex B, but not in B028 and Bact, confirming the absence of this crosslink, 
due to the absence of U4 snRNA at later stages of spliceosomal assembly. We didn’t 
observe any strong crosslinks with U1 probes in all three complexes, except a very weak 
slow migrating signal was detected in both B and B028 complexes, due to the presence 
small amounts of U1 snRNA (Fig. 3.18E), suggesting it might be the crosslink of U1 base 
paired with the 5’ splice site. Additionally, a crosslink between U6 snRNA and the pre-
mRNA was detected in all three complexes, providing evidence for the base pairing 
interaction of the U6 ACAGAG box intron nucleotides near the 5’ss. No crosslinks were 
detected with a U5 probe. However, lack of a crosslink doesn’t mean there were no 
interactions. 
3.2.8.2 Structure of U5 snRNA in B028 complexes 
To determine at which stage of activation compound 028 blocks splicing we investigated 
RNA-RNA interactions in B028 complex by performing RNA structure probing. Structure 
probing allows us to test the reactivity of each nucleotide towards specific chemical 
agents and to determine the secondary and tertiary structure of RNA molecules, and also 
whether they are engaged in interactions with proteins, via detection of the modified 
nucleotides. Bases in the RNA molecule are modified if they do not interact with other 
RNAs, i.e. it shows if a particular nucleotide in an RNA molecule is base paired or not. 
To study at which stage of RNA rearrangement compound 028 blocks spliceosome 
assembly, structure probing was performed with B, B028 and Bact complexes. All structure 
probing experiments were performed in collaboration with Dr. Maria Anokhina from our 
laboratory.  
Chemical modifications were performed with three chemical reagents: 1-cyclohexyl-3-(-
2-morpholinoethyl) carbodiimide metho-p-toluene sulfonate (CMCT), which modifies 
bases at positions normally involved in Watson-Crick interactions, mainly at positions 
 
 80 
N1-G and N3-U, dimethylsulfate (DMS) which reacts with N1-A and N3-C, and β-
ethoxy-α-ketobutyralaldehyde (Kethoxal), which modifies specifically N1-G and N2-G 
(Fig. 3.19; described in Material and Methods). After incubating spliceosomes with 
CMCT, DMS or Kethoxal, RNA was isolated by proteinase K digestion followed by 
phenol/chloroform extraction. Primer extension assays were then performed with 5’-end 
labelled oligonucleotides complementary to chosen sequences in the U snRNAs. Primer 
extension occurs (in the direction 3’ to 5’ end) by adding reverse transcriptase (RT). If 
chemical modification takes place on the RNA template, the elongation of the primer will 
be stopped exactly one nucleotide before the chemical modification point, resulting in 
truncated cDNA fragments instead of fully-elongated chains. To obtain a sequencing 
ladder, in vitro transcribed snRNAs were treated in an identical manner, but in the 
presence of 0.5 mM dideoxy-NTPs. Reverse transcripts were separated on denaturing 
polyacrylamide sequencing gels and visualized by autoradiography. Accessibility to a 
given chemical was indicated as strong, medium of weak depending the intensity of the 
RT-stop (minus the background which is seen without DMS, CMCT or Kethoxal). 
 
Figure 3.19 Positions of chemical modifications by chemical reagents DMS, CMCT and 
Kethoxal and schematic view of primer extension using modified RNA as a template. 
 
U5 snRNA undergoes only minor changes during the B to Bact transition, with IL2 and 
loop 1 more accessible in complex B versus Bact (Anokhina et al, 2012) (Fig. 3.20), 
because the latter contacts the 5’ exon before step I of splicing (Wyatt et al., 1992; 
Sontheimer and Steitz, 1993). Analysis of U5 modification in B, B028 and Bact complexes 
revealed that all regions involved in known internal base pair interactions were fully-
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protected in all three complexes. The RNA protection pattern observed within the 
complex B028 is identical to that seen with complex Bact (Fig. 3.20). In particular, the 
internal loop 2 nt G20 and the internal loop 1 nt G8 are more protected in B028 and Bact, 
compared to B, which indicates less accessibility in these regions. Nucleotides U42 and 
43 were found to be unreactive against chemical modification in all three tested 
complexes, consistent with U5 interacting with the 5’exon of the pre-mRNA via this 
these nucleotides. Nucleotides involved in formation of the internal loops 1 and 2 (IL1 
and IL2, respectively) have a nearly identical modification pattern in B, B028 and Bact, 
confirming that the structure of this region of U5 is not affected by the presence of 
compound 028. 
A.                                                                     B. 
        
Figure 3.20 U5 snRNA protection pattern in spliceosomal complexes is identical in B028 and 
Bact complexes. A. Schematic summary of U5 snRNA modification pattern in different spliceosomal 
complexes. The different sizes and colours of the dots indicate different modification accessibility for 
different spliceosomal complexes. B. Chemical modification pattern of B, Bact and B028 complexes 
formed on PM5-10 treated with the indicated reagents. (-) = no reagent (reveals background stops). 
Primer extension was performed with oligonucleotides complementary to U5 nts 83-103.  
 
3.2.8.3 Structure of U2 and U6 snRNAs in B028 complexes 
To clarify to which extend the interactions between U2 and U6 are formed in B028 
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investigated the U6 and U2 snRNA protection patterns in B, B028 and Bact. In the B 
complex, U4 and U6 snRNAs are engaged in base pair interactions building two long 
helices, stem I and stem II. This U4/U6 structure does not exist in Bact, because U4 is 
released. In the activated spliceosome, U6 snRNA undergoes remarkable structural 
rearrangements after Brr2-catalysed U4/U6 unwinding and U4 release. At this time U6 
snRNA base pairs with the 5' splice site and the U2 snRNA, and forms an internal stem-
loop (U6 ISL) (Fig. 3.16, 3.21A). This U6 ISL is extremely important for catalysis and is 
present in Bact. We first focused on the accessibility of nucleotides forming the U6 ISL. 
Nucleotides involved in the loop (A70-G67) of the U6 ISL are highly accessible in Bact 
and there is a very low modification of nucleotides involved in the formation of the stem 
of the ISL (C61-C63, G71-A73) (Fig. 3.21). Nucleotides involved in the formation of the 
U6 ISL loop are more protected in B028 compared to those in Bact (A69, C68, C66). 
However nucleotides G67, A69 and A70 are accessible to a low extend. This enhanced 
protection of loop nucleotides of the putative ISL sequence in B028 could potentially be 
explained by shielding due to bound proteins during modification. The other U6 
nucleotides involved in the ISL formation are protected against modification in B028, such 
as nts A56-G65, suggesting that the stem of the U6 ISL is formed. Because they are close 
to the 3’ end of U6, it was not possible to analyse the modification of nts on the other side 
of the stem. Moreover, U6 nucleotide A56 that is located close to the ISL sequence is 
well-protected in B028, compared to reproducible accessibility of this particular nucleotide 
in Bact, confirming that this nucleotide is either base-paired or shielded by proteins in 
B028. These results suggest that the RNP structure in this region is clearly different 
between B028 and Bact. However, because the U6 ISL loop nucleotides are only poorly 
accessible, we cannot conclude with certainty that U6 ISL has formed in B028.  
In B complex, the U6 nucleotides A50-C55 are base paired with nucleotides from U4 
snRNA under the formation of stem I. After U4 release, these U6 nucleotides interact 
with 5’ end of U2 snRNA to form U2/U6 helix I. U2/U6 helix I together with U6 ISL 
represent the catalytic centre of the spliceosome, and thus the RNA structure in these 
regions is of particular interest. The U6 snRNA modification pattern analysis revealed 
that U6 nucleotides A50-U52 are relatively well-protected in both B028 and Bact with only 
weak modification of A50 (G49 is accessible for chemical modification in both, Bact and 
B028) (Fig. 3.21), suggesting U2/U6 helix Ia is formed in the B028 complex. 
Complementary U2 nucleotides involved in helix Ia formation (G25-C28) are also 
protected against modification (Fig. 3.21A, 3.22). U6 nucleotides involved in the 
formation of U2/U6 helix Ib, i.e. nucleotides A53-C55, appear to be also protected 
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against chemical modification in both, B028 and Bact complexes (Fig. 3.21). In addition, 
U2 nucleotides (G20-U22) are also protected (Fig. 3.21A and 3.22), suggesting helix Ib is 
also formed in B028.  
 
Figure 3.21 Primer extension analysis of U6 snRNAs in chemically modified B, B028 and Bact 
complexes. A. Schematic summary of modification pattern for U2 and U6 snRNA interactions in 
spliceosomal complexes B028 and Bact. Different size and colour of the dots indicate different degrees of 
modification accessibility in the different spliceosomal complexes. B and C. Primer extension analysis 
of U6 snRNA from CMCT, DMS and KE modified complexes. Chemical modification pattern of B, 
B028 and Bact complexes formed on PM5-10 treated with reagents indicated. Primer extension was 
performed with oligonucleotides complementary to U6 nts 80-100.  
 
U2/U6 helix II, which involves base pairing interactions between the 5' end of the U2 
snRNA and 3' region of the U6 snRNA (Madhani and Guthrie, 1992) appears to be 
formed in all three tested complexes based of the chemical inaccessibility of U2 
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nucleotides 3-11 of this helix (Fig. 3.21A, 3.22 A and C). The accessibility of this RNA 
region in U6 snRNA wasn’t analysed, because its location on the RNA prevents primer 
extension analysis (it is too close to the 3’ end of U6).  
Previous work from our lab showed that U2/U6 interaction forms a 3-way junction in Bact 
as shown in Fig. 3.21 (Anokhina et al., 2013). An alternative conformation of U2/U6 (a 
4-way junction) was also previously proposed (Sun and Manley, 1995). In the proposed 
four-way junction model of U6/U2 interaction, but not in the 3-way junction model, the 
formation of U2 stem loop 1 (SL1) should be observed. Our results do not support the 
existence of this loop in both B028 and Bact complexes, based on accessibility of U2 nts 
C14 and G19, which should be base paired if there is formation of the short U2 stem in 
this model (Fig. 3.22). However, additional analyses after the extension of the 3’ end of 
U6 snRNA are necessary to rule out the 4W junction structure with certainty.  
 
 
Figure 3.22 U2 snRNA chemical modification pattern in B, Bact and B028 complexes. A and C. 
Primer extension analysis of U2 snRNA from DMS, CMCT and KE treated complexes. Primer 
extension was performed with oligonucleotides complementary to U2 nts 75-95 and 146-163. B. 
Scheme of modification pattern for U2 snRNA in the four-way junction (4WJ) model.  
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The nucleotides from the U6 ACAGA box (A40-A44 nts) were found to be protected 
against chemical modification in both Bact and B028 complexes (Fig. 3.20). Likewise, 
intron nts +4 to +8 were also protected from modification in B, B028 and Bact complexes 
(Fig. 3.23). Thus, the interactions of the U6 ACAGA box (A41-A45) with the pre-mRNA 
intron near the 5’ ss appears to be formed in B028 complexes. Chemical modification also 
supported the formation of the U2/BPS interaction; all U2 nucleotides involved (G33-
A38) with the exception of G33 were not accessible in B028 or Bact (Fig. 3.21A, 3.22).  
 
Figure 3.23 Pre-mRNA chemical modification pattern in B, Bact and B028 complexes. Primer 
extension analysis of the pre-mRNA from DMS and KE treated complexes. Primer extension was 
performed with an oligonucleotide complementary to PM5 pre-mRNA nts 281-262.  
 
Previously, it was reported that yeast U2 snRNA toggles between different intra-
molecular conformations (Fig. 3.24A). This includes the formation of so called helix IIc, 
which involves base pairing between loop nucleotides (53-60) of U2 stem loop IIa and 
nucleotides downstream of stem loop IIb (88-96) (Hilliker et al., 2007; Perriman et al., 
2007). As shown in figure 3.24, U2 nucleotides A88-A95 and U53-U60, which form base 
pairs if helix IIc is formed, are accessible to all reagents tested in Bact and B028 complexes. 
Thus, U2 helix IIc is not formed in the B028 complex; nor in all other human spliceosomal 
complexes tested thus far (Fig. 3.24).  
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Figure 3.24 U2 snRNA protection pattern in spliceosomal complexes reveals that U2 helix IIc 
is not formed in the B028 complex. A. Structure of U2 stem IIc and stem–loop IIa. Nucleotides 
involved in stem IIc and stem loop IIa are shadowed. The nucleotides of U2 that bind the intronic 
branch site consensus sequence are shown. B. Chemical modification of Bact and B028 complexes with 
the reagents indicated. (-) = background. Primer extension was performed with oligonucleotides 
complementary to U2 nts 75-95 and 146-163 and analyzed by denaturing PAGE. C. Schematic of U2 
snRNA modification pattern in spliceosomal complexes B028 and Bact. Different size and colour of the 
dots indicate different degrees of modification accessibility for different spliceosomal complexes.  
 
3.2.9 B028 complexes can be chased into catalytically active spliceosomes. 
We next tried to elucidate whether the complex formed in the presence of compound 028 
is functionally active or a dead-end complex. To this end, affinity-purified splicing 
complexes were incubated under in vitro splicing conditions either with buffer alone or 
with nuclear extract treated with micrococcal nuclease (MN). When incubated with 
micrococcal nuclease, the snRNAs are digested leading to disruption of all snRNPs. An 
excess of unlabelled pre-mRNA was also added together with the MN-treated extract to 
rule out a disassembly of B028 complexes with subsequent reassembly of spliceosomes as 
a possible cause of the observed splicing activity. When incubated in the presence of MN-
treated HeLa nuclear extract, the B028 complexes can be chased into catalytically active 
spliceosomes with the same efficiency of the first and second steps of splicing (Fig. 3.25, 
lanes 9-12) as B complexes chased in parallel as a control (Fig. 3.25, lanes 1-4). In 
contrast, when B028 or B complexes were incubated in the absence of nuclear extract, no 
splicing was observed in both cases (Fig. 3.25, lanes 5-8 and 13-16). This shows that 
protein factors in nuclear extract necessary for subsequent spliceosome activation and 
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catalytic activity can bind to B or B028. Exogenously-added, 32P-labelled pre-mRNA 
incubated with MN-digested nuclear extract under splicing conditions is not spliced, 
indicating that the treatment of nuclear extract with MN was efficient (Fig. 3.25, lanes 17-
20). We conclude that the affinity-purified stalled B028 complexes are not dead-end 
complexes that are irreversibly blocked at a step between B and Bact complexes, but 
instead are a functional assembly intermediate.  
 
Figure 3.25 B028 complexes can be chased into catalytically active spliceosomes in the 
presence HeLa nuclear extract treated with micrococcal nuclease. The affinity-purified splicing 
complexes were incubated under in vitro splicing conditions either with buffer alone (lanes 5-8 and 13-
16) or with nuclear extract treated with micrococcal nuclease plus an excess of unlabelled pre-mRNA 
(lanes 1-4 and 9-12) for the indicated time points. Lanes 17-20: [32P]-labeled pre-mRNA was incubated 
in the presence of micrococcal nuclease-treated HeLa nuclear extract. RNA was isolated, analyzed by 
denaturing PAGE and visualized by autoradiography. Position of splicing products, intermediates or 
unspliced MINX pre-mRNA is indicated at the left. 
 
3.3 Electron microscopy studies of affinity-purified B028 complexes 
The spliceosome undergoes major rearrangements concerning its RNA and protein 
composition during the activation step. These remarkable changes are reflected in 
different morphologies of the spliceosomal complex B and subsequently formed activated 
spliceosomes (Bact) that have been visualized by electron microscopy (EM) (Bessonov et 
al., 2010). A better understanding of this highly dynamic step is of particular importance, 
since this decisive step prepares the spliceosome to fulfil its main task, namely, the two 
subsequently performed transesterification reactions. Using electron microscopy, we 
endeavoured to determine the structure of complex B028, which represents an intermediate 
step during the transition of spliceosomal complex B to an activated spliceosome, to 
provide insight in the structural dynamics of this particular step. EM was performed in 
collaboration with Dr. Berthold Kastner, Dr. Prakash Dube and Prof. Dr. Holger Stark. 
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3.3.1 Negative stain 2D electron microscopy of affinity-purified B028 complexes  
To obtain the first images of the stalled B028 complex, we performed two-dimensional 
negative stain EM. We thus first isolated B028 spliceosomes via the MS2 affinity selection 
method (Fig. 3.10A). We then subjected the eluted B028 complexes to a second glycerol 
gradient centrifugation step, using the GraFix procedure (Kastner et al., 2008). The 
GraFix method stabilizes the individual particles by mild chemical fixation during the 
centrifugation step, and protects them against aggregation. For this purpose, the glycerol 
gradient is supplemented with a fixation agent, namely an increasing concentration of 
glutaraldehyde (0 to 0.1 %). During this second centrifugation step, the particles of 
interest can also be separated from aggregates and defective particles, reducing the 
heterogeneity. RNA analysis of the purified B028-containing fractions of the second 
gradient revealed an RNA pattern typical for B028 (Fig. 3.26). The B028-containing peak 
fractions were then subjected to negative staining EM performed by Dr. Berthold Kastner 
and Dr. Prakash Dube. Thereby, particles were absorbed onto a carbon film, using the 
single carbon film method, and negatively-contrasted with 2 % uranyl formate.  
 
Figure 3.26 RNA composition of the purified B028-containing fractions compared to B 
complexes formed in the presence of DMSO. RNA recovered from splicing complexes from each 
fraction was analysed by denaturing PAGE and detected by silver staining. RNA identities are 
indicated at the left. 
 
An overview of the negatively-stained raw images revealed a homogeneous population of 
monodisperse particles of the same basic morphology (Fig. 3.27A) with a maximum 
dimension of about approximately 40 nm. The majority of the B028 images exhibit a 
roughly triangular shape. One corner of the triangle appears mostly as a stick-like 
protrusion. In the gallery of typical B028 images (Fig. 3.27B) this protrusion is oriented to 
the bottom, thereby making it the foot of the particle. From this foot a ca 10 nm wide 
density runs up to the top in most images. This density axis is positioned in most cases 
directly at the left edge of the triangular shaped images (columns 1-4).  The remaining 
BDMSO
fraction nr.












part of the images has a more globular shape. It is positioned at the upper 2/3 of the 
elongated axis and makes up the right corner of the triangle. In more rare cases the B028 
images have a mushroom-like shape (columns 5-6). Here, the elongated density appears 
to be bent or is not traceable at all. Some images show features of both the triangular and 
mushroom shape. An example is shown in the last row of column 4 and 5, where one and 
the same image is oriented according to the triangular view (column 4) and the mushroom 
view (column 5). This suggests that both types of views can be generated by one and the 






Figure 3.27 Electron microscopy of negatively-stained B028 particles assembled on the MINX 
pre-mRNA substrate. (A) Overview of raw images of the B028 complex obtained by negative stain 
EM. (B) Gallery of raw images of stalled B028 complex with the most frequently found views. Scale 












The single particle images were then subjected to image processing. After several rounds 
of iterative translational and rotational image alignment and image classification, the data 
set was partitioned into 200 image classes and the class members averaged. With the class 
averages (Fig. 3.28, columns 1-4) more structural features of the B028 particle are now 
recognizable. Dominant are classes showing the typical triangular shapes with the long 
density axis on the left (columns 1-2). At the upper one-third, a dividing line of stain (see 
arrow) can often be seen at the 40 nm long and on average 10-12 nm wide axis. 
Typically, the delimited upper one-third density part frequently sticks out to the side like 
a beak (see arrowheads). The globular density element shows a lot of fine structure in the 
class averages. The complex distribution of stain accumulated in cavities and holes in the 
particle indicates an intricate network of structural elements. The classes with the typical 
mushroom-like shape (column 3-4, first three rows) were observed less frequently, 
similar to the classes showing both mushroom and triangular shape features (columns 3-4, 
last row). 
 
Figure 3.28 B028 particles exhibit a morphology between B and Bact. Selected class averages of 
the negatively-stained, stalled B028 complex (columns 1-4) compared to published spliceosomal 
complexes B (left) and activated spliceosomes (Bact) (right). The columns 1-2 versus columns 3-4 show 
the two major types of orientation of B028 particles on the carbon film which appear to be mirror 
images. Scale bars correspond to 50 nm. 
 
The views of the B028 particle show in their basic morphology similarities to the B 
complex (Fig. 3.28, left column), when the triangular views are considered, and 
similarities to the Bact complex (right column), when the mushroom views are compared. 
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The B complex shows dominant views with a rhombic and triangular shape (Deckert et 
al., 2006). In these views an elongated axis running along one edge also prevails (“foot-
stump axis”). There is a protrusion at the lower end of the B complex axis (“foot”) that 
shares similarities with the foot region of the B028 complex. The upper end of this B 
complex main axis, called the “stump” - structural designations are according to 
Boehringer et al. (2004), Deckert et al. (2006) and Wolf et al. (2009) - appears a bit 
different as the protruding beak-like feature is missing. Beside the axis-like element, the 
B complex images also have one additional domain that is attached to the upper part of 
the elongated structure (“head”) via short a “neck” region. But here it is in an upper right 
position pointing more upwards and even exceeds the height of the long axis, thereby 
creating rhombic-shaped views. This different arrangement makes up the most obvious 
global morphological difference compared to the B028 triangular views. The globular 
density is oriented in the B028 particle more toward the central region of the long density 
axis, creating the shape more like an isosceles triangle. The globular domain in the B 
complex classes shows much less fine structure than seen at the B028 complex. This 
domain might be more compact in the B complex. 
Mushroom-like views are not typical for the B complex but rather dominate in images of 
the Bact complex. The dominant Bact views show typically a centrally elevated and 
upward-oriented main body with a central stain accumulation and a more complex foot 
domain, consisting of two protuberances, which are situated in the center and at the right 
in the dominant classes (Fig. 3.28, right). The appearance of the main body seems to be 
mostly invariant, whereas the shape and position of the protuberances differ significantly 
in the various classes. In general the structural similarities between the Bact (right column) 
and B028 views are quite limited and the structural details seen in B028 are not recognizable 
in Bact. However, this is likely due to differences in their adsorption to the carbon film 
which leads to different views of B028 versus Bact. Nonetheless, the overall morphology of 
B028 appears to be between that of B and Bact. 
3.3.2 3D reconstruction of the B028 particle  
Because the B028 was very homogeneous in the 2D EM analysis, it appeared to be a good 
candidate for 3D EM structure analysis. To prepare B028 complexes for 3D reconstruction, 
splicing was performed under standard conditions, and the splicing reaction mixture was 
applied to the first glycerol gradient. Then B028-containing fractions were loaded onto the 
MS2 column. The eluate was then subjected to a second glycerol gradient this time 
containing two cross-linking agents, namely, an increasing concentration (0 to 0.1%) of 
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glutaraldehyde and a decreasing concentration (0.2 to 0 %) of N-(p-Maleimidophenyl) 
isocyanate (PMPI). Negatively-stained EM grids were first made from the B028 complex-
containing gradient fractions. EM imaging and image processing was performed by Dr. 
Holger Stark. 11360 images of single particles were extracted and processed with the 
CowEyes program (Prof. Dr. H. Stark). The aligned and classified data set was 
partitioned into image classes and the class members averaged.  
Raw images of B028 particles revealed again a homogeneous population and the class 
averages demonstrated the characteristic two-dimensional averages of the B028 complex. 
For the single-particle 3D reconstitution of the B028 particle, the angular reconstitution 
method was performed (van Heel, 1987; van Heel et al., 2000). The orientation of each 
particle in three-dimensional space can be described by Eulerian angles, representing the 
rotation degree/event. Determination of the Eulerian angles for each particle differently 
oriented using the angular reconstitution method allows us to assign the projection 
directions of the class averages. The 3D structure reconstitution was finally calculated 
computationally from images of ~ 3000 particles and resulted in a 3D 
structure/architecture of the B028 particle determined with a resolution of ca. 25 Å, 
shown in Fig. 3.29. 
 
Figure 3.29 The morphology of the B028 complex assembled on the MINX pre-mRNA. (C) 3D 




The B028 3D reconstruction has an approximately 20 nm thick isosceles triangle-like 
structure with a side length of 38 to 40 nm. Only the foot narrows down to a thickness of 
8 nm, while a region in the upper part (characterized by the domains labelled 1 and 2 in 
the figure) is up to 28 nm thick. The prominent elongated axis already seen in the images 
turned out to be indeed a continuous, elongated density element running from the foot via 
the central region (3) to the thick upper corner (1, 2). This upper corner consists of two 
structural elements, one with a more globular structure containing a central cavity (1) and 
one with a long, flat structure (2), which are connected to the central region (3) by two 
bridges (4, 5). The two upper corner structures are connected to each other. The flat one 
(2) forms the beak-like density seen already in the 2D images.  
3D reconstruction reveals a network of elongated structures in the globular domain. One 
slightly bent, that in total is nearly 30 nm long and has a 6 to 10 nm thick side arm (6), 
runs from a connecting point at the lower central position of the main axis directly to the 
outer corner of the globular domain. At this corner the side arm ends with a 6 x 8 x 10 nm 
sized globular structure (7). About half way down, the side arm is connected to another 
shorter arm (8), which originates also centrally from the elongated axis, but on the other 
side. Finally, at the top of the 3D reconstruction there is a complex density (9) that joins 
the flat structure of the upper region (2) of the long axis with both arms, the side arm (5) 
and the short arm (8).  
 
Figure 3.30 The mushroom-like view of the B028 complex tilted forward on its horizontal axis. 





When the B028 3D structure is oriented to show a mushroom-like view, the long axis runs 
also along one lateral side but it is now tilted toward the plain of the paper (Fig. 3.30). 
The flat upper structure (2) is now seen well above the globular structure (1). In the 
mushroom-view oriented B028 3D reconstruction, holes going straight through the center 
of the particle are present. The intense accumulation of stain seen in class averages of 
B028 mushroom-like images are easily explained by the presence of these holes.  
At present, the B028 complexes are being analysed by cryo-EM (in progress). Cryo-EM 
enables images of hydrated biological particles at low temperatures to be obtained and 
therefore protects the particles against radiation damage. To avoid poor vitrification quality 
due to the presence of glycerol in the gradient fractions, the purified B028 complexes were 
subjected to buffer exchange, so that the glycerol-containing environment was substituted 
with glycerol-free buffer. Then particles were transferred onto a copper EM grid, 
vitrificated by liquid nitrogen and stored in liquid nitrogen until imaging.  
 
3.4 B028 spliceosomes as a tool to investigate binding and release of 
proteins during activation.  
Remarkable rearrangements occur in the spliceosome during its activation step 
concerning both its conformation and composition, including an exchange of many 
proteins. The B028 complex is stalled apparently after U4 snRNA has been displaced by 
the helicase Brr2, but before release of B-specific (except FBP21) and Lsm proteins, and 
before Bact-specific and Prp19/CDC5L-associated proteins have interacted. Because B028 
complexes can be chased into catalytically active complexes they could potentially be 
used to study the recruitment and release of these proteins during activation.  
To this end, I performed splicing in vitro and separated the complexes, which were 
formed in the presence of compound 028, on a glycerol gradient. Complexes in the B/Bact 
peak fractions were bound to amylose beads and washed (Fig. 3.31). Then B028 
complexes still bound to the matrix were incubated either with buffer alone or with 
normal or MN-treated nuclear extract under splicing conditions in the presence or in the 
absence of ATP. To ensure the absence of ATP in the reaction mixture, the HeLa nuclear 
extract was treated with hexokinase and glucose. Then the extensively washed complexes 
were eluted with maltose (Fig. 3.31). The RNA composition was analysed by denaturing 





Figure 3.31 Schematic view of MS2-affinity purification of human spliceosomal B028 
complexes with subsequent chasing of isolated complexes with normal or MN-treated nuclear 
extract under splicing conditions. MS2-tagged pre-mRNA substrate was pre-incubated with MS2-
MBP fusion protein. Subsequently, splicing in vitro was performed in the presence of HeLa nuclear 
extract under standard splicing conditions. Spliceosomal complexes formed were then separated by 
32 -labelled pre-mRNA. 
Spliceosomal complexes from each peak were affinity-selected using amylose beads. After washing, 
the isolated complexes were incubated under splicing conditions in the presence of normal or MN-
treated nuclear and, after extensive washing, eluted with maltose. The recruitment or loss of proteins 
was determined by mass spectrometry. 
 
The RNA analysis revealed that B028 complexes (Fig. 3.32, lane 2) remain intact under 
these conditions. Interestingly, B028 complexes lose their U1 snRNA when incubated 
under splicing conditions (+ATP) in the presence of MN-treated extract (3.32, lane 3), 
showing an snRNA composition identical to that of the activated spliceosome (3.32, lane 
6). In the absence of ATP, U1 snRNA stays associated with the spliceosome (Fig. 3.32, 
lane 4). However, B028 chased in the presence of nuclear extract not digested with MN 
also contains U1 snRNA (Fig. 3.32, lane 5), but can be chased into activated 
spliceosomes very efficiently, based on the protein composition analysis (see below). 


















































Figure 3.32 RNA composition of B028 complexes after chasing with normal or MN-treated 
nuclear extract. RNA composition of MS2-affinity purified B, B028 and Bact splicing complexes and 
B028 complexes incubated with MN-treated or normal nuclear extract (nx). RNA recovered was 
analysed by denaturing PAGE and detected by silver staining. RNA identities are indicated at the left. 
 
We first tried chasing B028 complexes formed on the MINX substrate and could detect the 
recruitment of Bact-specific and Prp19/CDC5L complex proteins (data not shown). 
However, as spliceosome assembly continues past the activation step with this substrate, 
Bact-specific proteins are lost in the course of splicing, impeding the interpretation of 
whether or not they bind. Thus, we switched to the PM5-10 pre-mRNA substrate, to stall 
the spliceosome assembly prior to the catalytic activation step (i.e. B* formation) at the 
stage of Bact formation in order to study only the activation stage.  
The number of peptides sequenced for each protein in the various complexes is shown in 
Table 3.4. By comparing these numbers with those seen with purified Bact complexes, the 
amount of B028 converted to Bact can be estimated. There were little or no changes in the 
amounts of the Sm, U2, U5 or CBP20/80 proteins between B028, the chased complexes 
and Bact, which are not expected to be lost during activation. 
The human hPrp19/CDC5L complex proteins are stably recruited to the spliceosome 
during activation (Makarov et al. 2002; Makarova et al., 2004; Wahl et al. 2009), and 
remain associated throughout both catalytic steps, stabilizing the association of U5 and 
U6 with the spliceosome after U4 is released (Chan et al., 2003, 2005). Mass 
spectrometry analysis shows that B028 contains only low amounts of Prp19/CDC5L 
complex proteins, such as Prp19, CDC5L, SPF27, PRL1, as well as Prp19/CDC5L-
related proteins such as RBM22, Syf1, CRNKL1, Isy1, SKIP and KIAA0560 in 
comparison to both B and Bact (Table 3.4). However, after chasing with MN-treated 
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in the peptides sequenced for Prp19/CDC5L proteins and related proteins. Notably, in the 
absence of ATP these proteins appear to be less efficiently integrated into the 
spliceosome (i.e. fewer peptides were identified by mass spectrometry), demonstrating 
the requirement of ATP for the association of this group of proteins with the spliceosome 
during the activation step. Based on the number of peptides identified by MS, there are 
fewer Prp19/CDC5L and related proteins bound in the chased complexes compared to the 
Bact complex. This is an indication that not all B028 complexes can be chased to Bact. 
Interestingly, Npw38 and Npw38BP, which normally are released during the activation 
step, were found in high amounts in B028 and B028 complexes chased with MN-treated 
extract (+ATP), but lower amounts were found in the complex chased in the absence of 
ATP, or chased with normal nuclear extract. 
Bact-specific proteins, which integrate into the spliceosome during activation, are strongly 
underrepresented in B and B028 complexes. Remarkably, they are also recruited to the 
spliceosome after incubating with MN-treated extract or normal nuclear extract, but only 
in the presence of ATP. This suggests that their association is ATP-dependent or ATP is 
required at a stage prior to their recruitment. 
B-specific proteins, which leave the spliceosome during activation, are present in B028 
complexes as well as in B complexes, and they appear to be partially lost in chased 
complexes in an ATP-independent manner. Also, Lsm proteins, which should dissociate 
during activation, are partially lost when B028 complexes are incubated with normal or 
MN-treated extract. The 2nd step factor Prp22 and RES complex proteins, which are 
recruited during activation, are underrepresented in B028 complexes: upon incubation with 
MN-treated extract or normal extract they are recruited efficiently to the spliceosome, but 
only in the presence of ATP. Interestingly, some spliceosomal RNA helicases, including 
Prp5 und Prp43, bind to the spliceosome in large amounts in the absence of ATP, 
suggesting their dissociation is ATP-dependent. Generally, the chasing of the B028 
complexes was more efficient in the presence of normal nuclear extract relative to that in 
the presence of MN-treated extract. However, with non-treated nuclear extract, it cannot 
be ruled out that B028 complexes dissociate and new complexes form during the chase.  
Taken together, these results show that our B028 complexes can be chased into activated 
spliceosomes efficiently. Notably, the absence of ATP during chasing experiment 
prevents binding of an important set of proteins such as Prp19/CDC5L complex proteins, 
Bact-specific and RES complex proteins. The results demonstrate that ATP is required for 




Table 3.4 Proteins identified by LC-MS/MS in human spliceosomal complexes B, Bact, B028 
and in B028 chased in the presence of MN-treated HeLa extract (MNnx) with or without ATP or 
normal extract plus ATP. The number shown is the total number of peptides sequenced for the 
indicated protein. Proteins are grouped according to function or association. Proteins widely considered 





kDa B B2 8
B2 8  in  
MNnx
B2 8  in  
MNnx 
ΔATP
B2 8  in  nx Bact
pm ol 0 .5 0 .5 0 .5 0 .5 0 .5 0 .5
MS2 - MBP 8 9 1 7 0 4 0 6 4 8 2 3 7 4 5 8 6 3 4 7
Sm  proteins
B gi|4507125 2 4 .6 3 6 6 1 6 5 6 9 4 9 6 9
D1 gi|5902102 1 3 .3 1 0 1 4 1 1 1 3 1 5 1 9
D2 gi|29294624 1 3 .5 2 9 6 5 4 7 3 9 5 2 6 5
D3 gi|4759160 1 3 .9 3 6 5 2 4 6 4 8 4 7 6 4
E gi|4507129 1 0 .8 1 9 3 1 2 3 2 7 2 7 4 5
F gi|4507131 9 .7 2 4 2 4 2 5 2 0 2 7 2 7
G gi|4507133 8 .5 7 9 1 3 1 2 8 8
U1  snRNP
U1 - 7 0 K gi|29568103 5 1 .6
U1 - A gi|4759156 3 1 .3 1 2 1 8 1 6 1 9 1 2 7
U1  snRNP associated
FBP1 1 gi|151301228 1 0 5 .8 1 6 2 4 2 7 1 2 8
S1 6 4  ( fSAP9 4 ) gi|219520438 1 0 0 .1 0 1 8 3 9 3 7 1 7 1 0
1 7 S U2  snRNP
U2 A' gi|50593002 2 8 .4 3 2 6 6 6 6 5 9 7 9 1 0 0
U2 B'' gi|4507123 2 5 .4 2 1 3 7 3 4 3 0 3 5 4 6
SF3 a1 2 0 gi|5032087 8 8 .9 1 2 5 2 0 5 2 1 6 1 8 7 1 5 0 2 2 3
SF3 a6 6 gi|21361376 4 9 .3 2 0 1 6 2 4 2 6 1 5 2 0
SF3 a6 0 gi|5803167 5 8 .5 4 6 9 3 8 3 8 5 7 4 9 2
SF3 b1 5 5 gi|54112117 1 4 5 .8 2 1 3 4 1 0 3 7 0 3 7 7 2 6 3 3 0 9
SF3 b1 4 5 gi|55749531 1 0 0 .2 1 4 0 2 4 8 1 9 6 1 7 3 1 3 3 1 9 5
SF3 b1 3 0 gi|54112121 1 3 5 .5 3 0 5 5 5 7 5 0 3 5 0 7 4 4 3 5 2 9
SF3 b4 9 gi|5032069 4 4 .4 1 2 1 7 2 9 3 1 1 9 2 6
SF3 b1 4 a/ p1 4 gi|7706326 1 4 .6 2 8 4 3 4 3 4 8 4 8 5 3
SF3 b1 4 b gi|14249398 1 2 .4 5 1 6 1 4 1 3 1 6 1 7
SF3 b1 0 gi|13775200 1 0 .1 1 5 2 0 1 2 1 2 7 1 5
1 7 S U2  related
hPRP4 3 gi|68509926 9 0 .9 9 0 1 0 9 2 7 1 0 4 3 2 3 2
SPF4 5 gi|14249678 4 5 2 5 1 4 8 1 3 3 2
U2 AF6 5 gi|6005926 5 3 .5 1 1 6 3 0 3 6 9
U2 AF3 5 gi|5803207 2 7 .9 6 6 7 2
hPRP5 / DDX4 6 gi|664806097 1 1 7 .4 2 3 3 1 1 3 8
SR1 4 0  ( fSAPa) gi|122937227 1 1 8 .2 4 4 3 5 2 4 3 6 1 3 3
CHERP gi|119226260 1 0 0 2 5 1 0 3 1 1 2
PUF6 0 gi|74761960 5 9 .9 1 1 2 5 1 9 7 9
A proteins
THRAP3  gi|167234419 1 0 8 .5 5 2 7 9 2 6 7
BUB3 gi|56550081 3 7 .2 1 3 2 1 2 7 1 3 4
SF1 gi|42544130 6 8 .3 1 9 8 9 8
SF4  ( F2 3 8 5 8 ) gi|33469964 7 2 .5 2 7 1 0 7 1 2 1 6 9
U5  snRNP
2 2 0 K /  Prp8 gi|3661610 2 7 3 .7 3 6 7 5 5 4 5 0 6 4 4 7 5 2 1 6 6 9
2 0 0 K /  Brr2 gi|45861372 2 4 4 .5 3 7 9 6 0 4 5 9 2 4 7 2 6 2 0 7 6 4
1 1 6 K /  Snu1 1 4 gi|41152056 1 0 9 .4 1 8 6 3 2 6 3 4 1 3 2 1 3 6 1 4 0 3
4 0 K gi|4758560 3 9 .3 5 3 8 8 9 8 7 9 9 0 1 1 5
1 0 2 K /  Prp6 gi|40807485 1 0 6 .9 1 1 8 3 3 3 9 1 9 4 7 2 3
1 5 K /  Dib1 gi|5729802 1 6 .8 1 1 3 2 4 3
1 0 0 K /  Prp2 8 gi|41327771 9 5 .6 3 8 1 1 2 3 1 4 1 7 1 9
5 2 K /  Lin1 gi|5174409 3 7 .6 7 2 2 3 2 3
LSm  proteins
LSm 2 gi|10863977 1 0 .8 1 1 2 1 1 5 1 3 9 6
LSm 3 gi|7657315 1 1 .8 1 4 6 3 1 1
LSm 4 gi|6912486 1 5 .4 3 1 6 1 0 1 1 1 1 3
LSm 5 gi|10720081 9 .9 1 1 2 1 1
LSm 6 gi|5919153 9 .1 4 9 1 1 6 4 2
LSm 7 gi|7706423 1 1 .6 1 3 3 2 0
LSm 8 gi|7706425 1 0 .4 9 1 8 1 2 1 1 1 0 6
U4 / U6  di- snRNP
9 0 K /  Prp3 gi|4758556 7 7 .6 7 5 1 9 1 3 1 8 1 7 4
6 0 K /  Prp4 gi|45861374 5 8 .4 6 4 1 9 1 3 1 7 1 6 5
2 0 K gi|5454154 2 0 2 0 5 8 5 1 0 5
6 1 K /  Prp3 1 gi|40254869 5 5 .4 3 4 1 1 1 2 1 0 9 1







kDa B B2 8
B2 8  in  
MNnx
B2 8  in  
MNnx 
ΔATP
B2 8  in  nx Bact
pm ol 0 .5 0 .5 0 .5 0 .5 0 .5 0 .5
U4/U6.U5 tri-snRNP
110K / Snu66 gi|13926068 9 0 .2 1 0 9 7 4 3 6 2 5 3 0 1 4
65K / Sad1 gi|56550051 6 5 .4 5 2 9 8 1 1 9
27K gi|24307918 1 8 .9 1 1
B proteins
hSnu23 gi|52783532 2 3 .6 6 1 9 1 7 1 2 1 1 8
hPRP38 gi|24762236 3 7 .5 2 2 5 8 4 1 2 3 1 7 2 0
hSmu-1 (fSAP57) gi|8922679 5 7 .5 9 9 3 0 4 2 0 5 1 8 9 9 9 7 6
MFAP1 gi|50726968 5 1 .9 4 2 6 4 4 8 3 9 2 5 4 1
RED gi|10835234 6 5 .6 4 6 1 1 1 1 0 7 9 1 4 4 4 4
FBP21 gi|67461858 4 2 .5 7 2 1 4
hPRP1 9 / CDC5 L 
hPRP1 9 gi|7657381 5 5 .2 6 2 1 9 1 1 4 4 0 2 0 4 3 0 9
CDC5 L gi|11067747 9 2 .2 7 7 3 2 1 8 3 6 8 2 0 0 2 9 1
SPF2 7 gi|5031653 2 1 .5 1 8 8 2 8 1 4 4 4 5 4
PRL1 gi|4505895 5 7 .2 4 1 1 7 9 0 2 6 1 0 9 1 5 6
CCAP1  ( hsp7 3 ) gi|5729877 7 0 .4 4 9 8 3 4 5 4 3 6
CCAP2  ( hspc1 4 8 , AD- 0 0 2 ) gi|7705475 2 6 .6 9 1 5 4 2 0 1 9
cat enin, b- like 1  ( CTNNBL1 ) gi|18644734 6 5 .1 1 3 2 9 9 3 4 3 2
Npw 3 8 BP gi|7706501 7 0 2 7 1 0 2 1 4 1 8 4 4 3 3 1
Npw 3 8 gi|5031957 3 0 .5 3 2 1 2 4 1 2 1 2 5
hPRP1 9 / CDC5 L relat ed
PRCC gi|40807447 5 2 .4 6 1 3 1 0 9
RBM2 2  ( fSAP4 7 ) gi|8922328 4 6 .9 1 4 2 3 7 1 7 4 6 5 9
hSYF1  ( XAB2 ) gi|55770906 1 0 0 4 3 1 7 1 3 1 4 9 2 2 0 3 0 1
CRNKL1 / hSYF3 gi|30795220 1 0 0 .6 4 4 9 5 6 2 2 1 3 4 2 7 9
hI sy1  ( fSAP1 3 3 ) gi|20149304 3 3 1 2 1 5 9 7 7 6 2 2 1 8
SKI P gi|6912676 5 1 .1 4 5 1 3 1 1 5 5 1 8 0 1 1 7
Cyp- E gi|5174637 3 3 .4 9 3 2 1 6 4 7 8 4
PPI ase- like  1  ( PPI L1 ) gi|7706339 1 8 .2 1 0 3 1 8 9 2 3 3 2
KI AA0 5 6 0  ( fSAP1 6 4 ) gi|38788372 1 7 1 .3 7 7 1 7 1 7 4 7 4 3 0 6 4 5 5
G1 0  ( fSAP1 7 ) gi|32171175 1 7 7 1 0 1 9 1 5 2 3 2 2
A/ B proteins
TCERG1  ( CA1 5 0 ) gi|21327715 1 2 3 .9 3 2 3 1 5 0 1 0 8 7 6 1 2
RNPC2  ( CC1 .3 )  gi|28201880 5 8 .5 1 2 3 2 3 1 9 1 0
p7 2 / DDX 1 7 gi|3122595 8 0 .5 4 1 3 6 7 6 5 3 3 1 9
NFAR gi|62512150 9 5 .4 6 1 5 2 9 7
NF4 5 gi|24234747 4 3 1 0 2 1 1 7
LOC1 2 4 2 4 5 gi|24234748 1 0 4 1 0 2 2 6 6 5 7 5 9 1 0
YB- 1 gi|24234749 3 5 .9 3 1 3 7 7 8 7 8 3 7 5 7
p6 8  ( DDX 5 ) gi|24234751 6 9 .2 7 2 7 1 0 8 8 7 2 7 2 4
Recruited prior to Bact
hsp2 7 gi|4504517 2 2 .8 2 6 1 2 1 5 4
UBL5 gi|13236510 8 .5 6 1 2 1 2 1 0 7 4
hPRP4 -Kinase gi|89276756 1 1 7 .1 4 4 4 0 8 3 3 2
HsKin1 7 gi|13124883 4 5 .4 1 2 2 1 4 6 1 1
BCLAF1 gi|7661958 1 0 6 2 8 4 1 1 5
SKI V2 L2  ( KI AA0 0 5 2 ) gi|193211480 1 1 7 .8 5 1 2 1 3 3 5 2 0 1 2
Abundant  first  in Bact  
KI AA1 6 0 4  ( fSAPb) gi|55749769 1 0 5 .5 1 5 1 3 6 6 1 0 6 1 6 1
hPRP1 7 gi|7706657 6 5 .5 2 3 1 3 2 8 1 0 5 1 8 1
hPRP2 gi|4503293 1 1 9 .2 1 7 4 5 6 8 1 0 4 1 7 5
GPKOW  ( T5 4 , GPATC5 ) gi|15811782 5 2 .1 1 2 1 1 2 1 5 7 8 7
NY- CO- 1 0 gi|64276486 5 3 .8 9 1 2 4 3 4 7 2
RNF1 1 3 A gi|5902158 3 8 .8 4 9 1 1 3 4 1
MGC2 0 3 9 8 gi|49472814 4 2 9 2 1 7 2 3 4 1
PPI L2 / Cyp- 6 0 gi|7657473 5 9 .5 1 7 2 4 6 6 9 1 2 1
MGC2 3 9 1 8 gi|21389497 1 9 .2 7 1 2 3 1 6 3 7
FRG1 gi|4758404 2 9 .2 3 6 1 1
Detected in Bact
p3 0  DBC gi|9937501 1 0 2 .8 2 3 6
FAM5 8 A gi|156630447 2 6 1 2 3
NCOR1 gi|189441644 2 7 0 .1 2
TRI M2 4  ( TI F1 ,LOC5 1 5 9 1 ) gi|47419911 1 1 6 .7
LENG1 gi|24308289 3 0 .4 6 1 0
DDX5 0 gi|13129006 8 2 .4 5 2
CRI PT gi|7661798 1 1 .1 4 3
GTL3  ( fSAP2 3 ) gi|8392875 2 2 .6 3 2 3 1 1 2
MOV1 0 gi|14211540 1 1 3 .5 0 9 4 4 1 4
FUBP3 gi|100816392 6 1 .5 6 9 3 1 1 4 1 7 6
2 nd step factors
hPRP2 2 gi|4826690 1 3 9 .3 7 2 2 1 6 9 1 7 1








kDa B B2 8
B2 8  in  
MNnx
B2 8  in  
MNnx 
ΔATP
B2 8  in  nx Bact
pm ol 0 .5 0 .5 0 .5 0 .5 0 .5 0 .5
abundant  first  in C com plex
Abstrakt gi|21071032 6 9 .8 8 9 3 5 2 2
GCI P p2 9  ( fSAP2 9 ) gi|46371998 2 8 .7 1 8 2 2 2 2 6
DDX3 5 gi|20544129 7 8 .9 9 5 1 5 3 0
detected in C com plex
m atr in 3 gi|21626466 9 4 .6 9 4 1 3 4 1 4 1 3
EJC/ m RNP
eI F4 A3 gi|7661920 4 6 .9 5 6 3 3 2 5 2 7 4 0
Magoh gi|4505087 1 7 .2 4 4 1 4 1 5
Pinin gi|33356174 8 1 .6 1 2 9 2 1 1 0 1 5
RN PS1 gi|6857826 3 4 .2 1 8 7 3 3
DDX3 gi|87196351 7 3 .3 5 1 2 7 6 5 0 2 0 9
m RNA binding pro teins
PABP1 gi|46367787 7 0 .5
PABPC4 gi|4504715 7 0 .6 3 2 2 6 9 9
PABPN1 gi|4758876 3 2 .6 1 5 1
cap binding com plex
CBP2 0 gi|110349727 1 8 6 1 0 1 2 1 4 1 7 2 1
CBP8 0 gi|4505343 9 1 .8 1 0 1 1 9 9 1 6 7 1 5 8 1 7 6 2 2 1
TREX
THOC1  ( HPR1 ) gi|154448890 7 5 .6 1 5 1 6 5 9
THOC2 gi|125656165 1 6 9 .6 2 6 1 0 6 1 4
THOC3 gi|14150171 3 8 .8 4 3 4
THOC6  ( W DR5 8 , MGC2 6 5 5 ) gi|31543164 3 7 .5 1 1 1 1 5 8
THOC7  ( FLJ2 3 4 4 5 , fSAP2 4 ) gi|13376623 2 3 .7 6 6 3 5
RES com plex
SNI P1 gi|21314720 4 5 .8 1 7 1 2 3 1 3 7 5 8
MGC1 3 1 2 5  ( fSAP7 1 ) gi|14249338 7 0 .5
CGI - 7 9 gi|4929627 3 9 .7 1 0 2 1 0 2 2 7 4 9
SR proteins
SF2 / ASF gi|5902076 2 7 .8 1 4 9 1 7 7 6 2 6 3 5
9 G8 gi|72534660 2 7 .4 8 6 2 2 4 2 2 0 2 3
SRp2 0 gi|4506901 1 9 .4 3 7 1 2
SRp3 0 c gi|4506903 2 5 .5 7 9 4 2 4 6 1 4 3 2
SRp3 8 gi|5730079 3 1 .3 9 1 3 4 5 3 2 2 9 4 1
SRp4 6 gi|14141216 3 1 1 1 1 2 2 3
SRp5 5 gi|20127499 3 9 .6 2 2 4 1 0 1 1
SRp7 5 gi|21361282 5 6 .8 9
hTra- 2  a lpha gi|9558733 3 2 .7 3 1 2 8 4 7
hTra- 2  beta / SFRS1 0 gi|4759098 3 3 .7 2 4 1 6 2 2 1 6 1 5
SR re lated prote ins
SRm 1 6 0 gi|42542379 1 0 2 .5 4 4 1 5 1 9 2 6 3 7
SRm 3 0 0 gi|4759098 3 0 0 4 0 2 2 4 6 4 3 7 7 1 4 8
hnRN P
hnRN P A0 gi|8134660 3 0 .9 4 5 1
hnRN P A1 gi|4504445 3 8 .7 1 5 1 1 0 7 6 2 8 6
hnRN P A3 gi|34740329 3 9 .6 9 4 5 2 7 1 0 5
hnRN P A2 / B1 gi|14043072 3 7 .4 8 9 8 5 8 3 1 3
hnRN P D gi|14110420 3 8 .4 3 1 1 8 7 2
hnRN P F gi|148470406 4 5 .7 2 2 7 4 1 4 0 1 1 1 2
hnRN P G gi|56699409 4 2 .4 1 2 1 5 9 7 7 6 2 2 1 8
hnRN P H1 gi|5031753 4 9 .1 4 2 4 9 3 7 0 2 1 1 4
hnRN P H3 gi|23503095 3 6 .9 1 1 7 5 2
hnRN P K gi|14165435 5 1 1 9 1 7 2 1 4 5 3 0 6
hnRN P L gi|215274006 6 4 .1 1 2 2 1 7 1 0 2
hnRN P M gi|14141152 7 7 .5 7 1 3 6 2 6 8 2 1 2 2
hnRN P Q gi|15809590 6 9 .6 4 3 9 1 5 1 6 5
hnRN P R gi|5031755 7 0 .9 8 1 1 0 4 7 2 6 1 3
hnRN P U gi|14141161 9 0 .6 1 0 5 1 3 6 8 0
hnRNP U- L2 gi|118601081 8 5 1 3 5 0 1 4 7 5
Miscellaneous proteins
LOC5 1 3 2 5  gi|22035565 1 0 4 .8 1 8 4 2 1 2 2 0 1 7 1 3
BAT1  gi|114306812 5 1 1 6 1 4 9 1 8 1 1
HSPA5 gi|14916999 7 2 1 7 1 1 2 8 4 2 2 2
FNBP4 gi|313104235 3 2 4 1 2 1 2 2
W TAP gi|47117889 4 3 1 1 0 1 0 1 3
ZNF 3 1 8 gi|166215018 2 4 6 1 9 1 7 1 2 1 1 8
CCDC1 3 0 gi|134037158 3 1 4
FUBP2 gi|313104306 7 7 5 9 6 2 4 9 2 6
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3.5 Mechanism of inhibitory action of compound 028 
3.5.1 U4/U6.U5 tri-snRNP is stable in the presence of compound 028 
We next were interested in elucidating the mechanism how compound 028 blocks 
spliceosome assembly. Both A and B-like complexes accumulate when splicing is 
performed in the presence of compound 028. We thus checked if tri-snRNP 
formation/stability is affected by the presence of compound 028. To answer this question, 
HeLa nuclear extract was incubated under splicing conditions (except no pre-mRNA was 
added) in the presence of DMSO or 028, and the splicing mix was subjected to glycerol 
gradient centrifugation (Fig. 3.33). RNAs were isolated from gradient fractions, separated 
by denaturing PAGE, transferred to a nylon membrane and hybridized with 32P-labelled 
DNA probes specific for U1, U2, U4, U5 and U6 snRNAs.  
 
Figure 3.33 The U4/U6.U5 tri-snRNP is stable in the presence of compound 028. Control 
reaction in the absence of compound 028 (DMSO) was performed in parallel. HeLa nuclear extract 
plus DMSO (upper panel) or compound 028 (lower panel) was incubated under splicing conditions at 
30° for 20 min and subjected subsequently to 10-30 % glycerol gradient centrifugation. RNAs were 
isolated from gradient fractions, separated by denaturing PAGE, and analysed by northern blotting with 
radioactively labelled DNA probes against the U2, U1, U4, U5 and U6 snRNAs. Hybridized DNA 
probes were detected by autoradiography. RNA identities are indicated at the left. 
 
Northern blot analysis revealed that tri-snRNPs formed in the presence of DMSO peak in 
fractions 15 to 18, based on the presence of U4, U5 and U6 snRNAs. In the presence of 
DMSO, 20 '
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028, tri-snRNPs sedimented as a broader peak in fractions 14 to 23, suggesting compound 
028 leads to some aggregation of the tri-snRNP such that is sediments closer to the 
bottom of the gradient. However, there was was little increase in free U4/U6 snRNPs, 
which peak in fractions 9-12 in the DMSO control. Thus, the tri-snRNP remains to the 
most part intact. The sedimentation of U1 and U2 snRNPs was also largely unaffected by 
compound 028.  
To check if the stability of the U4/U6.U5 tri-snRNPs is affected by 028, we performed 
immunoprecipitations with splicing reactions and antibodies directed against the U4/U6 
60K/Prp4 protein and looked for coprecipitation of U5 (indicating tri-snRNP formation) 
at different salt concentrations. Likewise we used antibodies against the U5 116K/Snu114 
protein to check for coprecipitation of U4/U6. In the presence of 028 we observed a 
slightly decreased signal intensity of U5 coprecipitated with anti-U4/U6-60K antibodies, 
especially at 290 and 390 mM salt, in comparison to the control (Fig. 3.34, lanes 6-8 
versus 9-11). Likewise, less U4/U6 snRNP was coprecipitated with anti-U5-116K 
antibodies when compound 028 was added (Fig. 3.34, lanes 12-14 versus 15-17). In 
general, we conclude that compound 028 affects tri-snRNP stability to only a low extent, 
and that the majority of tri-snRNP is still intact under splicing conditions.  
 
 
Figure 3.34 U4/U6.U5 tri-snRNPs appear to be slightly less salt stable in the presence of 
compound 028. Tri-snRNP particles were immunoprecipitated with antibodies directed against U4/U6 
snRNP protein 60K/Prp4 or the U5 snRNP protein 116K/Snu114 or Sm proteins (Y12) as a control, at 
three different salt concentrations. Initially, HeLa nuclear extract was incubated under splicing 
conditions at 30° for 20 min in the presence or absence of compound 028, and then added to the PAS-
bounded antibodies, incubated for 4 h with end-over-end rotation and extensively washed in buffer 
containing 190, 290, 390 mM salt. Co-precipitated RNAs were isolated, separated by denaturing PAGE 
and analysed by northern blotting. Hybridized 32P-labelled DNA probes were detected by 
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3.5.2 Association of AD002 with the Prp19/CDC5L complex is affected by the 
presence of compound 028  
The hPrp19/CDC5L complex is required for spliceosome activation and for stabilization 
of interactions of U5 and U6 with the pre-mRNA in Bact (Chan et al., 2003, 2005). Based 
on mass spectrometry analysis, it was shown that the hPrp19/CDC5L complex is clearly 
underrepresented in our stalled B028 complexes (Table 3.3). Thus, the block during the 
activation step could be due to an effect of compound 028 on the Prp19/CDC5L complex. 
To test this, we next isolated hPrp19/CDC5L complexes from splicing reactions in the 
presence/absence of compound 028. For this purpose, splicing reactions containing HeLa 
nuclear extract expressing FLAG-tagged AD002/Cwc15 protein were performed under 
standard conditions in the presence of DMSO or compound 028. Then the salt 
concentration was adjusted to 250 mM. Complexes containing AD002-FLAG were bound 
to anti-FLAG-M2 agarose beads and, after extensive washing, eluted with FLAG peptide. 
SDS-PAGE analysis revealed that intact Prp19/CDC5L complexes containing CDC5L, 
CTNNBL1, HSP73, PRL1, Prp19 and AD002, were successfully isolated in the absence 
of compound 028 (Fig. 3.35). In the presence of compound 028, an equal amount of 
AD002 was precipitated, but only low levels of CDC5L, CTNNBL1, Hsp73, PRL1 and 
Prp19, compared to the control reaction, indicating that mainly free AD002-FLAG had 
been isolated. Taken together, these results suggest that the association of AD002 with 
the Prp19/CDC5L complex is affected by the presence of compound 028. 
 
Figure 3.35 The Prp19/CDC5L complex is affected by the presence of compound 028. 
Splicing reactions in the absence of pre-mRNA were performed in the presence or absence of 
compound 028 using 40 % HeLa nuclear extract expressing FLAG-tagged AD002 protein. FLAG-
tagged protein with interacting partners was bound to anti-FLAG-M2 agarose in buffer containing 250 
mM salt, washed and eluted with 0.2 mg/ml FLAG peptide. Eluted complexes were precipitated with 
TCA, separated by SDS-PAGE and stained with coomassie. The Prp19/CDC5L complex proteins were 









































3.5.3 Gradient analysis of Prp19/CDC5L complex in the presence/absence of 
compound 028  
To check the stability of the Prp19/CDC5L complex and the association of the 
AD002/Cwc15 protein with Prp19/CDC5L complexes in the presence of compound 028, 
we performed splicing under standard conditions (except no pre-mRNA was added) with 
HeLa nuclear extract expressing a FLAG-tagged version of AD002 protein in the 
presence or absence of compound 028. The splicing reaction mixture was subjected to 
glycerol gradient centrifugation (150 mM salt) and gradients were fractionated from the 
top. The proteins from each fraction were separated by SDS-PAGE, and selected proteins 
were then detected by western blotting with antibodies directed against CDC5L, Prp19 
and the FLAG tag. Western blot analysis revealed similar amounts of AD002-FLAG 
protein migrating alone (not in complex with Prp19 or CDC5L) in fractions 3 to 9 in both 
the DMSO control and when compound 028 was present (Fig. 3.36). Prp19 and CDC5L 
proteins sedimented together in fractions 16 to 18 in both preparations, demonstrating that 
the Prp19/CDC5L complexes do not dissociate once we add compound 028. In contrast, 
FLAG-tagged AD002 protein co-migrated in the control reaction, but showed a slight 
shift if incubated in the presence of compound 028, suggesting that the adjusting the salt 
concentration from 150 to 250 mM could lead to the dissociation of AD002 protein 
component from Prp19/CDC5L complex. Thus, additional experiments are needed to 
clarify the effect of compound 028 on the Prp19/CDC5L complex. 
 
Figure 3.36 The sedimentation of the Prp19/CDC5L complex is not affected by compound 
028. HeLa nuclear extract expressing FLAG-tagged AD002 protein was incubated under splicing 
conditions but no exogenous pre-mRNA was added. Complexes were separated using glycerol gradient 
centrifugation and subsequently fractionated from the top. The proteins from each fraction were 
separated on SDS-PAGE and subjected to western blotting procedure. Western blotting was performed 
using antibodies directed against selected Prp19/CDC5L complex proteins and against the FLAG tag.  
Molecular weight is indicated at the left, and the antibodies used are indicated at the right. 
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3.6 Structure-activity relationship (SAR) analysis of compound 028  
Our results showed that compound 028 completely inhibits pre-mRNA splicing in vitro at 
a concentration of 150 µM, with an IC50 value of 51 µM, leading to accumulation of A 
complexes as well as complexes stalled after the formation of B complex, but before Bact 
complexes emerge, i.e. during the activation step. However, the exact relationship 
between 028 compound structure and splicing inhibition is not clear. A structure–activity 
relationship analysis (SAR) of this compound can reveal molecule features essential for 
splicing inhibition. On the basis of a SAR study we hoped to enhance the inhibition 
property of compound 028 by modifying its original structure. Furthermore, we intended 
to identify parts of the molecule that could potentially be used for tagging without 
significant loss of its inhibition activity. A tagged version of 028 is of particular 
importance for further investigation of possible target(s) of compound 028 in the splicing 
reaction. 
To elucidate structural determinants (motifs) that confer splicing inhibition activity on 
compound 028, a number of structural modifications at specific sites of the original 
molecule were carried out by Javier Ceballos in Prof. Dr. Waldmann’s group (MPI for 
Molecular Physiology, Dortmund). The synthesis of 028 analogues was performed with a 
wide diversity of modifications introduced separately or combined at different positions. 
These modifications include reduction of the linker between the two heterocyclic motifs 
of the original molecule, modifications in the o-ethylphenyl group and/or in p-
fluorophenyl group (with the goal of changing electron properties on the rings and/or 
changing the size of the substitution), modifications in the furan group located between 
the p-fluorophenyl group and heterocyclic barbituric acid-related group, and 
modifications in the heterocyclic barbituric acid-related group based on the pyrimidine 
heterocyclic skeleton. Derivatives were synthesized and tested in an in vitro splicing 
assay. All together, I tested 31 derivatives, whose structures are shown in Fig. 3.37B and 
C and in Table 3.4. 
With the first set of analogues, we examined the importance of the double bond in the 
short unsaturated linker between the two heterocyclic motifs. The original compound is 
expected to behave reactively towards nucleophiles due to its Michael acceptor character. 
Therefore, this feature might be relevant for the splicing inhibition activity of the original 
compound. To check this, we tested the reduced derivative of compound 028 alone 
(343139) or in combination with other modifications like removing the ethyl group from 
the o-ethylphenyl group (343137) or removing the entire o-ethylphenyl group (343138). 
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For comparison, splicing was assayed with a version of compound 028 that was also 
synthesized by the Waldmann group whose structure is identical to the commercially 
available compound 028, called here 172312. 
3.6.1 Effect of the reduction of the linker between the two heterocyclic motifs on 
splicing inhibition in vitro 
To assay for enhanced inhibition we chose the concentration 50 µM, where only slight 
inhibition of splicing is observed by the synthesized compound 172312 (Fig. 3.37, lane 
10). At 50 µM all of the modified analogues (343139, 343137, 343138) (Fig. 3.37, lanes 
8, 7, 12, Table 3.6) were as active as the DMSO control and less potent than 172312, 
displaying a slight increase in inhibition activity relative to 172312. At the same time, 
removing the ethyl group alone from the non-reduced molecule (343134) did not change  
 
A.                                                                                    B.  
       
C. 
 
Figure 3.37 Analysis of in vitro splicing performed in the presence of various derivatives of 
compound 028 at a concentration of 50 µM. Splicing was performed with radioactively-labelled 
adenovirus-derived, MINX-MS2 pre-mRNA as a substrate. A. Effects of different analogues on the 
splicing of 32P-labeled MINX-MS2 pre-mRNA in HeLa nuclear extract after 60 min. RNA was 
analysed by denaturing PAGE and visualized by autoradiography (DMSO: control reaction with 
solvent). The positions of the lariat-intron/3′-exon, pre-mRNA, spliced mRNA, (top to bottom) are 
indicated on the left. B. Chemical structure of the original molecule synthesized for this study. C. 
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the inhibition activity compared to 172312 (Fig. 3.37, lane 6, Table 3.6). However, we 
could observe slightly enhanced inhibition activity (accumulation of pre-mRNA), when 
the entire o-ethylphenyl group was removed without reduction of the double bond of the 
linker (343135) (Fig. 3.37, lane 9) when compared to the synthesized original compound 
172312. In addition, we tested a molecule with the p-fluorophenyl group substituted by 
bromine in combination with the removal of the ethyl residue from the o-ethylphenyl 
group (343136) (Fig. 3.37). The bromine was added as a substitute for reactive fluorine. 
This compound was less effective in inhibiting splicing in vitro in comparison to the 
original hit compound (Fig. 3.37 lane 11, 3.38). Taken together, our initial results suggest 
that the Michael acceptor character of the original compound is necessary for splicing 
inhibition. However, to be able to make a more precise conclusion, we decided to test the 
activity of the more promising analogues at higher concentrations. 
 
Figure 3.38 Effect of increasing concentrations of selected analogues of compound 028 on the 
splicing of 32P-labeled MINX-MS2 pre-mRNA. Splicing was performed in the presence of various 
concentrations (25-200 µM) of three analogues in HeLa nuclear extract for 1 h. Formation of the 
splicing products and intermediates was analysed by denaturing PAGE and visualized by 
autoradiography. The positions of lariat-intron/3′-exon, lariat-intron, pre-mRNA, spliced mRNA are 











































To analyse the splicing inhibition efficiency of 343134, 343135 and 343136 in more 
detail, I carried out a titration of these compounds (Fig. 3.38). From this experiment it is 
clear that compounds 343134 and 343136 are less potent than 172312. Thus, deletion of 
the ethyl group (343134) or substitution of the p-fluorophenyl group with bromine in 
combination with the elimination of ethyl group from o-ethylphenyl (343136) reduced 
somewhat splicing inhibition activity (Fig. 3.38, upper panel). In contrast, 
removal/elimination of the entire o-ethylphenyl group did not significantly alter the 
potency of 343135 compared to 172312 (Fig. 3.38, lower panel), suggesting it is not 
required for inhibition activity. Interestingly, the lariat-intron 3’exon intermediate is more 
abundant at a concentration of 125-150 µM of 172312 compared to 343135. This 
suggests that the mechanism of inhibition might differ somewhat if the o-ethylphenyl 
group is removed.  
3.6.2 Effect of further modifications on splicing inhibition in vitro 
We next analysed the effect of a wide variety of modifications on the splicing inhibition 
activity of compound 028 (172312). Changing the position of fluorine from para- to 
ortho-position abolished inhibition activity completely (343876) as well as replacing the 
p-fluorophenyl group with heterocycle piperidine (non aromatic ring) (344353). Two 
neighbouring halogens in the meta- and para-positions (343872) reduced the inhibitory 
activity dramatically as well as the replacement of fluorine on the p-fluorophenyl group 
by a methyl group (electron donator) (343875) or bulky phenyl group (343868). 
Eliminating the furan group from the heterocyclic barbituric acid-related group, which 
leads to the phenyl group being directly connected via unsaturated short linker with a 
halogen (chlorine or bromine) substituting the fluorine in the para-position (343878, 
343879) also clearly weakens inhibition activity in comparison to the original hit. Thus, 
our study revealed that the p-fluorophenyl group together with reactive fluorine, as well 
as the furan group are required for the inhibition activity/function.  
Minor modifications in the p-fluorophenyl group such as changing the position of 
fluorine from the para- to meta-position (343867) or substituting fluorine with chlorine in 
the meta-position (343871) clearly enhanced the inhibition effect of the original 
compound, suggesting once again that the p-fluorophenyl group is extremely important 








Figure 3.39 Effects of various analogues of compound 028 on the splicing of 32P-labeled 
MINX-MS2 pre-mRNA in HeLa nuclear extract after 60 min. RNA was analysed by denaturing 
PAGE and visualized by autoradiography (DMSO: control reaction with solvent). Positions of lariat-
intron/3′-exon, lariat-intron, pre-mRNA, spliced mRNA, and 5′-exon (top to bottom) are indicated on 
the left. 
 
The other modifications in the p-fluorophenyl group, such as two halogens in the meta-
positions (343873), dimethylamino group (electron donating group) attached to the 
phenyl group (343869) or an acetyl group (electron withdrawing group) in para-position 
(343870) didn’t change the potency of the molecule significantly. Substituting fluorine 
with a trifluoromethyl ether group (344355) appears to show rather strong inhibition. 
Introducing a methoxy group in the ortho-position leads to reduced splicing inhibition 
(343874), whereas two methoxy groups in the para- and meta-position (343877) restore 
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Figure 3.40 Effect of increasing concentrations of selected synthesized analogues of 
compound 028 on the splicing of 32P-labeled MINX-MS2 pre-mRNA. Splicing was performed in 
the presence of various concentrations of four analogues in HeLa nuclear extract for 1 h. Formation of 
the splicing products and intermediates was analysed by denaturing PAGE (upper panel), and 
spliceosomal complexes were analysed on an agarose gel (lower panel). The positions of lariat-
intron/3′-exon, lariat-intron, pre-mRNA, spliced mRNA and the positions of spliceosomal complexes 
C, B, A, H are indicated on the left. Gels were visualized by autoradiography. DMSO, control reaction 
(solvent).  
 
The modification on the o-ethylphenyl group generally also didn’t have a strong effect on 
the activity of compound. The elimination of the ethyl group from the o-ethylphenyl 
group and introduction of fluorine, chlorine or bromine in para- or meta-position (Table 
3.5 and 3.6, 344342, 344345, 344347 and 344350) had a minimal effect on the splicing 
inhibition potency (Fig. 3.39B). Interestingly, the introduction of fluorine in a meta-
position (344350) weakened the inhibition potency of the molecule in comparison to 
chlorine, which appears to slightly enhance inhibition potency. Changing the position or 
substitution of the ethyl group with methyl (344349, 344346) didn’t affect inhibition 
activity significantly, as well as methyl groups in the meta-/para- or meta-/ortho-positions 
(344348, 344352). No strong effect was also observed by the substitution of the ethyl 
group with an ethoxy group attached to phenyl at the meta-position (344343) or in the 
para-position (344344). Also a methylenedioxy- group (very strong electron donating 
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group) attached to the phenyl composing a methylenedioxyphenyl functional group, 
which is widely found in natural products, including multiple drugs (344354) didn’t 
significantly affect the inhibition activity of the original inhibitor. 
Eliminating the p-fluorophenyl group alone or accompanied by the introduction of 
additional groups like a phenyl to the nitrogen in the heterocyclic barbituric acid-related 
group (elimination of N-H moiety) weakened inhibition (344339, 164205), while the 
addition of methoxy groups to both phenyl groups in the para- or ortho-positions reduced 
the potency to a lesser extent, especially when the methoxy groups are in o-positions 
(344340, 344341). Substituting the oxygen with a sulphur atom in the barbituric acid-
related group (344351) had a negative impact on the inhibitor potency. Taken together, 
these modifications had only minimal or no effect on the inhibition activity. Thus, their 
positions in the original molecule can potentially be used for tagging. 
We failed in our efforts to find an analogue that was significantly more active than the 
original molecule. The most promising two active analogues found were 343867 and 
343871, which possessed only minor modifications in the o-fluorophenyl group. Their 
inhibition potency was slightly higher than that of 028.  
From the results obtained, we can conclude that the presence of the unsaturated linker 
between two heterocyclic motifs in the original compound appears to be required for 
inhibiting the splicing of pre-mRNA in vitro. Our studies also revealed that a reactive 
fluorine on the p-fluorophenyl group is necessary for the inhibition activity. Changing the 
position of fluorine from the para- to ortho-position or the presence of two neighbouring 
halogens in the meta- and para-positions abolishes the inhibition effect. The highest 
inhibitory potencies were observed using highly reactive halogens like fluorine or 
chlorine at the meta-position compared to fluorine at the para-position of the original 
molecule. Substituting the p-fluorophenyl group with heterocycle piperidine (344353) 
abolishes the inhibition potency. We also showed that analogues with eliminated or 
substituted ethyl on the o-ethylphenyl group have a similar or slightly decreased 
inhibition activity compared to the original product. These observations indicate that the 
primary ethyl group is not essential for the inhibition of pre-mRNA splicing in vitro and 




Table 3.5 Summary of modifications to compound 028 and their effect on the inhibition of 
pre-mRNA splicing in vitro at 150 µM. 








Reduced analogue and removed ethyl group from o-ethylphenyl group 
Reduced analogue with removed o-ethylphenyl group 
Removed ethyl group from o-ethylphenyl group 
Removed o-ethylphenyl group 
Substitution of p-fluorophenyl group with bromine as a substitute for the 
entire reactive group in combination with eliminated ethyl group from o-
ethylphenyl 
less active at 50 µM 
less active at 50 µM 
less active at 50 µM 
less active at 50 µM 
same as 028 













Changing the position of fluorine from para- to ortho-position 
Replacing the p-fluorophenyl group with heterocycle piperidine (non aromatic 
ring) 
Two neighbouring halogens in meta- and para-position 
Replacement of fluorine on the p-fluorophenyl group by methyl group (an 
electron donor group) 
Replacement of fluorine on the p-fluorophenyl group by phenyl group 
Eliminating the furan group with heterocyclic barbituric acid-related group 
connected to phenyl group with chlorine in para-position  
Eliminating the furan group with heterocyclic barbituric acid-related group 














Changing position of fluorine from para- to meta-position 










Elimination of ethyl group from the o-ethylphenyl group and introduction of 
bromine in para-position 
Elimination of ethyl group from the o-ethylphenyl group and introduction of 
bromine in meta-position 
Elimination of ethyl group from the o-ethylphenyl group and introduction of 
chlorine in meta-position 
Elimination of ethyl group from the o-ethylphenyl group and introduction of 
fluorine in meta-position 
same as 028 
 
same as 028 
 
slightly more active 
 






Changing the position of the ethyl group from ortho- to para-position (same 
electron properties of the ring)  
Substitution of the ethyl group with methyl (same electron properties) 
Di-methylation in meta-/para-positions 
Di-methylation in meta-/ortho-positions 
same as 028 
 
same as 028 
same as 028 








Substitution of the ethyl group with an ethoxy group attached to phenyl in 
para-position (more electron donating properties) 
Substitution of the ethyl group with an ethoxy group attached to phenyl in 
meta-position 
Methylenedioxy group attached to phenyl composing methylenedioxyphenyl 
functional group (very strong electron donating group) 
Substituting the oxygen with sulphur atom in barbituric acid-related group 
same as 028 
 
slightly less active  
 







Two halogens in meta-positions 
Substituting fluorine with trifluoromethyl ether group 
same as 028 





Dimethylamino group attached to a phenyl group (very strong donating) 
Acetyl in para-position (electron withdrawing group) 
Substituting the fluorine with methoxy group in ortho-position  
Two methoxy groups in para- and meta-position  
slightly less active  
slightly less active 
less active  







Eliminating the p-fluorophenyl group  
Eliminating the p-fluorophenyl group, introduction of phenyl group to the 
nitrogen in heterocyclic barbituric acid-related group (Elimination of N-H 
moiety) 
Additing the methoxy groups to both phenyl groups in para- position 





less active  
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Pre-mRNA splicing is a highly intricate process due to the highly complex composition 
of the spliceosome and its continuous structural rearrangements during splicing. The 
dynamic nature of the spliceosome is a serious impediment for the investigation of its 
structure. Stalling spliceosome assembly at distinct stages is a powerful tool for 
understanding the compositional and structural dynamics of the spliceosome, because it 
potentially allows us to isolate homogeneous/stabilised populations of spliceosomes for 
structural and functional studies. The aim of this work was to identify new small 
molecule inhibitors of pre-mRNA splicing that stall spliceosome assembly and enable the 
isolation of more homogeneous complexes or complexes stalled at a new intermediate 
stage of splicing. In the presented work, I not only managed to identify several inhibitors 
of pre-mRNA splicing in vitro, which block pre-mRNA splicing at different stages of 
spliceosome assembly, but also succeeded with one compound (028) to stall the 
spliceosome at a novel stage of the splicing cycle – i.e. during its catalytic activation. 
This new assembly intermediate was subsequently isolated and characterized in terms of 
its composition, its RNA-RNA network, and also its overall structure by EM. The stalled 
complex was functionally active, as it could be chased into a catalytically active 
spliceosome in the presence of HeLa nuclear extract treated with micrococcal nuclease. 
Furthermore, we carried out an initial structure-activity relationship study that revealed 
the structural motifs of compound 028 essential for its inhibition activity.  
4.1 Identification of new small molecule inhibitors of pre-mRNA 
splicing  
We first screened large chemical libraries to search for small molecule inhibitors of pre-
mRNA splicing. Several approaches to screen for inhibitors of pre-mRNA splicing were 
previously reported. Some of them take advantage of reporter constructs, allowing the 
screening for an increase in a fluorescent reporter protein that is expressed from pre-
mRNA designed such that only the unspliced version generates active protein (O'Brien et 
al., 2008). Alternative splicing modulators were identified using a two-color fluorescent 
reporter system in cellular assays that allows detection of the inclusion or exclusion of a 
particular exon (Stoilov et al., 2008). High throughput splicing assays were also 
developed using other techniques, such as reverse transcription followed by quantitative 
PCR readout (Effenberger et al., 2013). For my research I used an in vitro, high 
throughput screening assay that was developed in our lab (Samatov et al., 2012). This 
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assay was shown to be an effective method to screen large chemical libraries to identify 
compounds that inhibit pre-mRNA splicing prior to the formation of the spliceosomal 
complex C (Pawellek et al., 2014; Samatov et al., 2012). It measures the interaction of the 
spliceosomal C-specific DEAD box ATPase Abstract with the spliceosome and therefore 
is used as a marker for catalysis of the first step of splicing (described in detail in section 
3.1.1). Using this assay ca. 172000 compounds were screened, and 10 novel compounds 
were initially confirmed to be inhibitors of pre-mRNA splicing in vitro. None of these 
compounds were structurally related, excluding compounds designed 296 and 187042. 
The detected compounds inhibit splicing in a dose-dependent manner with IC50 values 
ranging from 2 to 55 µM. This is significantly less potent compared to some known 
splicing inhibitors, such as spliceostatin A that inhibits splicing at nanomolar 
concentration (Kaida et al., 2007), but similar to others, such as psoromic acid with an 
IC50 value of 56 µM or norstictic acid with an IC50 value of 28 µM (Samatov et al., 2012). 
These compounds inhibited spliceosome assembly mainly at the A and/or B/Bact complex 
stage. The most extensive accumulation of these complexes was seen with the compound 
denoted as 028. Thus, the effect of this particular compound on spliceosome assembly 
was studied in more detail. 
4.2 Purification of a novel spliceosome assembly intermediate  
4.2.1 Composition of affinity-purified spliceosomal complexes stalled by compound 
028 
To characterize the complexes accumulating in the presence of the identified compounds 
in detail, I purified them via the MS2 selection method and analysed their RNA and 
protein composition via denaturing gel analysis and/or northern blotting (RNA) or mass 
spectrometry and/or western blotting (protein). Previously, various human spliceosomal 
complexes were purified and their RNA and protein compositions were characterized 
(Bessonov et al., 2010; Bessonov et al., 2008). These known intermediates (B or Bact 
complexes) were isolated in parallel and used for comparison with the complexes stalled 
by small molecule inhibitors. 
The isolated B-like complexes stalled by compound 120 were nearly identical to B 
complexes formed with DMSO, whereas complexes formed in the presence of 
compounds 296 and 297 appeared to be a mixture of B, Bact and later complexes. Thus, 
these complexes were not studied further (120) or will be studied in more detail in the 
future (296 and 297) after optimization of their isolation conditions.  
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Both A and B-like complexes accumulated when splicing was carried out in the presence 
of compound 028. Interestingly, the A complexes formed in the presence of compound 
028 (A028) peaked on glycerol gradients one fraction closer to the top compared to the A 
complexes formed under the inhibitor-free conditions, suggesting that their composition 
or structure may be different. However, the RNA composition of these complexes was 
unchanged and their protein composition was affected only to a small extend, containing 
lesser amounts of several U2-related proteins (SPF45, SPF30, CHERP), as well as the A 
or A/B proteins DDX9 and RBM5 compared to A complexes formed in the presence of 
DMSO. Recently, functional studies showed that SPF30 is an essential splicing factor that 
associates with both U4/U6.U5 tri-snRNP and U2 snRNP components (Rappsilber et al., 
2001). Its immunodepletion from nuclear extract was shown to inhibit the first step of 
pre-mRNA splicing by preventing the formation of complex B (Meister et al., 2001; 
Rappsilber et al., 2001). Taking into account the necessity of the SPF30 protein for the 
formation of complex B, we suggest that the accumulation of A complexes in the 
presence of compound 028 could potentially be caused by the absence of SPF30, 
blocking the transition from the A to B complex. Compound 028 could alternatively 
hinder other proteins needed for B complex formation, such as SRPK2 (Mathew et al., 
2008) or the tri-snRNP proteins 65K and 110K (Makarova et al., 2001).  
Since A, and also B-like complexes, accumulate during the inhibition of spliceosome 
assembly by compound 028, we tested whether tri-snRNP formation/stability might be 
affected by the presence of compound 028. The sedimentation behaviour on glycerol 
gradients of tri-snRNPs formed in the presence of compound 028 suggests that compound 
028 leads to some aggregation of the tri-snRNP (Fig. 3.30). However, the tri-snRNP, and 
also U1 and U2 snRNP, appeared to be for the most part intact and unaffected by 
compound 028. The stability of the U4/U6.U5 tri-snRNPs in the presence of compound 
028 was assayed by immunoprecipitation studies performed at different salt 
concentrations with antibodies directed against selected tri-snRNP proteins (U4/U6 
60K/Prp4 and U5 116K/Snu114) to check for coprecipitated U5 and U4/U6, respectively, 
which demonstrates tri-snRNP formation (Fig. 3.31). The stability of the U4/U6.U5 tri-
snRNPs was shown to be only slightly affected in the presence of compound 028. Thus, 
alterations in tri-snRNP formation do not appear to contribute to the accumulation of A or 
B complexes in the presence of compound 028.  
The sedimentation behaviour and composition of affinity-purified B-like complexes 
formed in the presence of compound 028 (B028) demonstrated clear and intriguing 
differences compared to B or Bact complexes. First, B028 complex sedimented on glycerol 
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gradients with a lower S-value compared to that of complexes Bact and B formed under 
inhibitor-free conditions, suggesting that it might be a novel spliceosome assembly 
intermediate. The RNA composition of the stalled B028 complexes revealed that they 
contain equimolar amounts of unspliced pre-mRNA and U2, U5 and U6, but a lesser 
amount of U1 snRNA, and almost no U4 snRNA. This RNA composition suggests that 
splicing inhibition occurs during or after the activation stage of spliceosome assembly.  
4.2.2 Determination of the stage at which the spliceosome assembly is stalled in the 
presence of compound 028 by protein composition analysis 
Dramatic protein exchanges occur during the transition from B to Bact complexes, as 
evidenced by mass spectrometry analysis (Bessonov et al., 2010). Many proteins (about 
30) dissociate from the spliceosome during this stage of spliceosome assembly, including 
the B-specific proteins and U6-associated Lsm proteins. The latter is thought to enable 
the base-pairing interaction of the U6 snRNA with intron nucleotides near the 5’ SS 
(Chan et al., 2003). Our research shows that the inhibition of spliceosome assembly by 
compound 028 occurs before destabilisation of Lsm proteins because they are clearly 
present in B and B028 complexes, but not in Bact complexes (Fig. 4.1). Similarly, B-
specific proteins, which are released during activation, are still present in B and B028 
complexes in similar amounts. However, the B-specific FBP21 protein, which was shown 
to bind to several splicing factors, such as the core splicing proteins SmB/B′ and SF3b49, 
and to be important for splicing (Huang et al., 2009; Klippel et al., 2011), is 
underrepresented in B028 complexes, suggesting its association with the spliceosome is 
affected by compound 028 or the inhibition takes place after FBP21 release during 
activation. The role of the FBP21 protein in the observed inhibition by compound cannot 
be estimated, since the function of this particular protein in pre-mRNA splicing is still 
poorly understood. 
Several groups of proteins were detected in B028 and B complexes formed in the presence 
of DMSO in equal/similar amounts (Fig. 4.1). These include all proteins associated with 
U1 snRNP, U2 snRNP, and most associated with U5 snRNP, including the DExD/H-box 
protein hBrr2, hPrp8 and the GTPase hSnu114, which are involved in Brr2-catalysed 
unwinding of U4/U6 base-pair interactions. The inhibition by compound 028 takes place 
after the Brr2-catalysed unwinding of U4/U6 base-pair interactions as shown by the 
release of U4 snRNA in inhibitor-treated reactions, which is accompanied by dissociation 
of U4/U6 snRNP proteins. The release of U4 snRNP makes B028 similar to Bact. Thus, the 
inhibited complexes appear to proceed further during the activation step, compared to B 
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complexes. Moreover, several U5-specific proteins, which dissociate during activation, 
are underrepresented in B028 such as 102K/Prp6, 15K/Dib1 and the DEAD-box 
phosphoprotein 100K/hPrp28, which catalyses the release of U1 from the 5’SS of pre-
mRNA during spliceosome activation, so that U6 can interact with the 5’ SS (Chen et al., 
2001; Staley and Guthrie, 1999). This suggests that the U5 snRNP is at least partially 
remodeled in B028.  
 
Figure 4.10 Summary of selected proteins identified by mass spectrometry in the affinity-
purified spliceosomal complexes B, B028 and Bact. The distribution of color in each protein box 








U1 proteins U1 proteins 
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About 30 proteins are stably recruited to the spliceosome upon activation. These include 
Bact-specific spliceosomal proteins and non-snRNP Prp19/CDC5L complex proteins, as 
well as Prp19/CDC5L-related factors (Bessonov et al., 2010; Chan and Cheng, 2005; 
Chan et al., 2003). Our results demonstrate that the inhibition by compound 028 occurs 
during the B to Bact transition based on the absence of Bact-specific spliceosomal proteins 
in the affinity-purified B028 complexes. Interestingly, Prp19/CDC5L complex proteins 
and related factors, which stabilize the interactions of U5 and U6 with the pre-mRNA in 
Bact (Chan and Cheng, 2005; Chan et al., 2003), are also underrepresented in B028 
complexes compared to Bact complexes, suggesting that the inhibition could potentially be 
caused by an effect of compound 028 on the association or stable binding of the 
Prp19/CDC5L complex with the spliceosome. Strikingly, our results show that the 
Prp19/CDC5L complexes remain largely intact upon addition of compound 028 to the 
splicing reaction, but the association of the FLAG-tagged Prp19/CDC5L component 
AD002 with the Prp19/CDC5L complex appeared to be affected by the presence of 
compound 028 (Fig. 3.32). Surprisingly, the Npw38BP and Npw38 proteins, which 
dissociate during activation and are not detected in Bact, are highly abundant in the B028 
complex (based on peptide counts and immunoblotting), suggesting that the inhibition of 
spliceosome assembly in the presence of compound 028 occurs prior to Npw38 and 
Npw38BP dissociation. Thus, proteins in the Prp19/CDC5L complex appear to be 
potential targets of compound 028 and interference with their activity could lead to the 
inhibition of pre-mRNA splicing in vitro by compound 028. 
The U2-associated SF3b155 protein, which is known to be phosphorylated during/after 
the activation step but prior to the first catalytic step (Wang et al., 1998), was in a non-
phosphorylated state in B and B028, but phosphorylated in Bact, as shown by 
immunoblotting with antibodies specific for phosphorylated SF3b155 (Fig. 3.13). This 
indicates that the inhibition takes place before phosphorylation of SF3b155. 
4.2.3 Characterization of the RNA-RNA network in spliceosomes stalled by 
compound 028  
Monitoring the RNA-RNA network in B028 complexes by UV light-induced psoralen 
crosslinking allowed the identification of double-stranded regions between RNA 
molecules of the stalled complexes. To determine what the RNA-RNA network looks like 
in B028 and thus at which precise stage it is blocked, we also performed RNA structure 
probing with B, B028 and Bact complexes, via chemical modification of snRNA 
nucleotides in these three complexes.  
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B complex formation is accompanied by the base pairing interactions between the 5’ end 
of U2 snRNA and 3’ end of U6 snRNA, building a U2/U6 helix II (Madhani and Guthrie, 
1992). Our results show that U2/U6 helix II is formed in B028 and Bact complexes based on 
the chemical inaccessibility of the corresponding U2 region. Psoralen-mediated 
crosslinking confirmed the formation of U2/U6 helix II in B028. However, there was a 
weaker crosslink signal in both B and B028 complexes compared to Bact. This could be due 
to shielding of this RNA region by proteins at early stages of spliceosome activation. To 
further confirm the presence of U2/U6 helix II in B028 complexes, inaccessibility of the 3’ 
end of U6 snRNA has to be shown. To look at protection in this region, the 3’ end of U6 
snRNA must be extended by an RNA “adaptor” fragment to enable the primer extension 
analysis of the 3’ end of U6. However, taken together our results indicate that the U2/U6 
helix II remains unaffected in stalled B028 spliceosomes. 
In complex B, the U6 snRNA is base-paired with the U4 snRNA, forming U4/U6 stem I 
and stem II. During activation, the helicase Brr2 catalyses the disruption of U4/U6 base 
pair interactions and U4 release occurs (Laggerbauer et al., 1998; Raghunathan and 
Guthrie, 1998; Staley and Guthrie, 1999), enabling further RNA rearrangements 
necessary for the formation of the activated spliceosome, such as the formation of an U6 
snRNA internal stem-loop (U6 ISL), base pairing between U6 snRNA and the 5' splice 
site, and additional base pairing with U2 snRNA. It follows from its RNA and protein 
composition that the B028 complex is inhibited after the Brr2-catalysed disruption of 
U4/U6 base-pair interactions. Indeed, psoralen-mediated crosslinking revealed U4/U6 
and U2/U4/U6 crosslinks in complex B exclusively, but not in B028 or Bact, which can be 
attributed to the release of U4 snRNA in B028 and Bact complexes. Our results also show 
the presence of a weak crosslink of U1 snRNA with the pre-mRNA in B and B028 
complexes, consistent with the low levels of U1 in these spliceosomes.  
The most important events occurring during activation are the formation of an U6 snRNA 
internal stem-loop (U6 ISL) and base pairing interactions of U6 snRNA with the 5' SS of 
pre-mRNA and the U2 snRNA, leading to the formation of short U2/U6-duplexes (helix 
Ia and helix Ib), which brings the 5' SS and BS in close proximity to each other for the 
first step of splicing. A psoralen-mediated crosslink between U6 snRNA and the pre-
mRNA was detected in all three complexes, consistent with a base pairing interaction of 
the U6 ACAGAG box with intron nucleotides near the 5’SS. Structure probing revealed 
that the nucleotides from the U6 ACAGA box (nts A40-A44), as well as intron nts +4 to 
+8 are protected against chemical modification in both Bact and B028 complexes, 
confirming the interaction of the U6 ACAGA box (A41-A45) with the pre-mRNA intron 
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near the 5’ SS in B028 complexes. However, the presence of Lsm proteins and absence of 
Prp19/CDC5L complex proteins in B028 complexes suggest that this interaction is still not 
stabilised (Chan and Cheng, 2005), and the structural rearrangements typical for Bact in 
this region might not be fully-formed. The formation of the U2/BPS interaction also 
appears to be formed in B028 complexes, based on the inaccessibility of the U2 
nucleotides involved (G33-A38) for chemical modification.  
Whether the U6 ISL, which plays a key role in splicing catalysis, is formed in B028 
spliceosomes is not clear based on our current results. Based on the accessibility of U6 
snRNA nucleotides involved, the formation of the U6 ISL loop appears to be at least 
partially formed in B028. But some loop nucleotides are less reactive against chemical 
modification compared to those in Bact. However, this could be due to the presence of 
proteins that shield these nucleotides. The stem of the U6 ISL appears to be at least 
partially formed in B028 based on the RNA protection pattern of U6 nts G65-A56 (Fig. 
3.20). However, analysis of the U6 snRNA region C79-86 still needs to be performed to 
clarify this question. This will require the addition of an 3’ end adaptor to allow annealing 
of a primer before the 3’ end of U6. 
The formation of the U2/U6 helices Ia and Ib, through interactions of U6 nucleotides with 
the 5’ end of U2 snRNA after U4 release, appears to occur in B028. This is supported by 
the inaccessibility of the involved U6 nucleotides (A50-U52 and A53-C55) and 
complementary U2 nucleotides (G25-C28 and G20-U22, respectively) revealed by the U6 
and U2 snRNAs modification pattern analysis (Fig. 3.20, 3.21).  
Previously it was shown that U2 and U6 snRNAs form a structure called a 3-way junction 
in activated human spliceosomes (Anokhina et al., 2013). An alternative four-way 
junction model for the U6/U2 interaction was also proposed (Sun and Manley, 1995). The 
four-way junction model of U6/U2 interaction includes the formation of U2 stem loop 1 
(SL1), and was not observed in either B028 and Bact complexes. This conclusion is based 
on the accessibility of U2 nts C14 and G19, which are basepaired in the U2 stem in SL1 
(Fig. 3.21). Thus, U2 and U6 don’t appear to form a four-way junction in the B028 
complex. However, the detailed investigation of the secondary structure of the 3’ end of 
U6 snRNA is required to decisively exclude the existence of a 4 way junction.  
The U5 snRNA undergoes only minor changes during the B to Bact transition, with IL2 
and loop 1 more accessible in complex B versus Bact (Anokhina et al., 2013). This is 
consistent with the fact that loop 1 contacts the 5’ exon before step I of splicing 
(Sontheimer and Steitz, 1993; Wyatt et al., 1992). Our analysis revealed that the RNA 
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protection pattern within the B028 and Bact complexes are identical, confirming that the 
structure of this region of U5 is not affected by the presence of compound 028. The loop 
1 nucleotides U42 and 43 might interact with the 5’exon of the pre-mRNA in B028, as 
well as in B and Bact due to their inaccessibility to chemical modification.  
Finally, the toggling of yeast U2 snRNA between two different intra-molecular 
conformations was reported previously (Hilliker et al., 2007; Perriman and Ares, 2007). 
This toggling involves the formation of helix IIc, which is formed by base pairing 
between loop nucleotides (53-60) of U2 stem loop IIa and nucleotides downstream of 
stem loop IIb (88-96). Analysis of the RNA protection pattern of nucleotides involved in 
U2 helix IIc (nucleotides A88-A95 and U53-U60) in both B028 and Bact complexes 
demonstrated that all nucleotides involved in helix IIc are accessible to chemical 
modification. Thus, the existence of U2 helix IIc was not detected in the B028 complex.  
4.3 Electron microscopy studies of affinity-purified B028 complexes 
We also succeeded to visualize the stalled B028 complex by two-dimensional negative 
stain electron microscopy and compared its 2D overall structure with the previously 
reported 2D structures of human B and Bact complexes (Bessonov et al., 2010). The 
typical B028 complex images have a maximum dimension of ca. 40 nm and show shapes 
ranging from isosceles triangles to mushroom-like forms. The triangular views are 
characterized by an up to 40 nm long density axis present on one side of the B028 particle 
(left edge in Fig. 3.28 columns 1-2), and a more globular density on the opposite side of 
the particle. A mushroom-like projection form of the B028 complex was observed less 
frequently. This B028 complex form typically has a relatively flat mushroom head and a 
mushroom foot that is displaced to one side. Sometimes a density axis running from the 
foot to one corner of the head can also be seen in the mushroom-like views. The presence 
of such intermediate views indicates that the triangular and mushroom-like views 
represent structurally similar particles bound to the carbon carrier film via different 
particle faces.   
The B028 complex exhibits roughly the same size as the B and Bact complexes and also 
shares some structural similarities with both complexes, but it also exhibits obvious 
differences. Typical images of the B complex (Deckert et al., 2006) also show an 
elongated density axis on one edge (Fig. 4.1). The B complex also contains a globular 
domain (designated the “head”). However, compared to B028, it exhibits a different 
position relative to the density axis, being oriented more upwards and thereby giving rise 
to the typical rhombic-shaped views of the B complex. In the B028 complex the globular 
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domain is shifted more toward the center of the elongated density axis, so that triangular 
views dominate (Fig. 4.1; 3.28, columns 1-4). In the B complex images, the globular 
domain has very different shapes with hardly any fine structure visible and thus it appears 
in class averages typically as a quite diffuse density area. The long density axis, called 
“foot-stump axis” in the B complex (Wolf et al., 2008), as well as the “arm” element 
linking the globular domain to the center of the axis, show a great deal of fine structure in 
the class averages. The intricate differences between B and B028 images demonstrate that 
the B028 complex is not just a B complex that has lost one structural element, i.e., the U4 
snRNP. Instead, there appears to be extensive rearrangements in the globular domain. 
Like the B028 complex, the human Bact complex also exhibits mushroom-like views. 
Mushroom-like views appear to be typical for Bact complexes, as they are the dominant 
views displayed by the yeast Bact particle (Fabrizio et al., 2009). The similarities between 
the B028 images and those of the human Bact images are more or less limited to the 
presences of views with mushroom-like outlines (Fig 3.28, 4.1, column 3-4, first three 
rows). As such mushroom-like views are not seen in B complex images, the appearance 
of mushroom-like views in the B028 particle can be taken as an indication that the 
conversion of the B to the B028 complex is morphologically a step towards the Bact 
configuration. A likely reason why human Bact views are so different is the presence of a 
large numbers of additional proteins in the Bact complex, in particular the large 
Prp19/CDC5L complex. Because the B028 and Bact images do not just differ by the 
presence or absence of additional domains, the proteins additionally present in the Bact 
particle likely create new preferred carbon film binding sites on the particle so that 
different views are seen in the EM images.  
The globular head domain in the human B complex was reported to contain U2 snRNP 
components (U2-associated SF3b155 protein), as well as the intron and both exons of the 
pre-mRNA (Wolf et al., 2009). More recent immuno-EM labeling experiments in our lab 
with yeast B complexes, which are morphologically very similar to human B complexes, 
indicate that U5 proteins like Prp8 and Brr2 are located in the long density axis of the B 
complex, while the neck contains U4/U6 proteins (Dr. Norbert Rigo and Dr. Berthold 
Kastner, personal communication) (Fig. 4.2B). Based on their morphological similarities 
the gross organisation of the components of the long axis in the B complex seem to be 
maintained to a large degree in the B028 complex. In contrast, the globular head domain of 
the B complex, containing the pre-mRNA and U2 snRNP proteins, appears to have 
undergone major structural changes during the transition to the B028 complex, moving 
downwards toward the central part of the long axis. The U5 snRNP protein Prp8 is of 
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central importance for formation and maintaining the spliceosome’s catalytic center. The 
apparent movement of the pre-mRNA and the U2 proteins present in the globular domain 
closer to the center of the long axis that harbors Prp8, suggests that there has been 
initiation of catalytic center formation in the B028 complex.  
 
     A.                                                   B. 
 
Figure 4.2 Comparison of 2D structures of spliceosomal complexes B, Bact and intermediate 
B028. A. The typical negative stained 2D structures are shown. Scale bar corresponds to 50 nm. B. The 
position of the U2, U4/U6 and U5 snRNPs within the B complex is indicated.  
 
The quality of the isolated B028 complexes in terms of their structural homogeneity 
allowed us to perform 3D EM structure analysis and to generate a 3D reconstruction of 
the intact B028 spliceosome (performed by Prof. Dr. Holger Stark) (Fig. 3.29, 3.30) with a 
resolution of ca. 25 Å. The reconstructed B028 structure demonstrated a unique 3D shape, 
distinct from all known spliceosomal complexes. It exhibited an almost triangular 
structure formed from an elongated, relatively massive main axis running from the foot to 
the upper corner, which is composed of a globular structure with a central cavity and a 
flatter structure with a beak-like protuberance (Fig. 3.29, 1, 2). Attached to the main axis 
is a more globular domain (Fig. 3.29, 7). The main axis and globular domain, are 
connected to each other by a complicated network of structural elements (described in 
detail in section 3.3.2). Notably, by slightly tilting the 3D structure (Fig. 3.30) a 
mushroom-like shape as observed in the 2D class averages can be envisaged. 
A 3D structure of a human B-type spliceosomal complex was reconstructed from EM 














with heparin and were not stabilized by GraFix, and the 3D structure could only be 
determined to about 4 nm because of substantial structural heterogeneity in its globular 
head domain. The fairly flat 3D structure shows the foot-stump axis as a compact mass 
with quite similar dimensions as the long density axis of the B028 complex 3D structure 
(Fig. 4.2). Even a hole between the upper and lower portion of in the main density axis, as 
seen in B028, is visible in the BU1 3D structure (marked with an arrow in Fig. 4.2). Due 
to structual heterogeneity, the head domain appears as a smaller globular density in the 
BU1 3D structure and is connected via the U4-containing neck structure to the centre of 
the foot-stump main axis. As discussed in the original paper (Boehringer et al., 2004), the 
reduced head domain must be enlarged drastically to better reflect the B complex 
structure. Nevertheless, comparison of the BU1 3D structure with that of the B028 
complex (Fig. 4.3) gives an initial hint as to how the globular domain of the B complex 
might be bent downward toward the main axis during formation of the B028 complex. 
 
Figure 4.3 Comparison of the 3D structures of B028 and human BU1. 
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The future EM investigation of the spliceosome, especially generating a 3D structure of 
the human Bact complex and a B complex structure at a higher resolution, will allow a 
better, more detailed comparison with the B028 complex 3D structure. This could provide 
deeper insight into the structural dynamics during activation and help localize 
spliceosomal components, e.g. those present in B or Bact but missing in B028. Moreover, 
the cryo-EM grids already successfully produced should allow a higher resolved cryo-EM 
3D reconstitution of the B028 complex that should give a more detailed insight into its 
architecture in the near future. 
4.4 Identification of chemical groups important for compound 028's 
splicing inhibition activity 
A structure–activity relationship study (SAR) was performed to reveal structural motifs 
that are important for the splicing inhibition activity of compound 028. To this end a wide 
spectrum of structural modifications were introduced at specific sites of the original 
molecule and the effect of these modifications on pre-mRNA splicing was tested in an in 
vitro splicing assay using radioactively-labeled MINX pre-mRNA. 
Analysis of compound 028 derivatives with a reduced linker between the two 
heterocyclic motifs of the original molecule indicated the importance of the Michael 
acceptor character of compound 028 for its splicing inhibition activity, suggesting the 
reactivity of compound 028 towards nucleophiles. In the next set of experiments, we 
investigated the effect of modifications in the o-ethylphenyl group and/or in p-
fluorophenyl group, with the goal of changing the electron properties on the rings 
(electron donor or electron withdrawing) and/or changing the size of the substitution. Our 
study revealed that the p-fluorophenyl group, including its particular components like a 
singular reactive fluorine at the para- or meta-positions, as well as an aromatic phenyl 
group and the furan group located between the heterocyclic barbituric acid-related group 
and the p-fluorophenyl group, are required for splicing inhibition activity, as evidenced 
by the negative effect of modifications introduced at these positions. Changing the 
fluorine position from the para- to meta-position (343867) or substituting fluorine with 
chlorine in the meta-position (343871) clearly enhanced the splicing inhibition effect of 
the original compound, confirming that the p-fluorophenyl group is extremely important 
for the activity of compound 028, and suggesting that it might play a direct role in the 
inhibition reaction or reaction cascade (i.e. in the targeting of compound 028 to its 
inhibition partner). Interestingly, the replacement of fluorine by a methyl group (electron 
donator) (343875) or bulky phenyl group (343868) abolished the inhibition activity. 
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However, some of the modifications introduced into the p-fluorophenyl group, such as 
two halogens in the meta-positions (343873), a dimethylamino group (electron donating 
group) attached to the phenyl group (343869) or an acetyl group (electron withdrawing 
group) in the para-position (343870) didn’t have any significant effect on the inhibition 
activity, whereas substituting a fluorine with a trifluoromethyl ether group (344355) 
appears to enhance inhibition. Likewise, nearly all modifications in the o-ethylphenyl 
group didn’t alter the inhibition activity of compound 028 significantly, suggesting it is 
not required for the observed splicing inhibition.  
Taken together, these results revealed the importance of the unsaturated linker between 
two heterocyclic motifs, the reactive fluorine on the p-fluorophenyl group and the entire 
aromatic p-fluorophenyl group for inhibiting the splicing of pre-mRNA in vitro. 
Unfortunately, we succeeded only in minimally enhancing the inhibition activity of 
compound 028 by minor modification in its original structure. Due to the rather high IC50 
value for compound 028 (i.e. 51 µM) enhancing its potency remains an important goal in 
the future. Moreover, we identified parts of the molecule, which appear not to contribute 
to the inhibition activity, based on our results that the modifications located in these parts 
have only minimal or no effect on the splicing inhibition activity of compound 028. Thus, 
these particular sites can potentially be used to introduce a tag into compound 028, 
without significant loss of its inhibition activity. We suggest the primary ethyl group on 
the o-ethylphenyl group is a very promising site for tagging. A tagged version of 028 
could be used for further investigation of possible target(s) of compound 028 in the 
splicing reaction. To this end, covalently attaching biotin to the compound might be 
highly useful due to its efficiency, specificity and small size. To identify the binding 
partners of compound 028, a biotinylated version could be added to the splicing reaction 
and affinity selection with streptavidin beads, followed by extensive washing and elution 
of bound molecules could be carried out. The co-purified proteins can be finally 
identified by mass spectrometry and/or immunoblotting. Alternatively, we could use a 
fluorescence- or photoaffinity-tagged version of compound 028 for subsequent cross-
linking studies, to search for the protein(s) that specifically bind to compound 028.  
4.5 B028 spliceosomes can be used to investigate binding and release of 
proteins during activation.  
The investigation of the composition of the B028 complex formed in the presence of 
compound 028 revealed a novel intermediate between B and Bact not detected previously. 
Furthermore, we demonstrate that a large fraction of the affinity-purified B028 complexes 
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can be chased into catalytically active spliceosomes that catalyse both steps of splicing 
when incubated with MN-treated HeLa nuclear extract. Thus, the block by compound 028 
can be overcome by incubating with the pool of spliceosomal proteins in nuclear extract. 
This means that compound 028 might prevent certain proteins from binding (this is 
overcome by adding NE without the inhibitor) or there is a displacement of a protein 
bound by 028 in the B028 complex with a protein not bound by the inhibitor, which is now 
active in splicing and activation can proceed. The affinity-purified stalled B028 complex is 
a functionally active assembly intermediate, which is stalled after Brr2-catalysed U4 
snRNA release, but before release of B-specific and Lsm proteins, and before the 
recruitment of the Bact-specific and Prp19/CDC5L-associated proteins to the spliceosome. 
We thus used stalled B028 complexes to investigate the dynamics of the subsequent 
recruitment/release of proteins during the activation step. This was done by incubating 
purified B028 complexes that were bound to amylose beads either with buffer alone or 
with normal or MN-treated nuclear extract in the presence or in the absence of ATP. The 
binding or loss of proteins was determined by mass spectrometry. To stall the 
spliceosome assembly after activation, i.e. at the stage of Bact formation, we used the 
PM5-10 pre-mRNA substrate. This was important to follow whether Bact-specific proteins 
were recruited, since they are released again already when the C complex forms. 
The RNA analysis of the “chased” B028 complexes showed that the complexes stay intact 
during the 60 min chase. Indeed, mass spectrometry analysis showed that nearly all 
proteins that are not expected to be lost during activation were present in the chased B028 
complexes in similar or same amounts compared to the unchased B028, including the U2 
and U5 snRNP proteins. This also shows that the complexes do not dissociate under chase 
conditions. In contrast, several groups of proteins were incorporated and some lost, 
showing the suitability of the B028 complexes for examining the exchange of proteins 
during activation. 
The human hPrp19/CDC5L complex proteins incorporate into the spliceosome stably 
during activation (Makarov et al., 2002; Makarova et al., 2004; Wahl et al., 2009), and 
remain associated throughout both transesterification reactions, stabilizing the association 
of U5 and U6 with the spliceosome after U4 release (Chan et al., 2003, 2005). The mass 
spectrometry analysis shows that B028, in contrast to both B and Bact, contains 
underrepresented amounts of Prp19/CDC5L complex proteins, as well as many 
Prp19/CDC5L-related proteins. The incubation of B028 with MN-treated nuclear extract or 
untreated nuclear extract under splicing conditions leads to a substantial increase in the 
amounts of bound Prp19/CDC5L complex proteins and related proteins. However, the 
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efficient recruitment of this group of proteins requires ATP, based on the result that only 
small amounts of Prp19/CDC5L proteins are detected in the B028 spliceosomes chased 
under ATP-free conditions. However, even in the presence of ATP, the number of 
peptides identified for the Prp19/CDC5L and related proteins (as well as Bact-specific 
proteins) in the chased complexes is significantly below that identified in the purified Bact 
complex. Thus, not all B028 complexes can be chased into Bact under these conditions. 
Interestingly, Npw38 and Npw38BP, which are normally released during activation but 
accumulate in the stalled B028 spliceosomes, were not released from B028 complexes 
chased with MN-treated extract (+ATP) (i.e. peptide counts went up), but were found in 
lower amounts only when the complexes were chased with MN-treated extract in the 
absence of ATP, or chased with normal nuclear extract (+ATP). This particular difference 
between complexes chased in the presence of MN-treated extract and those chased in the 
presence of normal extract, suggests that there is a negative effect of MN treatment on the 
composition and/or splicing activity of nuclear extract components, but only in the 
presence of ATP. Generally, the efficiency of chasing the B028 complexes into activated 
complexes (based on protein composition) was better in the presence of normal nuclear 
extract compared to that in the presence of the MN-treated extract. However, in case of 
the non-treated nuclear extract, it cannot be entirely ruled out that the observed splicing 
activity is due to the disassembly of B028 complexes and subsequent reassembly of new 
spliceosomes. 
Another group of spliceosomal proteins integrated into the spliceosome during activation 
are the Bact-specific proteins. We demonstrate that these proteins are also recruited to the 
B028 spliceosome after incubating with the MN-treated extract or with the normal nuclear 
extract in an ATP-dependent manner. This could be a direct requirement (at the time 
when the Bact-specific proteins bind) or ATP could be needed for the binding or release of 
other spliceosomal proteins, which is a prerequisite for the binding of the Bact-specific 
proteins. Also as mentioned below, the requirement for ATP could also reflect the need 
for a protein phosphorylation event. 
B-specific and Lsm proteins are present in B complexes, but dissociate from the 
spliceosome during activation. Stalled B028 complexes were shown to contain both groups 
of proteins, indicating that the inhibition takes place before their dissociation. Our chase 
experiments suggest that they leave the B028 spliceosome in an ATP-independent manner, 
when incubated with normal or MN-treated extract. However, mass spectrometry analysis 
shows significant amounts of these groups of proteins remaining in our Bact complexes, 
impeding the estimation of the efficiency of their release during activation. In contrast, 
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the 2nd step factor Prp22 and the RES complex proteins are recruited to the spliceosome 
upon incubation with the MN-treated extract or the normal extract under the splicing 
conditions, but only in the presence of ATP. Moreover, the spliceosomal RNA helicases 
Prp5 und Prp43 were identified in the chased spliceosomes in large amounts in the 
absence of ATP, suggesting their dissociation is ATP-dependent.  
Thus, B028 complexes are functionally active and they can proceed to activated 
spliceosomes under splicing conditions when supplemented with spliceosomal proteins in 
nuclear extract. The initial chase experiments indicate a requirement of ATP for the 
recruitment of key proteins such as Prp19/CDC5L complex proteins, Bact-specific and 
RES complex proteins and/or to enable the release of other proteins. Why might ATP be 
required after U4 snRNA release to form an activated spliceosome? A simple reason 
might be that ATP is needed to “free up” a protein needed for activation that is in an 
inactive complex in the extract. Another is that enzymatic activity (hydrolysis ATP) is 
required, such as kinase activity, for the recruitment or release of proteins during 
activation. Thus, phosphorylation of proteins might play a role here. This in turn suggests 
that compound 028 might possibly block the activity of a kinase catalysing the proposed 
phosphorylation event that is need for activation to proceed. It will be of interest to see if 
ATP hydrolysis is really required by using a non-hydrolysable form of ATP in future 
experiments. Also, a kinetic analysis (shorter incubation time points) might provide 
information about the order of binding – for example, if loss of Lsm proteins must occur 
before the release of B-specific proteins. 
4.6 Perspectives 
Additional studies with B028 complexes should be performed in the future to elucidate the 
mechanism by which spliceosome assembly is stalled by compound 028, and to extend 
our understanding of structural and compositional dynamic rearrangements occurring 
during the activation step. Further EM studies with the goal of improving resolution could 
be done to learn more about the structural organization of stalled B028 complexes (in 
collaboration with Prof. Dr. Holger Stark). A higher resolution structure would provide 
the opportunity to model proteins or snRNPs into the density map and thus localize them 
in the B028 spliceosomes. To elucidate the RNA-RNA network in B028 in more detail, the 
analysis of the RNA protection pattern at the 3’ end of U6 snRNA in B028 complexes will 
be undertaken. This will require that the 3’ end of U6 snRNA is extended by an RNA 
“adaptor” fragment and analysed using the structure probing procedure to clarify whether 
the U6 ISL is formed in B028 complex. The tagging of the compound 028 on the basis of 
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the obtained SAR data might be helpful to identify its target(s), with a goal to uncover the 
mechanism of the inhibition of pre-mRNA splicing by compound 028. In addition, the 
investigation of the inhibition activity of compound 028 in yeast (S. cerevisiae) pre-
mRNA splicing system should elucidate whether the inhibition target is common to both 
yeast and human spliceosomes. Further chasing experiments are of particular importance 
with the goal of understanding the dynamics of protein recruitment by the analysis of 
protein exchange after shorter kinetic steps. Additionally, chasing experiments could be 
performed with non-hydrolysable ATP analogues to determine whether ATP hydrolysis is 
needed for the binding of Bact-specific and Prp19/CDC5L complex proteins. Moreover, it 
will be interesting to clarify the phosphorylation status of different proteins during the 
chasing of B028 complexes in the presence/absence of ATP. Finally, the inhibition of 
spliceosome assembly by other identified compounds (296/297) will be investigated in 
the future in more detail, to obtain hopefully new information about the dynamic protein 
recruitment/release and structural rearrangements during the activation step. Taken 
together, these studies will deepen our understanding of the structural and compositional 
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